Community Health Systems (CYH) 10-K 17 Feb 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Feb. 11, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity File Number	001-15925
Entity Registrant Name	COMMUNITY HEALTH SYSTEMS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3893191
Entity Address, Address Line One	4000 Meridian Boulevard
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	615
Local Phone Number	465-7000
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	CYH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		132,116,361
Entity Central Index Key	0001108109
Amendment Flag	false
Entity Public Float			$ 1,894,957,351
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
ICFR Auditor Attestation Flag	true
Auditor Firm ID	34
Auditor Name	Deloitte & Touche LLP
Auditor Location	Nashville, Tennessee
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Certain information required for Part III of this annual report is incorporated by reference to portions of the Registrant’s definitive proxy statement for its 2022 annual meeting of stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2021.

Consolidated Statements of Inco

Consolidated Statements of Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Net operating revenues	$ 12,368	$ 11,789	$ 13,210
Operating costs and expenses:
Salaries and benefits	5,242	5,411	5,947
Supplies	2,042	1,963	2,151
Other operating expenses	2,958	2,957	3,303
Government and other legal settlements and related costs			93
Electronic health records incentive reimbursement			(1)
Lease cost and rent	308	327	321
Pandemic relief funds	(148)	(601)
Depreciation and amortization	540	558	608
Impairment and (gain) loss on sale of businesses, net	24	48	138
Total operating costs and expenses	10,966	10,663	12,560
Income from operations	1,402	1,126	650
Interest expense, net of interest income of $3 in 2021, 2020 and 2019	885	1,031	1,041
Loss (gain) from early extinguishment of debt	79	(317)	54
Gain on sale of equity interests in Macon Healthcare, LLC	(39)
Equity in earnings of unconsolidated affiliates	(22)	(10)	(15)
Income (loss) before income taxes	499	422	(430)
Provision for (benefit from) income taxes	131	(185)	160
Net income (loss)	368	607	(590)
Less: Net income attributable to noncontrolling interests	138	96	85
Net income (loss) attributable to Community Health Systems, Inc. stockholders	$ 230	$ 511	$ (675)
Earnings (loss) per share attributable to Community Health Systems, Inc. stockholders:
Basic	$ 1.82	$ 4.43	$ (5.93)
Diluted	$ 1.76	$ 4.39	$ (5.93)
Weighted-average number of shares outstanding:
Basic	126,754,852	115,491,022	113,739,046
Diluted	130,597,410	116,544,561	113,739,046

Consolidated Statements of In_2

Consolidated Statements of Income (Loss) (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Interest income	$ 3	$ 3	$ 3

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 368	$ 607	$ (590)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax of $0 for the years ended December 31, 2021 and 2020 and $1 for the year ended December 31, 2019		(1)	(3)
Net change in fair value of available-for-sale debt securities, net of tax	(5)	4	4
Amortization and recognition of unrecognized pension cost components, net of tax of $0, $2 and $0 for the years ended December 31, 2021, 2020 and 2019, respectively	3	(7)
Other comprehensive (loss) income	(2)	(4)	1
Comprehensive income (loss)	366	603	(589)
Less: Comprehensive income attributable to noncontrolling interests	138	96	85
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders	$ 228	$ 507	$ (674)

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net change in fair value of interest rate swaps, tax	$ 0	$ 0	$ 1
Amortization and recognition of unrecognized pension cost components, tax	$ 0	$ 2	$ 0

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 507	$ 1,676
Patient accounts receivable	2,062	1,927
Supplies	355	335
Prepaid income taxes	94	50
Prepaid expenses and taxes	192	184
Other current assets	269	338
Total current assets	3,479	4,510
Property and equipment
Land and improvements	534	515
Buildings and improvements	6,050	5,749
Equipment and fixtures	3,173	3,088
Property and equipment	9,757	9,352
Less accumulated depreciation and amortization	(4,204)	(4,030)
Property and equipment, net	5,553	5,322
Goodwill	4,219	4,219
Deferred income taxes	53	59
Other assets, net of accumulated amortization of $1,216 and $1,118 at December 31, 2021 and 2020, respectively	1,913	1,896
Total assets	15,217	16,006
Current liabilities:
Current maturities of long-term debt	31	123
Current operating lease liabilities	147	142
Accounts payable	830	783
Accrued liabilities:
Employee compensation	655	637
Accrued interest	225	150
Other	476	980
Total current liabilities	2,364	2,815
Long-term debt	12,109	12,093
Deferred income taxes	192	29
Long-term operating lease liabilities	535	524
Other long-term liabilities	827	1,599
Total liabilities	16,027	17,060
Redeemable noncontrolling interests in equity of consolidated subsidiaries	480	484
Commitments and contingencies (Note 15)
Community Health Systems, Inc. stockholders’ deficit:
Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued
Common stock, $.01 par value per share, 300,000,000 shares authorized; 132,146,282 shares issued and outstanding at December 31, 2021, and 129,612,117 shares issued and outstanding at December 31, 2020	1	1
Additional paid-in capital	2,118	2,094
Accumulated other comprehensive loss	(14)	(13)
Accumulated deficit	(3,477)	(3,707)
Total Community Health Systems, Inc. stockholders’ deficit	(1,372)	(1,625)
Noncontrolling interests in equity of consolidated subsidiaries	82	87
Total stockholders’ deficit	(1,290)	(1,538)
Total liabilities and stockholders’ deficit	$ 15,217	$ 16,006

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Accumulated amortization	$ 1,216	$ 1,118
Preferred stock, par value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.01	$ 0.01
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	132,146,282	129,612,117
Common stock, shares outstanding	132,146,282	129,612,117

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($) $ in Millions	Total	Redeemable Noncontrolling Interests (Non- Equity)	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Noncontrolling Interest
Equity, beginning balance at Dec. 31, 2018	$ (1,463)		$ 1	$ 2,017	$ (10)	$ (3,543)	$ 72
Redeemable Noncontrolling Interests, beginning balance at Dec. 31, 2018		$ 504
Shares, outstanding, beginning balance at Dec. 31, 2018			116,248,376
Comprehensive income (loss)	(641)				1	(675)	33
Comprehensive income (loss) attributable to redeemable noncontrolling interest		52
Contributions from noncontrolling interests	7						7
Contributions from redeemable noncontrolling interests		3
Distributions to noncontrolling interests	(31)						(31)
Distributions to redeemable noncontrolling interests		(68)
Purchase of subsidiary shares from noncontrolling interests	(3)	(8)		3			(6)
Other reclassifications of noncontrolling interests	2						2
Other reclassifications of redeemable noncontrolling interests		(2)
Adjustment to redemption value of redeemable noncontrolling interests	(21)	21		(21)
Cancellation of restricted stock for tax withholdings on vested shares	(1)			(1)
Cancellation of restricted stock for tax withholdings on vested shares, shares			(298,182)
Income tax payable increase from vesting of restricted shares			333
Stock-based compensation	10			10
Stock-based compensation, shares			1,872,104
Equity, ending balance at Dec. 31, 2019	(2,141)		$ 1	2,008	(9)	(4,218)	77
Redeemable Noncontrolling Interests, ending balance at Dec. 31, 2019		502
Shares, outstanding, ending balance at Dec. 31, 2019			117,822,631
Comprehensive income (loss)	545				(4)	511	38
Comprehensive income (loss) attributable to redeemable noncontrolling interest		58
Contributions from noncontrolling interests	15						15
Distributions to noncontrolling interests	(34)						(34)
Distributions to redeemable noncontrolling interests		(82)
Purchase of subsidiary shares from noncontrolling interests	3	(4)		3
Other reclassifications of noncontrolling interests	(9)						(9)
Other reclassifications of redeemable noncontrolling interests		9
Disposition of less-than-wholly owned hospital		(14)
Adjustment to redemption value of redeemable noncontrolling interests	(15)	15		(15)
Cancellation of restricted stock for tax withholdings on vested shares	(1)			(1)
Cancellation of restricted stock for tax withholdings on vested shares, shares			(288,859)
Issuance of common stock in connection with the exercise of stock options, shares			18,166
Income tax payable increase from vesting of restricted shares			333
Section 3(a)(9) exchange	86			86
Section 3(a)(9) exchange, shares			10,000,000
Stock-based compensation	13			13
Stock-based compensation, shares			2,059,846
Equity, ending balance at Dec. 31, 2020	(1,538)		$ 1	2,094	(13)	(3,707)	87
Redeemable Noncontrolling Interests, ending balance at Dec. 31, 2020	484	484
Shares, outstanding, ending balance at Dec. 31, 2020			129,612,117
Comprehensive income (loss)	266				(2)	230	38
Comprehensive income (loss) attributable to redeemable noncontrolling interest		100
Contributions from redeemable noncontrolling interests		1
Distributions to noncontrolling interests	(39)						(39)
Distributions to redeemable noncontrolling interests		(82)
Purchase of subsidiary shares from noncontrolling interests	13	(32)		17			(4)
Other reclassifications of noncontrolling interests	1				1
Other reclassifications of redeemable noncontrolling interests		1
Disposition of less-than-wholly owned hospital		(7)
Noncontrolling interests in acquired entity		2
Adjustment to redemption value of redeemable noncontrolling interests	(13)	13		(13)
Cancellation of restricted stock for tax withholdings on vested shares	(5)			(5)
Cancellation of restricted stock for tax withholdings on vested shares, shares			(584,379)
Issuance of common stock in connection with the exercise of stock options, shares			65,499
Stock-based compensation	25			25
Stock-based compensation, shares			3,053,045
Equity, ending balance at Dec. 31, 2021	(1,290)		$ 1	$ 2,118	$ (14)	$ (3,477)	$ 82
Redeemable Noncontrolling Interests, ending balance at Dec. 31, 2021	$ 480	$ 480
Shares, outstanding, ending balance at Dec. 31, 2021			132,146,282

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income (loss)	$ 368	$ 607	$ (590)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization	540	558	608
Deferred income taxes	170	(187)	203
Government and other legal settlements and related costs			51
Stock-based compensation expense	25	13	10
Impairment and (gain) loss on sale of businesses, net	24	48	138
Loss (gain) from early extinguishment of debt	79	(317)	54
Gain on sale of equity interests in Macon Healthcare, LLC	(39)
Other non-cash expenses, net	78	131	182
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:
Patient accounts receivable	(136)	309	93
Supplies, prepaid expenses and other current assets	1	(15)	38
Medicare accelerated payments		1,158
Repayment/derecognition of Medicare accelerated payments	(1,081)	(77)
Pandemic relief funds		104
Accounts payable, accrued liabilities and income taxes	16	(67)	(157)
Other	(176)	(87)	(245)
Net cash (used in) provided by operating activities	(131)	2,178	385
Cash flows from investing activities:
Acquisitions of facilities and other related businesses	(3)	(1)	(13)
Purchases of property and equipment	(469)	(440)	(438)
Proceeds from disposition of hospitals and other ancillary operations	17	648	604
Proceeds from sale of property and equipment	10	4	3
Purchases of available-for-sale debt securities and equity securities	(171)	(178)	(80)
Proceeds from sales of available-for-sale debt securities and equity securities	102	194	92
Purchases of investments in unconsolidated affiliates	(7)	(1)	(14)
Proceeds from sale of equity interests in Macon Healthcare, LLC	110
Increase in other investments	(113)	(49)	(156)
Net cash (used in) provided by investing activities	(524)	177	(2)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements	(5)	(1)	(1)
Deferred financing costs and other debt-related costs	(313)	(156)	(46)
Proceeds from noncontrolling investors in joint ventures		15	10
Redemption of noncontrolling investments in joint ventures	(19)	(1)	(11)
Distributions to noncontrolling investors in joint ventures	(121)	(116)	(99)
Proceeds from sale-lease back		2	60
Other borrowings	60	53	37
Issuance of long-term debt	4,310	4,262	3,042
Proceeds from ABL Facility		540	202
Repayments of long-term indebtedness	(4,426)	(5,493)	(3,557)
Net cash used in financing activities	(514)	(895)	(363)
Net change in cash and cash equivalents	(1,169)	1,460	20
Cash and cash equivalents at beginning of period	1,676	216	196
Cash and cash equivalents at end of period	507	1,676	216
Supplemental disclosure of cash flow information:
Interest payments	(778)	(1,039)	(1,011)
Income tax (payments) refunds, net	$ (4)	$ (2)	$ 3

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Business. Community Health Systems, Inc. is a holding company and operates no business in its own name. On a consolidated basis, Community Health Systems, Inc. and its subsidiaries (collectively the “Company”) own, lease and operate general acute care hospitals as well as outpatient facilities in communities across the country. As of December 31, 2021, the Company owned or leased 83 hospitals, including two stand-alone rehabilitation or psychiatric hospitals, licensed for 13,289 beds in 16 states. Throughout these notes to the consolidated financial statements, Community Health Systems, Inc. (the “Parent”) and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly-traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc. As of December 31, 2021, Indiana, Florida, Texas and Alabama represent the only areas of significant geographic concentration. Net operating revenues generated by the Company’s hospitals in Indiana, as a percentage of consolidated net operating revenues, were 16.4% in 2021, 15.0% in 2020 and 13.7% in 2019. Net operating revenues generated by the Company’s hospitals in Florida, as a percentage of consolidated net operating revenues, were 12.2% in 2021, 13.0% in 2020 and 14.3% in 2019. Net operating revenues generated by the Company’s hospitals in Texas, as a percentage of consolidated net operating revenues, were 11.0% in 2021 and 12.2% in both 2020 and 2019. Net operating revenues generated by the Company’s hospitals in Alabama, as a percentage of consolidated net operating revenues, were 13.0% in 2021, 12.1% in 2020 and 10.6% in 2019. Use of Estimates . The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions. Principles of Consolidation . The consolidated financial statements include the accounts of the Parent, its subsidiaries, all of which are controlled by the Parent through majority voting control, and variable interest entities for which the Company is the primary beneficiary. All intercompany accounts, profits and transactions have been eliminated. Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity to distinguish between the interests of the Parent and the interests of the noncontrolling owners. Revenues, expenses and income from these subsidiaries are included in the consolidated amounts as presented on the consolidated statements of income (loss), along with a net income measure that separately presents the amounts attributable to the controlling interests and the amounts attributable to the noncontrolling interests for each of the periods presented. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the consolidated balance sheets. Reclassifications . Certain prior period amounts have been reclassified to conform to the current period presentation within the consolidated statements of cash flows. Cost of Revenue . Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company would include the Company’s corporate office costs at its Franklin, Tennessee office which were collectively $222 million, $190 million and $184 million for the years ended December 31, 2021, 2020 and 2019, respectively. Included in these corporate office costs is stock-based compensation of $25 million, $13 million and $10 million for the years ended December 31, 2021, 2020 and 2019, respectively. Operating costs for the year ended December 31, 2021 reflect increased stock compensation expense and annual cash incentive compensation expense compared to the years ended December 31, 2020 and 2019. Cash Equivalents . The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. Supplies. Supplies, principally medical supplies, are stated at the lower of cost (first-in, first-out basis) or market. Marketable Securities. The Company’s marketable securities consist of debt securities that are classified as trading or available-for-sale and equity securities. Available-for-sale debt securities are reported at fair value as determined by quoted market prices, with unrealized gains and losses reported as a separate component of stockholders’ deficit. Trading securities are reported at fair value with unrealized gains and losses included in earnings. Other comprehensive loss, net of tax, included an unrealized loss of $5 million during the year ended December 31, 2021, and an unrealized gain of $4 million for both of the years ended December 31, 2020 and 2019 related to these available-for-sale debt securities. Property and Equipment . Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the land and improvements (3 to 20 years), buildings and improvements (5 to 40 years) and equipment and fixtures (3 to 18 years). Costs capitalized as construction in progress were $225 million and $194 million at December 31, 2021 and 2020, respectively. Expenditures for renovations and other significant improvements are capitalized; however, maintenance and repairs which do not improve or extend the useful lives of the respective assets are charged to operations as incurred. Interest capitalized related to construction in progress was $13 million, $15 million and $20 million for the years ended December 31, The Company also leases certain facilities and equipment under finance leases (see Note 9). Such assets are amortized on a straight-line basis over the lesser of the term of the lease or the remaining useful lives of the applicable assets. During the year ended December 31, 2021, the Company had non-cash investing activity of $166 million related to certain facility and equipment additions that were financed through finance leases and other debt. Goodwill. Goodwill represents the excess of the fair value of the consideration conveyed in the acquisition over the fair value of net assets acquired. Goodwill arising from business combinations is not amortized. Goodwill is required to be evaluated for impairment at the same time every year and when an event occurs or circumstances change such that it is more likely than not that impairment may exist. The Company performs its annual testing of impairment for goodwill in the fourth quarter of each year. There was no goodwill impairment charge during the years ended December 31, 2021, 2020 and 2019 as a result of the Company’s annual impairment evaluation. Other Assets. Other assets consist of the insurance recovery receivable from excess insurance carriers related to the Company’s self-insured malpractice general liability and workers’ compensation insurance liability; costs to recruit physicians to the Company’s markets, which are deferred and expensed over the term of the respective physician recruitment contract, generally three years, and included in amortization expense; equity method investments; and capitalized internal-use software costs, which are expensed over the expected useful life, which is generally three years for routine software, and included in amortization expense. Revenue Recognition. Net Operating Revenues Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing goods and services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these goods and services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the goods and services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and other patient price concessions. During each of the years ended December 31, 2021, 2020 and 2019, the impact of changes to the inputs used to determine the transaction price was considered immaterial. Currently, several states utilize supplemental reimbursement programs for the purpose of providing reimbursement to providers that is not specifically tied to an individual’s care, some of which offsets a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services (“CMS”) and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. Under these supplemental programs, the Company recognizes revenue and related expenses in the period in which amounts are estimable and payment is reasonably assured. Reimbursement under these programs is reflected in net operating revenues and fees, taxes or other program-related costs are reflected in other operating expenses. The Company’s net operating revenues during the years ended December 31, 2021, 2020 and 2019 have been presented in the following table based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in millions): Year Ended December 31, 2021 2020 2019 Medicare $ 2,650 $ 2,813 $ 3,331 Medicaid 1,671 1,578 1,736 Managed Care and other third-party payors 7,937 7,400 8,014 Self-pay 110 (2 ) 129 Total $ 12,368 $ 11,789 $ 13,210 Patient Accounts Receivable Patient accounts receivable are recorded at net realizable value based on certain assumptions determined by each payor. For third-party payors including Medicare, Medicaid, and Managed Care, the net realizable value is based on the estimated contractual reimbursement percentage, which is based on current contract prices or historical paid claims data by payor. For self-pay accounts receivable, which includes patients who are uninsured and the patient responsibility portion for patients with insurance, the net realizable value is determined using estimates of historical collection experience without regard to aging category. These estimates are adjusted for estimated conversions of patient responsibility portions, expected recoveries and any anticipated changes in trends. Patient accounts receivable can be impacted by the effectiveness of the Company’s collection efforts. Additionally, significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the net realizable value of accounts receivable. The Company also continually reviews the net realizable value of accounts receivable by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net revenue and admissions by payor classification, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables, the impact of recent acquisitions and dispositions and the impact of current economic and other events. Final settlements for some payors and programs are subject to adjustment based on administrative review and audit by third parties. As a result of these final settlements, the Company has recorded amounts due to third-party payors of $118 million and $98 million as of December 31, 2021 and 2020, respectively, and these amounts are included in accrued liabilities-other in the accompanying consolidated balance sheets. Amounts due from third-party payors were $114 million and $136 million as of December 31, 2021 and 2020, respectively, and are included in other current assets in the accompanying consolidated balance sheets. Substantially all Medicare and Medicaid cost reports are final settled through 2017. Charity Care In the ordinary course of business, the Company renders services to patients who are financially unable to pay for hospital care. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges for those patients who are financially unable to pay and that otherwise do not qualify for reimbursement from a governmental program are not reported in net operating revenues, and are thus classified as charity care. The Company determines amounts that qualify for charity care based on the patient’s household income relative to the federal poverty level guidelines, as established by the federal government. These charity care services are estimated to be $1.1 billion, $1.0 billion and $540 million for the years ended December 31, 2021, 2020 and 2019, respectively, representing the value (at the Company’s standard charges) of these charity care services that are excluded from net operating revenues. The estimated cost incurred by the Company to provide these charity care services to patients who are unable to pay was approximately $123 million, $ 122 Leases. The right-of-use (“ROU”) asset recorded at commencement of the lease represents the right to use the underlying asset over the lease term in exchange for the lease payments. Leases with an initial term of 12 months or less that do not have an option to purchase the underlying asset that is deemed reasonably certain to be exercised are not recorded on the balance sheet; rather, rent expense for these leases is recognized on a straight-line basis over the lease term, or when incurred if a month-to-month lease. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company’s incremental borrowing rate is utilized. The Company calculates its incremental borrowing rate on a quarterly basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. Physician Income Guarantees . The Company enters into physician recruiting agreements under which it supplements physician income to a minimum amount over a period of time, typically one year, while the physicians establish themselves in the community. As part of the agreements, the physicians are committed to practice in the community for a period of time, typically three years, which extends beyond their income guarantee period. The Company records an asset and liability for the estimated fair value of minimum revenue guarantees on new agreements and the asset is amortized over the life of each respective agreement. Adjustments to the ultimate value of the guarantee paid to physicians are recognized in the period that the change in estimate is identified. As of December 31, 2021 and 2020, the unamortized portion of these physician income guarantees was $13 million and $16 million, respectively, and is recorded in other assets in the consolidated balance sheets. Concentrations of Credit Risk . The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company’s facilities and non-governmental third-party payors, Medicare represents the only significant concentration of credit risk from payors. Accounts receivable, net of contractual allowances, from Medicare was $211 million and $232 million at December 31, 2021 and 2020, respectively, representing 5% and 6% of consolidated net accounts receivable at December 31, 2021 and 2020, respectively. Accounting for the Impairment or Disposal of Long-Lived Assets. During the year ended December 31, 2021, the Company recorded a net loss on disposal of approximately $24 million, of which (i) approximately $ 29 million was recorded to adjust the carrying value of long-lived assets at several hospitals that were sold at a sales price below carrying value, (ii) approximately $3 million was recorded related to divestiture related expenses, and (iii) approximately $8 million of gain was recorded related to the disposal of the Company’s majority interest in a surgery center that was sold on January 1, 2021. Approximately $5 million of goodwill was allocated to facilities disposed of during the year ended December 31, 2021. During the year ended December 31, 2020, the Company recorded a total combined net impairment charge and loss on disposal of approximately $48 million, of which (i) 59 was recorded to reduce the carrying value of closed hospitals and certain hospitals that have been sold or deemed held for sale based on the difference between the carrying value of the hospital disposal groups compared to estimated fair value less costs to sell 74 was recorded primarily to adjust the carrying value of other long-lived assets at several underperforming hospitals or where the Company was in discussions with potential buyers for divestiture at a sales price that indicated a fair value below carrying value 3 1 The impairment charge was 89 110 Income Taxes. The Company accounts for income taxes under the asset and liability method, in which deferred income tax assets and liabilities are recognized for the tax consequences of “temporary differences” by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred taxes of a change in tax rates is recognized in the consolidated statements of income (loss) during the period in which the tax rate change becomes law. Comprehensive Loss . Comprehensive loss is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Segment Reporting . A public company is required to report annual and interim financial and descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet the criteria established by U.S. GAAP. The Company operates a single operating segment represented by hospital operations (which includes the Company's acute care hospitals and related healthcare entities that provide inpatient and outpatient healthcare services). COVID-19 Pandemic. COVID-19, a disease caused by a novel strain of coronavirus, materially affected the Company’s results of operations during 2020 and continued to affect the Company’s results of operations during the year ended December 31, 2021. Federal and state governments have passed legislation, promulgated regulations and taken other administrative actions intended to assist healthcare providers in providing care to COVID-19 and other patients during the public health emergency. Sources of relief include the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), the Paycheck Protection Program and Health Care Enhancement Act (the “PPPHCE Act”), the Consolidated Appropriations Act, 2021 (the “CAA”), and the American Rescue Plan Act of 2021 (the “ARPA”). Together, these stimulus laws authorize over $186 billion in funding to be distributed to hospitals and other healthcare providers through the Public Health and Social Services Emergency Fund (the “PHSSEF” or “Provider Relief Fund”). In addition to the relief funding, the CARES Act provided for an expansion of the Medicare Accelerated and Advance Payment Program whereby inpatient acute care hospitals and other eligible providers were able to request accelerated payment of up to 100% of their Medicare payment amount for a six-month Providers are required to repay accelerated payments beginning one year after the payment was issued. Repayments occur through withholding of future Medicare fee-for-service payments. Various state and local programs also exist to provide relief, either independently or through distribution of monies received via the CARES Act and other enacted federal legislation. The Company’s accounting policies for the recognition of these stimulus monies are as follows: Pandemic Relief Funds Through December 31, 2021, net of amounts that have been repaid to the respective federal, state, or local agency, the Company received approximately $763 million in payments through the PHSSEF and various state and local programs on a cumulative basis since their enactment. Of the net amount received through December 31, 2021, approximately $705 million was received during the year ended December 31, 2020 and the remainder was received during the year ended December 31, 2021. The recognition of amounts received is conditioned upon the provision of care for individuals with possible or actual cases of COVID-19 after January 31, 2020, certification that payment will be used to prevent, prepare for and respond to coronavirus (such amounts shall reimburse the recipient only for healthcare-related expenses or lost revenues, as defined by the U.S. Department of Health and Human Services Agency (“ The Company’s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met is updated each reporting period and considers, among other things, the requirements set forth in the CARES Act and subsequent relief legislation, responses to all applicable frequently asked questions and other interpretive guidance issued by HHS, including the various Post-Payment Notices of Reporting Requirements, the Company’s expenses incurred attributable to the coronavirus, the Company’s results of operations during such period as compared to the Company’s 2020 budget, and the allocation of general and targeted fund distribution payments among subsidiaries of the Company during such period. The HHS guidance, specifically the various Post-Payment Notices of Reporting Requirements and frequently asked questions, set forth the allowable methods for quantifying eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to coronavirus that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. The use of funds calculation takes into account expenses attributable to each respective entity, which for the Company primarily relate to incremental labor and supply costs, as well as lost revenues. The deadlines for using and required timelines for reporting on the use of funds depend on the dates of receipt of the funds. Pandemic relief funds of approximately $148 million and $601 million were recognized during the years ended December 31, 2021 and 2020, respectively. Amounts received through the PHSSEF or state and local programs that have not yet been recognized or otherwise have not been refunded to HHS or the various state and local agencies as of December 31, 2021, total approximately $14 million and are reflected within accrued liabilities-other in the consolidated balance sheets. Such unrecognized amounts may either be returned to HHS or the respective state or local agency, as applicable, or may be recognized in future periods if the underlying conditions for recognition are reasonably assured of having been met. HHS’ interpretation of the underlying terms and conditions of such PHSSEF payments, including auditing and reporting requirements, continues to evolve. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such PHSSEF payments may result in changes in the Company’s estimate of amounts for which the terms and conditions are reasonably assured of being met, and any such changes may be material. Additionally, any such changes may result in the Company’s inability to recognize additional PHSSEF payments or may result in the derecognition of amounts previously recognized, which (in any such case) may be material. Medicare Acceler ated Payments With respect to the Medicare Accelerated and Advanced Payment Program, the Company received Medicare accelerated payments of approximately $1.2 billion in April 2020. No additional Medicare accelerated payments have been received by the Company since such time. In addition, because CMS is no longer accepting new applications for accelerated payments, the Company does not expect to receive additional Medicare accelerated payments. CMS began recouping Medicare accelerated payments in April 2021. As of December 31, 2021, all Medicare accelerated payments received by the Company have been recouped or repaid to CMS or assumed by buyers related to hospitals the Company divested. Approximately $1.1 billion and $77 million of Medicare accelerated payments received by the Company were recouped or repaid to CMS or assumed by buyers related to hospitals the Company divested during the years ended December 31, 2021 and 2020, respectively . New Accounting Pronouncements . In November 2021, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2021-10, “Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance.” This ASU provides specific authoritative guidance for the disclosure of government assistance including the nature of assistance received, the accounting for and presentation of assistance received and the significant terms and conditions, including commitments and contingences. This ASU is effective for all entities for financial statements issued for annual periods beginning after December 15, 2021 and may be early adopted. The Company early adopted this ASU beginning with this Annual Report on Form 10-K (“Form 10-K”) for the year ended December 31, 2021. The Company has evaluated all other recently issued, but not yet effective, ASUs and does not expect the eventual adoption of these ASUs to have a material impact on its consolidated financial position or results of operations.

Accounting for Stock-Based Comp

Accounting for Stock-Based Compensation	12 Months Ended
	Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
ACCOUNTING FOR STOCK-BASED COMPENSATION	2. ACCOUNTING FOR STOCK-BASED COMPENSATION Stock-based compensation awards have been granted under the Community Health Systems, Inc. Amended and Restated 2009 Stock Option and Award Plan, which was amended and restated as of March 17, 2021 and approved by the Company’s stockholders at the annual meeting of stockholders held on May 11, 2021 The 2009 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code (“IRC”) and for the grant of stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Persons eligible to receive grants under the 2009 Plan include the Company’s directors, officers, employees and consultants. To date, all options granted under the 2009 Plan have been “nonqualified” stock options for tax purposes. Generally, these options vest in one-third increments on each of the first three anniversaries of the award date and have a 10-year contractual term. As of December 31, 2021, 12,522,282 shares of unissued common stock were reserved for future grants under the 2009 Plan. The exercise price of all options granted under the 2009 Plan is equal to the fair value of the Company’s common stock on the option grant date. The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions): Year Ended December 31, 2021 2020 2019 Effect on income (loss) before income taxes $ (25 ) $ (13 ) $ (10 ) Effect on net income (loss) $ (20 ) $ (10 ) $ (8 ) At December 31, 2021, $27 million of unrecognized stock-based compensation expense related to outstanding unvested stock options, restricted stock and restricted stock units (the terms of which are summarized below) was expected to be recognized over a weighted-average period of 22 months. Of that amount, $4 million related to outstanding unvested stock options was expected to be recognized over a weighted-average period of 22 months and $23 million related to outstanding unvested restricted stock and restricted stock units was expected to be recognized over a weighted-average period of 22 months. There were no modifications to awards during the years ended December 31, 2021, 2020 and 2019. The fair value of stock options was estimated using the Black Scholes option pricing model with the following assumptions and weighted-average fair values during the years ended December 31, 2021, 2020 and 2019: Year Ended December 31, 2021 2020 2019 Expected volatility 84.3% - 88.9% 73.5% 68.4 % Expected dividends — — — Expected term 3.0 - 6.0 years 6.0 years 5.6 years Risk-free interest rate 0.3% - 0.9% 1.0% 2.6 % In determining the expected term, the Company examined concentrations of option holdings and historical patterns of option exercises and forfeitures, as well as forward-looking factors, in an effort to determine if there were any discernable employee populations. From this analysis, the Company identified two primary employee populations, one consisting of certain senior executives and the other consisting of substantially all other recipients. The expected volatility rate was estimated based on historical volatility. In determining expected volatility, the Company also reviewed the market-based implied volatility of actively traded options of its common stock and determined that historical volatility utilized to estimate the expected volatility rate did not differ significantly from the implied volatility. The expected term computation is based on historical exercise and cancellation patterns and forward-looking factors, where present, for each population identified. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company adjusts the estimated forfeiture rate to its actual experience. Options outstanding and exercisable under the 2009 Plan as of December 31, 2021, and changes during each of the years in the three-year period prior to December 31, 2021, were as follows (in millions, except share and per share data): Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value as of December 31, 2021 Outstanding at December 31, 2018 624,938 $ 31.21 Granted 658,500 4.95 Exercised — — Forfeited and cancelled (173,304 ) 23.04 Outstanding at December 31, 2019 1,110,134 16.90 Granted 946,500 4.93 Exercised (18,166 ) 4.99 Forfeited and cancelled (220,943 ) 33.52 Outstanding at December 31, 2020 1,817,525 8.77 Granted 749,250 8.81 Exercised (65,499 ) 5.03 Forfeited and cancelled (199,523 ) 33.14 Outstanding at December 31, 2021 2,301,753 $ 6.77 8.0 years $ 16 Exercisable at December 31, 2021 730,828 $ 6.76 6.8 years $ 5 The weighted-average grant date fair value of stock options granted during the years ended December 31, 2021, 2020 and 2019, respectively, was $6.22, $3.17 and $3.05. The aggregate intrinsic value (calculated as the number of in-the-money stock options multiplied by the difference between the Company’s closing stock price on the last trading day of the reporting period ($13.31) and the exercise price of the respective stock options) in the table above represents the amount that would have been received by the option holders had all option holders exercised their options on December 31, 2021. This amount changes based on the market value of the Company’s common stock. The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was less than $1 million for both years. There were no options exercised during the year ended December 31, 2019. The aggregate intrinsic value of options vested and expected to vest approximates that of the outstanding options. The Company has also awarded restricted stock under the 2009 Plan to employees of certain subsidiaries. With respect to time-based vesting restricted stock that has been awarded under the 2009 Plan, the restrictions on these shares have generally lapsed in one-third increments on each of the first three anniversaries of the award date. In addition, certain of the restricted stock awards granted to the Company’s senior executives have contained performance objectives required to be met in addition to any time-based vesting requirements. If the applicable performance objectives are not attained, these awards will be forfeited in their entirety. For performance-based awards, the performance objectives are measured cumulatively over a three-year Restricted stock outstanding under the 2009 Plan as of December 31, 2021, and changes during each of the years in the three-year period prior to December 31, 2021, were as follows: Shares Weighted- Average Grant Date Fair Value Unvested at December 31, 2018 3,308,907 $ 7.00 Granted 1,989,000 4.94 Vested (1,160,667 ) 8.89 Forfeited (279,838 ) 5.60 Unvested at December 31, 2019 3,857,402 5.47 Granted 2,205,500 4.90 Vested (1,123,329 ) 5.84 Forfeited (383,838 ) 8.58 Unvested at December 31, 2020 4,555,735 4.84 Granted 2,929,250 8.16 Vested (2,312,328 ) 4.68 Forfeited (177,343 ) 6.33 Unvested at December 31, 2021 4,995,314 6.30 Restricted stock units (“RSUs”) have been granted to the Company’s non-management directors under the 2009 Plan. Each of the Company’s then serving non-management directors received grants under the 2009 Plan of 34,068 RSUs, 34,483 RSUs and 19,296 RSUs on March 1, 2019, 2020 and 2021, respectively, except for the non-management director who was newly appointed in September 2021 who will begin receiving RSUs effective March 1, 2022. Each of the 2019, 2020 and 2021 grants had a grant date fair value of approximately $170,000. Vesting of these RSUs occurs in one-third increments on each of the first three anniversaries of the award date or upon the director’s earlier cessation of service on the board, other than for cause. Beginning with the 2020 grant, each non-management director may elect, prior to the beginning of the calendar year in which the award is granted, to defer the receipt of shares of the Company’s common stock issuable upon vesting until either his or her (i) separation from service with the Company or (ii) attainment of an age specified in advance by the non-management director. A total of four directors elected to defer the receipt of RSUs granted on March 1, 2021 to a future date, and a total of five directors elected to defer the receipt of RSUs granted on March 1, 2020 to a future date. RSUs outstanding under the 2009 Plan as of December 31, 2021, and changes during each of the years in the three-year period prior to December 31, 2021, were as follows: Shares Weighted- Average Grant Date Fair Value Unvested at December 31, 2018 397,906 $ 6.17 Granted 306,612 4.99 Vested (162,942 ) 7.42 Forfeited — — Unvested at December 31, 2019 541,576 5.13 Granted 310,347 4.93 Vested (238,184 ) 5.47 Forfeited — — Unvested at December 31, 2020 613,739 4.89 Granted 173,664 8.81 Vested (300,805 ) 5.09 Forfeited — — Unvested at December 31, 2021 486,598 6.17

Acquisitions and Divestitures

Acquisitions and Divestitures	12 Months Ended
	Dec. 31, 2021
Acquisitions And Divestitures [Abstract]
ACQUISITIONS AND DIVESTITURES	3. ACQUISITIONS AND DIVESTITURES Acquisitions The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded when identified. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired. Effective June 1, 2019, one or more subsidiaries of the Company completed the acquisition of Northwest Mississippi Medical Center in Clarksdale, Mississippi. This healthcare system includes 181 licensed beds and other outpatient and ancillary services. The total cash consideration paid for operating assets was approximately $2 million with additional consideration of $9 million in assumed liabilities, for a total consideration of $11 million. This hospital was acquired in conjunction with the bankruptcy proceedings for the previous owner that acquired the hospital from the Company in 2017 as part of an agreement with the local county government associated with its lease of the hospital building. Based on the Company’s final purchase price allocation relating to this acquisition as of December 31, 2019, no goodwill has been recorded. Prior to the completion of the acquisition, the Company initiated a plan to sell this hospital and as such the hospital was classified as held for sale at December 31, 2019 and 2020. This disposition was completed on February 1, 2021. Other Acquisitions During the years ended December 31, 2021, 2020 and 2019, one or more subsidiaries of the Company paid approximately $3 million, $1 million and $8 million, respectively, to acquire the operating assets and related businesses of certain physician practices, clinics and other ancillary businesses that operate within the communities served by the Company’s affiliated hospitals. In connection with these acquisitions, during the year ended December 31, 2021, the Company allocated the purchase price to property and equipment, working capital, noncontrolling interests and goodwill, and d he Company allocated the majority of the purchase price to goodwill. Divestitures The following table provides a summary of hospitals that the Company divested during the years ended December 31, 2021, 2020 and 2019. Hospital Buyer City, State Licensed Beds Effective Date 2021 Divestitures: Lea Regional Medical Center Covenant Health System Hobbs, NM 84 January 1, 2021 Tennova Healthcare - Tullahoma Vanderbilt University Medical Center Tullahoma, TN 135 January 1, 2021 Tennova Healthcare - Shelbyville Vanderbilt University Medical Center Shelbyville, TN 60 January 1, 2021 Northwest Mississippi Medical Center Delta Health System Clarksdale, MS 181 February 1, 2021 AllianceHealth Midwest SSM Health Care of Oklahoma, Inc. Midwest City, OK 255 April 1, 2021 2020 Divestitures: Berwick Hospital Center Fayette Holdings, Inc. Berwick, PA 90 December 1, 2020 Brownwood Regional Medical Center Hendrick Health System Brownwood, TX 188 October 27, 2020 Abilene Regional Medical Center Hendrick Health System Abilene, TX 231 October 27, 2020 San Angelo Community Medical Center Shannon Health System San Angelo, TX 171 October 24, 2020 Bayfront Health St. Petersburg Orlando Health, Inc. St. Petersburg, FL 480 October 1, 2020 Hill Regional Hospital AHRK Holdings, LLC Hillsboro, TX 25 August 1, 2020 St. Cloud Regional Medical Center Orlando Health, Inc. St. Cloud, FL 84 July 1, 2020 Northern Louisiana Medical Center Allegiance Health Management, Inc. Ruston, LA 130 July 1, 2020 Shands Live Oak Regional Medical Center HCA Live Oak, FL 25 May 1, 2020 Shands Starke Regional Medical Center HCA Starke, FL 49 May 1, 2020 Southside Regional Medical Center Bon Secours Mercy Health System Petersburg, VA 300 January 1, 2020 Southampton Memorial Hospital Bon Secours Mercy Health System Franklin, VA 105 January 1, 2020 Southern Virginia Regional Medical Center Bon Secours Mercy Health System Emporia, VA 80 January 1, 2020 2019 Divestitures: Bluefield Regional Medical Center Princeton Community Hospital Association Bluefield, WV 92 October 1, 2019 Lake Wales Medical Center Adventist Health System Lake Wales, FL 160 September 1, 2019 Heart of Florida Regional Medical Center Adventist Health System Davenport, FL 193 September 1, 2019 College Station Medical Center St. Joseph Regional Health Center College Station, TX 167 August 1, 2019 Tennova Healthcare - Lebanon Vanderbilt University Medical Center Lebanon, TN 245 August 1, 2019 Chester Regional Medical Center Medical University Hospital Authority Chester, SC 82 March 1, 2019 Carolinas Hospital System - Florence Medical University Hospital Authority Florence, SC 396 March 1, 2019 Springs Memorial Hospital Medical University Hospital Authority Lancaster, SC 225 March 1, 2019 Carolinas Hospital System - Marion Medical University Hospital Authority Mullins, SC 124 March 1, 2019 Memorial Hospital of Salem County Community Healthcare Associates, LLC Salem, NJ 126 January 31, 2019 Mary Black Health System - Spartanburg Spartanburg Regional Healthcare System Spartanburg, SC 207 January 1, 2019 Mary Black Health System - Gaffney Spartanburg Regional Healthcare System Gaffney, SC 125 January 1, 2019 The following table discloses amounts included in the consolidated balance sheets for the hospitals classified as held for sale as of December 31, 2020 (in millions). Other assets, net primarily includes the net property and equipment for hospitals held for sale. No hospitals were classified as held for sale as of December 31, 2021 and no divestitures or potential divestitures meet the criteria for reporting as a discontinued operation as of December 31, 2021, 2020, or 2019. December 31, 2020 Other current assets $ 12 Other assets, net 11 Accrued liabilities 16 Financial and statistical data reported in th is Form 10-K includes operating results for the hospitals that were divested during 20 21, 2020 and 201 9 through the effective date of each respective transaction . Summary financial results of these hospitals for the periods included in the accompanying consolidated statements of income (loss) are as follows (in millions): Year Ended December 31, 2021 2020 2019 (Loss) income before income taxes $ (36 ) $ 83 $ (61 ) Less: Loss attributable to noncontrolling interests — (6 ) (8 ) (Loss) income from operations before income taxes attributable to Community Health Systems, Inc. stockholders $ (36 ) $ 89 $ (53 ) The operating results for these divested hospitals included net impairment charges and (gain) loss on disposal of approximately $29 million, $(80) million and $(5) million during the years ended December 31, 2021, 2020 and 2019, respectively. On November 30, 2020, one or more subsidiaries of the Company completed the sale of 50% ownership interest in Merit Health Biloxi (153 licensed beds) and its associated healthcare businesses in Biloxi, Mississippi to Memorial Properties, Inc., an affiliate of Memorial Hospital of Gulfport pursuant to the terms of a definitive agreement which was entered into on October 12, 2020. Merit Health Biloxi and its associated healthcare businesses remain consolidated entities of the Company. Other Hospital Closures Effective September 30, 2020, one or more affiliates of the Company finalized an agreement to terminate the lease and cease operations of Shands Lake Shore Regional Medical Center (99 licensed beds) in Lake City, Florida, including transferring leased assets back to the landlord, the Lake Shore Hospital Authority. The Company recorded an impairment charge of approximately $3 million during the year ended December 31, 2020 in conjunction with exiting the lease to operate this hospital.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	4. GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows (in millions): Balance, beginning balance 2021 2020 Goodwill $ 7,033 $ 7,142 Accumulated impairment losses (2,814 ) (2,814 ) 4,219 4,328 Goodwill acquired as part of acquisitions during current year 5 1 Goodwill allocated to hospitals divested or held for sale (5 ) (110 ) Balance, end of year Goodwill 7,033 7,033 Accumulated impairment losses (2,814 ) (2,814 ) $ 4,219 $ 4,219 Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segment meets the criteria to be classified as a reporting unit. At December 31, 2021, after giving effect to 2021 acquisition and divestiture activity, the Company had approximately $4.2 billion of goodwill recorded. Goodwill is evaluated for impairment annually and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. The Company performed its last annual goodwill impairment evaluation during the fourth quarter of 2021 using an October 31, 2021 measurement date, which indicated no impairment. The Company estimates the fair value of the reporting unit using both a discounted cash flow model as well as a market multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions. The determination of fair value in the Company’s goodwill impairment analysis is based on an estimate of fair value for the reporting unit utilizing known and estimated inputs at the evaluation date. Some of those inputs include, but are not limited to, the most recent price of the Company’s common stock and fair value of long-term debt, estimates of future revenue and expense growth, estimated market multiples, expected capital expenditures, income tax rates, and costs of invested capital. A detailed evaluation of potential impairment indicators was performed as of December 31, 2021, which specifically considered the volatility of the fair market value of the Company’s outstanding senior secured and unsecured notes and common stock during the year ended December 31, 2021. On the basis of available evidence as of December 31, 2021, no indicators of impairment were identified. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the assumptions described above changes materially in the future, including a decline in the Company’s stock price and the fair value of its long-term debt, an increase in the volatility of the Company’s stock price and the fair value of its long-term debt, lower than expected hospital volumes and/or net operating revenues, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value, the risks of which may be amplified by the COVID-19 pandemic, could result in a material impairment charge in the future. The determination of fair value of the Company’s hospital operations reporting unit as part of its goodwill impairment measurement represents a Level 3 fair value measurement in the fair value hierarchy due to its use of internal projections and unobservable measurement inputs. Intangible Assets No intangible assets other than goodwill were acquired during the years ended December 31, 2021 and 2020. The gross carrying amount of the Company’s other intangible assets subject to amortization was $1 $1 The weighted-average remaining amortization period for the intangible assets subject to amortization is approximately three years. There are no expected residual values related to these intangible assets. Amortization expense on these intangible assets was less than $1 million, less than $1 million and $1 million during the years ended December 31, 2021, 2020 and 2019, respectively. Amortization expense on intangible assets is estimated to be less than $1 million in 2022. The gross carrying amount of capitalized software for internal use was approximately $992 million and $1.1 billion at December 31, 2021 and 2020, respectively, and the net carrying amount was approximately $215 million and $251 million at December 31, 2021 and 2020, respectively. The estimated amortization period for capitalized internal-use software is generally three years. There is no expected residual value for capitalized internal-use software. At December 31, 2021, there were approximately $79 million of capitalized costs for internal-use software that is currently in the development stage and will begin amortization once the software project is complete and ready for its intended use. Amortization expense on capitalized internal-use software was $108 million, $123 million and $121 million during the years ended December 31, 2021, 2020 and 2019, respectively. Amortization expense on capitalized internal-use software is estimated to be $90 million in 2022, $62 million in 2023, $40 million in 2024, $9 million in 2025, $7 million in 2026 and $7 million thereafter.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	5. INCOME TAXES The provision for (benefit from) income taxes consists of the following (in millions): Year Ended December 31, 2021 2020 2019 Current: Federal $ (46 ) $ (1 ) $ (38 ) State 6 3 (5 ) (40 ) 2 (43 ) Deferred: Federal 161 (162 ) 179 State 10 (25 ) 24 171 (187 ) 203 Total provision for (benefit from) income taxes for income (loss) $ 131 $ (185 ) $ 160 The following table reconciles the differences between the statutory federal income tax rate and the effective tax rate (dollars in millions): Year Ended December 31, 2021 2020 2019 Amount % Amount % Amount % Provision for (benefit from) income taxes at statutory federal rate $ 105 21.0 % $ 89 21.0 % $ (90 ) 21.0 % State income taxes, net of federal income tax benefit 44 8.7 (15 ) (3.6 ) (104 ) 24.3 Net income attributable to noncontrolling interests (29 ) (5.8 ) (20 ) (4.7 ) (18 ) 4.2 Change in valuation allowance 33 6.8 (267 ) (63.2 ) 340 (79.2 ) Nondeductible goodwill — — 41 9.8 11 (2.6 ) Amended return adjustments (22 ) (4.4 ) — — — — Nondeductible loss on divestiture — — (15 ) (3.4 ) 15 (3.5 ) Other — — 2 0.3 6 (1.4 ) Provision for (benefit from) income taxes and effective tax rate for income (loss) $ 131 26.3 % $ (185 ) (43.8 )% $ 160 (37.2 )% The Company’s effective tax rates were 26.3%, (43.8)% and (37.2)% for the years ended December 31, 2021, 2020 and 2019, respectively. The increase in the Company’s effective tax rate for the year ended December 31, 2021, when compared to the year ended December 31, 2020, was primarily due to a decrease in the valuation allowance in 2020 as a result of an increase to the deductible interest expense allowed for 2019 and 2020 under the CARES Act; the CARES Act related benefits for deductibility of interest recognized in 2020 did not reoccur in 2021. The decrease in the Company’s effective tax rate for the year ended December 31, 2020, when compared to the year ended December 31, 2019, was primarily due to a decrease in the valuation allowance recognized on IRC Section 163(j) interest carryforwards and original issue discount deferred tax asset as a result of (i) an increase to the deductible interest expense allowed for 2019 and 2020 under the CARES Act and (ii) tax impacts of 2020 financing activity Deferred income taxes are based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities under the provisions of the enacted tax laws. Deferred income taxes as of December 31, 2021 and 2020 consist of (in millions): December 31, 2021 2020 Assets Liabilities Assets Liabilities Net operating loss and credit carryforwards $ 833 $ — $ 873 $ — Property and equipment — 343 — 300 Self-insurance liabilities 49 — 58 — Prepaid expenses — 30 — 29 Intangibles — 144 — 127 Investments in unconsolidated affiliates — 58 — 57 Other liabilities — 9 — 9 IRC Section 481(a) - mixed service cost — — — 106 Long-term debt and interest 48 — 154 — Accounts receivable 22 — 52 — IRC Section 163(j) interest limitation 329 — 108 — Accrued vacation 22 — 22 — Accrued bonus 31 — 32 — Other comprehensive income 5 — 6 — Right-of-use assets — 137 — 150 Right-of-use liability 142 — 155 — Stock-based compensation 4 — 4 — Deferred compensation 64 — 69 — IRC Section 481(a) Adjustments — 191 — — Other 38 — 57 — Total 1,587 912 1,590 778 Valuation allowance (814 ) — (781 ) — Total deferred income taxes $ 773 $ 912 $ 809 $ 778 The Company believes that the net deferred tax assets will ultimately be realized, except as noted below. Its conclusion is based on its estimate of future taxable income and the expected timing of temporary difference reversals. The Company has gross federal net operating loss carryforwards of approximately $763 million and state net operating loss carryforwards of approximately $9.4 billion, which expire from 2022 to 2041. The Company’s tax affected federal and state net operating loss and credit carryforwards are approximately $195 million and $638 million, respectively. A valuation allowance of approximately $814 million has been recognized for state net operating loss carryforwards, state credit carryforwards and federal and state deferred tax assets that the Company does not expect to be able to utilize prior to the expiration of the carryforward period. With respect to the deferred tax liability pertaining to intangibles, as included above, goodwill purchased in connection with certain of the Company’s business acquisitions is amortizable for income tax reporting purposes. However, for financial reporting purposes, there is no corresponding amortization allowed with respect to such purchased goodwill. The valuation allowance for federal and state jurisdictions where the Company concluded that the associated deferred tax assets would not be realized increased by $64 million and decreased by $31 million, respectively, for the year ended December 31, 2021, and decreased by $265 million and $2 million, respectively, for the year ended December 31, 2020. The total amount of unrecognized benefit that would affect the effective tax rate, if recognized, was less than $1 million as of December 31, 2021. A total of less than $1 million of interest and penalties is included in the amount of the liability for uncertain tax positions at December 31, 2021. It is the Company’s policy to recognize interest and penalties related to unrecognized benefits in its consolidated statements of income (loss) as income tax expense. It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, the Company does not anticipate the change will have a material impact on the Company’s consolidated results of operations or consolidated financial position. The following is a tabular reconciliation of the total amount of unrecognized tax benefit for the years ended December 31, 2021, 2020 and 2019 (in millions): Year Ended December 31, 2021 2020 2019 Unrecognized tax benefit, beginning of year $ 45 $ 26 $ 29 Gross increases — tax positions in current period 5 19 10 Reductions — tax positions in prior period (8 ) — — Settlements — — (13 ) Unrecognized tax benefit, end of year $ 42 $ 45 $ 26 The Company’s income tax return for the 2018 tax year remains under examination by the Internal Revenue Service. The Company believes the result of this examination will not be material to its consolidated results of operations or consolidated financial position. The Company has extended the federal statute of limitations through June 30, 2022 for Community Health Systems, Inc. for the tax periods ended December 31, 2014 and 2015. In addition, the Company has extended the federal statute of limitations through December 31, 2023 for the tax period ended December 31, 2018. Cash paid for income taxes, net of refunds received, resulted in net cash paid of $4 million, net cash paid of $2 million and net cash refund of $3 million during the years ended December 31, 2021, 2020 and 2019, respectively.

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2021
Long Term Debt And Capital Lease Obligations [Abstract]
LONG-TERM DEBT	6. LONG-TERM DEBT Long-term debt, net of unamortized debt issuance costs and discounts or premiums, consists of the following (in millions): December 31, 2021 2020 6⅞ $ — $ 126 6¼ — 95 8⅝ — 1,033 6⅝ 1,462 1,462 8% Senior Secured Notes due 2026 2,101 2,101 8% Senior Secured Notes due 2027 700 700 5⅝ 1,900 1,900 6⅞ 767 767 6% Senior Secured Notes due 2029 900 900 4¾ 1,095 — 9⅞ — 1,769 8⅛ — 1,348 6⅞ 1,775 — 6⅛ 1,440 — ABL Facility — — Finance lease and financing obligations 398 239 Other 37 26 Less: Unamortized deferred debt issuance costs and note premium (435 ) (250 ) Total debt 12,140 12,216 Less: Current maturities (31 ) (123 ) Total long-term debt $ 12,109 $ 12,093 6⅞% Senior Notes due 2022 On January 27, 2014, CHS/Community Health Systems, Inc. (“CHS”) completed a private offering of $3.0 billion aggregate principal amount of 6⅞% Senior Notes due February 1, 2022 (the “6⅞% Senior Notes due 2022”). The net proceeds from this issuance were used to finance the Company’s acquisition by merger of Health Management Associates, Inc. (“HMA”). The 6⅞% Senior Notes due 2022 bore interest at a rate of 6.875% per annum, payable semiannually in arrears on February 1 and August 1 of each year. Interest on the 6⅞% Senior Notes due 2022 accrued from the date of original issuance. Interest was calculated on the basis of a 360-day year comprised of twelve 30-day months. T he 6⅞% Senior Notes due 2022 were unconditionally guaranteed on a senior-priority unsecured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the revolving asset-based loan facility (the “ ABL Facility ”) , any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS. CHS was entitled, at its option, to redeem all or a portion of the 6⅞% Senior Notes due 2022 upon not less than 30 nor more than 60 days’ notice, at a redemption price of 100% (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed prior to the maturity date. Pursuant to a registration rights agreement entered into at the time of the issuance of the 6⅞% Senior Notes due 2022, as a result of an exchange offer made by CHS, all of the 6⅞% Senior Notes due 2022 issued in January 2014 were exchanged in October 2014 for new notes (the “6⅞% Exchange Notes”) having terms substantially identical in all material respects to the 6⅞% Senior Notes due 2022 (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act). References to the 6⅞% Senior Notes due 2022 shall be deemed to be the 6⅞% Exchange Notes unless the context provides otherwise. On June 22, 2018, CHS issued approximately $276 million aggregate principal amount of the 8⅛% Junior-Priority Secured Notes due 2024 in exchange for approximately $368 million of 6⅞% Senior Notes due 2022. On November 19, 2019, CHS issued approximately $700 million aggregate principal amount of 8% Senior Secured Notes due December 15, 2027 and approximately $1.7 billion aggregate principal amount of 6⅞% Senior Notes due April 1, 2028 in exchange for approximately $2.4 billion of 6⅞% Senior Notes due 2022 (the “2019 Exchange Offer”). Following the 2019 Exchange Offer, CHS had approximately $231 million aggregate principal amount of 6⅞% Senior Notes due 2022 outstanding. During the year ended December 31, 2020, the Company extinguished $34 million in principal related to the 6⅞% Senior Notes due 2022 through open market repurchases and approximately $72 million via a tender offer which commenced on October 30, 2020, and expired on November 30, 2020. On March 1, 2021, the Company redeemed the remaining principal amount of the 6⅞% Senior Notes due 2022 using cash on hand. 6¼% Senior Secured Notes due 2023 On March 16, 2017, CHS completed a public offering of $2.2 billion aggregate principal amount of 6¼% Senior Secured Notes due March 31, 2023 (the “6¼% Senior Secured Notes due 2023”). The net proceeds from this issuance were used to finance the purchase or redemption of $700 million aggregate principal amount of CHS’ then outstanding 5⅛% Senior Secured Notes due 2018 and related fees and expenses, and the repayment of $1.445 billion of the then outstanding Term F Facility. On May 12, 2017, CHS completed a tack-on offering of $900 million aggregate principal amount of 6¼% Senior Secured Notes due 2023, increasing the total aggregate principal amount of 6¼% Senior Secured Notes due 2023 to $3.1 billion. A portion of the net proceeds from this issuance were used to finance the repayment of approximately $713 million aggregate principal amount of CHS’ then outstanding Term A Facility and related fees and expenses. The tack-on notes had identical terms, other than issue date and issue price, as the 6¼% Senior Secured Notes due 2023 issued on March 16, 2017. The 6¼% Senior Secured Notes due 2023 bore interest at a rate of 6.250% per annum, payable semiannually in arrears on March 31 and September 30 of each year. Interest on the 6¼% Senior Secured Notes due 2023 accrued from the date of original issuance. Interest was calculated on the basis of a 360-day year comprised of twelve 30-day months. The 6¼% Senior Secured Notes due 2023 are scheduled to mature on March 31, 2023. The 6¼% Senior Secured Notes due 2023 were unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS. The 6¼% Senior Secured Notes due 2023 and the related guarantees were secured by shared (i) first-priority liens on the collateral (the “Non-ABL Priority Collateral”) that also secures on a first-priority basis CHS’s senior-priority secured notes and (ii) second-priority liens on the collateral (the “ABL-Priority Collateral”), in each case subject to permitted liens described in the indenture governing the 6¼% Senior Secured Notes due 2023. CHS was entitled, at its option, to redeem all or a portion of the 6¼% Senior Secured Notes due 2023 at any time prior to March 31, 2020, upon not less than 30 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 6¼% Senior Secured Notes due 2023 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 6¼% Senior Secured Notes due 2023. In addition, CHS had the option to redeem up to 40% of the aggregate principal amount of the 6¼% Senior Secured Notes due 2023 at any time prior to March 31, 2020 using the net proceeds from certain equity offerings at the redemption price of 106.250 % of the principal amount of the 6¼% Senior Secured Notes due 2023 redeemed, plus accrued and unpaid interest, if any. CHS had the option to redeem some or all of the 6¼% Senior Secured Notes due 2023 at any time on or after March 31, 2020 upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price March 31, 2020 to March 30, 2021 103.125 % March 31, 2021 to March 30, 2022 101.563 % March 31, 2022 to March 30, 2023 100.000 % Approximately $426 million aggregate principal amount of 6¼% Senior Secured Notes due 2023 were purchased in one or more privately negotiated transactions on February 6, 2020. On December 28, 2020, the Company redeemed approximately $2.579 billion of the 6¼% Senior Secured Notes due 2023 using proceeds from the issuance of $1.9 billion aggregate principal amount of 5⅝% Senior Secured Notes due 2027 and $900 million aggregate principal amount of 6% Senior Secured Notes due 2029. The remaining principal value of 6¼% Senior Secured Notes due 2023 that were not redeemed on December 28, 2020 of approximately $95 million were redeemed on January, 28, 2021 using cash on hand. 9⅞% Junior-Priority Secured Notes due 2023 On June 22, 2018, CHS completed a private offering of $1.770 billion aggregate principal amount of the 9⅞% Junior-Priority Secured Notes due June 30, 2023 (the “9⅞% Junior-Priority Secured Notes due 2023”) in exchange for the same amount of 8% Senior Notes due 2019. The 9⅞% Junior-Priority Secured Notes due 2023 bore interest at a rate of 11.000% per annum, solely for the period from the issue date of such 9⅞% Junior-Priority Secured Notes due 2023 to, but excluding, June 22, 2019, after which they bore interest at a rate of 9.875% per annum. Interest was payable semi-annually in arrears on June 30 and December 31 of each year. The 9⅞% Junior-Priority Secured Notes due 2023 were scheduled to mature on June 20, 2023. The 9⅞% Junior-Priority Secured Notes due 2023 were unconditionally guaranteed on a junior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS᾿ ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS. The 9⅞% Junior-Priority Secured Notes due 2023 and the related guarantees were secured by shared (i) second-priority liens on the Non-ABL Priority Collateral that secures on a first-priority basis the CHS’s senior-priority secured notes and (ii) third-priority liens on the ABL-Priority Collateral that secures on a first-priority basis the ABL Facility (and also secures on a second-priority basis CHS’s senior-priority secured notes), in each case subject to permitted liens described in the indenture governing the 9⅞% Junior-Priority Secured Notes due 2023. Prior to June 30, 2020, CHS may redeem some or all of the 9⅞% Junior-Priority Secured Notes due 2023 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 9⅞% Junior-Priority Secured Notes due 2023. In addition, at any time prior to June 30, 2020, CHS had the option to redeem up to 40% of the aggregate principal amount of the with the proceeds from certain equity offerings at the redemption price of 109.875%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date. After June 30, 2020, CHS was entitled, at its option, to redeem all or a portion of the 9⅞% Junior-Priority Secured Notes due 2023 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price June 30, 2020 to June 29, 2021 107.406 % June 30, 2021 to June 29, 2022 103.703 % June 30, 2022 to June 29, 2023 100.000 % The Company redeemed approximately $2 million of the 9⅞% Junior-Priority Secured Notes due 2023 via a tender offer which commenced on October 30, 2020, and expired on November 30, 2020. In conjunction with the issuance of $1.775 billion aggregate principal amount of 6⅞% Junior-Priority Secured Notes due 2029, all remaining 9⅞% Junior-Priority Secured Notes due 2023 were purchased pursuant to a tender offer on February 2, 2021 or, to the extent not tendered, pursuant to a notice of redemption as completed on February 4, 2021. 8⅛% Junior-Priority Secured Notes due 2024 On June 22, 2018, CHS completed a private offering of $1.355 billion aggregate principal amount of the 8⅛% Junior-Priority Secured Notes due June 30, 2024 (the “8⅛% Junior-Priority Secured Notes due 2024”) in exchange for approximately $1.079 billion of 7⅛% Senior Notes due 2020 and approximately $368 million of 6⅞% Senior Notes due 2022. The 8⅛% Junior-Priority Secured Notes due 2024 bore interest at a rate of 8.125% per annum, payable semi-annually in arrears on June 30 and December 31 of each year. The 8⅛% Junior-Priority Secured Notes due 2024 were scheduled to mature on June 20, 2024. The 8⅛% Junior-Priority Secured Notes due 2024 were unconditionally guaranteed on a junior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS᾿ ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS. The 8⅛% Junior-Priority Secured Notes due 2024 and the related guarantees were secured by shared (i) second-priority liens on the Non-ABL Priority Collateral that secures on a first-priority basis the CHS’s senior-priority secured notes and (ii) third-priority liens on the ABL-Priority Collateral that secures on a first-priority basis the ABL Facility (and also secures on a second-priority basis CHS’s senior-priority secured notes), in each case subject to permitted liens described in the indenture governing the 8⅛% Junior-Priority Secured Notes due 2024. Prior to June 30, 2021, CHS had the option to redeem some or all of the 8⅛% Junior-Priority Secured Notes due 2024 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8⅛% Junior-Priority Secured Notes due 2024. In addition, at any time prior to June 30, 2021, CHS had the option to redeem up to 40% of the aggregate principal amount of the 8⅛% Junior-Priority Secured Notes due 2024 with the proceeds from certain equity offerings at the redemption price of 108.125%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date. After June 30, 2021, CHS was entitled, at its option, to redeem all or a portion of the 8⅛% Junior-Priority Secured Notes due 2024 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price June 30, 2021 to June 29, 2022 104.063 % June 30, 2022 to June 29, 2023 102.031 % June 30, 2023 to June 29, 2024 100.000 % The indentures governing each of the and 8 % Junior-Priority Secured Notes due 2024 also prohibited CHS from purchasing, repurchasing, redeeming, defeasing or otherwise acquiring or retiring any outstanding with: (a) cash or cash equivalents on hand as of the consummation of such 2018 exchange offers; (b) cash generated from operations; (c) proceeds from assets sales; or (d) proceeds from the issuance of, or in exchange for, secured debt, in each case, prior to May 15, 2020. CHS received a waiver from requisite holders of each series of the and 8 % Junior-Priority Secured Notes due 2024 waiving these restrictions prior to consummating the 2019 Exchange Offer. During the year ended December 31, 2020, the Company extinguished $1 million in principal related to the 8⅛% Junior-Priority Secured Notes due 2024 through open market repurchases and approximately $6 million via a tender offer which commenced on October 30, 2020, and expired on November 30, 2020. On May 19, 2021, CHS redeemed the remaining principal amount of the 8⅛% Junior-Priority Secured Notes due 2024 using proceeds from the issuance of the 6⅛% Junior-Priority Secured Notes due 2030 on May 19, 2021. 8⅝% Senior Secured Notes due 2024 On July 6, 2018, CHS completed a private The 8⅝% Senior Secured Notes due 2024 and the related guarantees were secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 8⅝% Senior Secured Notes due 2024. Prior to January 15, 2021, CHS had the option to redeem some or all of the 8⅝% Senior Secured Notes due 2024 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8⅝% Senior Secured Notes due 2024. In addition, at any time prior to January 15, 2021, CHS had the option to redeem up to 40% of the aggregate principal amount of the 8⅝% Senior Secured Notes due 2024 with the proceeds from certain equity offerings at the redemption price of 108.625%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date. After January 15, 2021, CHS was entitled, at its option, to redeem all or a portion of the 8⅝% Senior Secured Notes due 2024 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price January 15, 2021 to January 14, 2022 104.313 % January 15, 2022 to January 14, 2023 102.156 % January 15, 2023 to January 14, 2024 100.000 % In conjunction with the issuance of $1.095 billion aggregate principal amount of 4¾% Senior Secured Notes due February 15, 2031, all remaining 8⅝% Senior Secured Notes due 2024 were redeemed on February 9, 2021. 6⅝% Senior Secured Notes due 2025 On February 6, 2020, CHS completed a private offering of $1.462 billion aggregate principal amount of 6⅝% Senior Secured Notes due February 15, 2025 (the “6⅝% Senior Secured Notes due 2025”). CHS used the net proceeds of the offering of the 6⅝% Senior Secured Notes due 2025 to (i) purchase any and all of its 5⅛% Senior Secured Notes due 2021 validly tendered and not validly withdrawn in the cash tender offer announced on January 23, 2020, (ii) redeem all of the 5⅛% Senior Secured Notes due 2021 that were not purchased pursuant to such tender offer, (iii) purchase in one or more privately negotiated transactions approximately $426 million aggregate principal amount of its 6¼% Senior Secured Notes due 2023 and (iv) pay related fees and expenses. The 6⅝% Senior Secured Notes due 2025 bear interest at a rate of 6.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year, commencing on August 15, 2020. The 6⅝% Senior Secured Notes are scheduled to mature on February 15, 2025. The 6⅝% Senior Secured Notes due 2025 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS. The 6⅝% Senior Secured Notes due 2025 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 6⅝% Senior Secured Notes due 2025. At any time prior to February 15, 2022, CHS may redeem some or all of the 6⅝% Senior Secured Notes due 2025 at a price equal to 100% of their principal amount plus accrued and unpaid interest, if any, to, but excluding the applicable redemption date plus a make-whole premium as defined in the indenture agreement dated February 6, 2020. After February 15, 2022, CHS is entitled, at its option, to redeem some or all of the 6⅝% Senior Secured Notes at a redemption price equal to the percentage of principal amount below plus accrued and unpaid interest, if any, to, but excluding the applicable redemption date, if redeemed during the twelve-month period beginning on February 15 of the years set forth below: Period Redemption Price February 15, 2022 to February 14, 2023 103.313 % February 15, 2023 to February 14, 2024 101.656 % February 15, 2024 to February 14, 2025 100.000 % As further described in Note 16 and in conjunction with the issuance of $1.535 billion aggregate principal amount of 5¼% Senior Secured Notes due May 15, 2030, all 6⅝% Senior Secured Notes due 2025 were redeemed on February 4, 2022. 8% Senior Secured Notes due 2026 On March 6, 2019, CHS completed a private The 8% Senior Secured Notes due 2026 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS. The 8% Senior Secured Notes due 2026 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 8% Senior Secured Notes due 2026. Prior to March 15, 2022, CHS may redeem some or all of the 8% Senior Secured Notes due 2026 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8% Senior Secured Notes due 2026. In addition, at any time prior to March 15, 2022, CHS may redeem up to 40% of the aggregate principal amount of the 8% Senior Secured Notes due 2026 with the proceeds from certain equity offerings at the redemption price of 108.000%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date. After March 15, 2022, CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Secured Notes due 2026 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price March 15, 2022 to March 14, 2023 104.000 % March 15, 2023 to March 14, 2024 102.000 % March 15, 2024 to March 14, 2026 100.000 % 8% Senior Secured Notes due 2027 On November 19, 2019, CHS issued approximately $700 million aggregate principal amount of the 8% Senior Secured Notes due December 15, 2027 (the “8% Senior Secured Notes due 2027”) in connection with the 2019 Exchange Offer. No cash proceeds were received from the 2019 Exchange Offer. The 8% Senior Secured Notes due 2027 bear interest at a rate of 8.000% per annum, payable semi-annually in arrears on June 15 and December 15 of each year. Interest on the 8% Senior Secured Notes due 2027 accrues from the initial issuance date of the 8% Senior Secured Notes due 2027. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 8% Senior Secured Notes due 2027 are scheduled to mature on December 15, 2027. The 8% Senior Secured Notes due 2027 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of CHS ’ current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt se curities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS. The 8% Senior Secured Notes due 2027 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 8% Senior Secured Notes due 2027. CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Secured Notes due 2027 at any time prior to December 15, 2022, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 8% Senior Secured Notes due 2027 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8% Senior Secured Notes due 2027. In addition, CHS may redeem up to 40% of the aggregate principal amount of the 8% Senior Secured Notes due 2027 at any time prior to December 15, 2022 using the net proceeds from certain equity offerings at the redemption price of 108.000% of the principal amount of the 8% Senior Secured Notes due 2027 redeemed, plus accrued and unpaid interest, if any. CHS may redeem some or all of the 8% Senior Secured Notes due 2027 at any time on or after December 15, 2022 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price December 15, 2022 to December 14, 2023 104.000 % December 15, 2023 to December 14, 2024 102.000 % December 15, 2024 to December 14, 2027 100.000 % 5⅝% Senior Secured Notes due 2027 On December 28, 2020, CHS completed a private offering of $1.9 billion aggregate principal amount of 5⅝% Senior Secured Notes due March 15, 2027 (the “5⅝% Senior Secured Notes due 2027”). The proceeds of the offering were used to repurchase approximately $2.579 billion of the outstanding principal amount of 6¼% Senior Secured Notes due 2023 that were validly tendered and accepted for purchase pursuant to the early tender deadline of a tender offer that launched on December 11, 2020, and to pay related fees. The remaining principal value of 6¼% Senior Secured Notes due 2023 that were not validly tendered as of the early tender deadline were redeemed or repurchased via the completion of the tender offer on January 11, 2021 or redemption on January, 28, 2021. The , which mature on March 15, 2027, bear interest at a rate of 5⅝% per year payable semi-annually in arrears on March 15 and September 15 of each year, commencing on September 15, 2021. The are unconditionally guaranteed on a senior-priority secured basis by the Company and each of CHS’ current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS. The 5⅝% Senior Secured Notes due 2027 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 5⅝% Senior Secured Notes due 2027. CHS is entitled, at its option, to redeem all or a portion of the 5⅝% Senior Secured Notes due 2027 at any time prior to December 15, 2023, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 5⅝% Senior Secured Notes due 2027 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 5⅝% Senior Secured Notes due 2027. In addition, CHS may redeem up to 40% of the aggregate principal amount of the 5⅝% Senior Secured Notes due 2027 at any time prior to December 15, 2023 using the net proceeds from certain equity offerings at the redemption price of 105.625% of the principal amount of the 5⅝% Senior Secured Notes due 2027 redeemed, plus accrued and unpaid interest, if any. At any time and from time to time on or after December 15, 2023, CHS may redeem the 5⅝% Senior Secured Notes due 2027 in whole or in part, upon not less than 15 no more than 60 days’ prior written notice at a redemption price equal to the percentage of principal amount set forth below plus accrued and unpaid interest, if any, on the 5⅝% Senior Secured Notes due 2027 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the twelve-month period beginning on December 15 of the years indicated below: Period Redemption Price December 15, 2023 to December 14, 2024 102.813 % December 15, 2024 to December 14, 2025 101.406 % December 15, 2025 to December 14, 2027 100.000 % 6⅞% Senior Notes due 2028 On November 19, 2019, CHS issued approximately $1.7 billion aggregate principal amount of the 6⅞% Senior Notes due April 1, 2028 (“the 6⅞% Senior Notes due 2028”) in connection with the 2019 Exchange Offer. No cash proceeds were received in the 2019 Exchange Offer. The 6⅞% Senior Notes due 2028 bear interest at a rate of 6.875% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. Interest on the 6⅞% Senior 2028 Notes accrues from the initial issuance date of the 6⅞% Senior Notes due 2028. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 6⅞% Senior Notes due 2028 are scheduled to mature on April 1, 2028. The 6⅞% Senior Notes due 2028 are unconditionally guaranteed on a senior-priority unsecured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS. CHS is entitled, at its option, to redeem all or a portion of the 6⅞% Senior Notes due 2028 at any time prior to April 1, 2023, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 6⅞% Senior Notes due 2028 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 6⅞% Senior Notes due 2028. In addition, the Issuer may redeem up to 40% of the aggregate principal amount of the 6⅞% Senior Notes due 2028 at any time prior to April 1, 2023 using the net proceeds from certain equity offerings at the redemption price of 106.875% of the principal amount of the 6⅞% Senior Notes due 2028 redeemed, plus accrued and unpaid interest, if any. CHS may redeem some or all of the 6⅞% Senior Notes due 2028 at any time on or after April 1, 2023 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price April 1, 2023 to March 31, 2024 103.438 % April 1, 2024 to March 31, 2025 101.719 % April 1, 2025 to March 31, 2028 100.000 % On December 7, 2020, CHS entered into a privately negotiated agreement with a multi-asset investment manager who has certain funds and accounts which are holders (the “Holders”) of the 6⅞% Senior Notes due 2028. Pursuant to the agreement, the Company exchanged $700 million aggregate principal amount of the 6⅞% Senior Notes due 2028 for an aggregate consideration of $400 million of cash and 10 million newly issued shares of the Company’s common stock. The exchange transaction was completed on December 9, 2020 and the shares of common stock issued in the exchange were not, and are not required to be, registered under the Securities Act of 1933 pursuant to an exemption from registration provisions via Section 3(a)(9) of the Securities Act of 1933. During the year ended December 31, 2020, the Company extinguished $226 million in principal of the 6⅞% S

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	7. FAIR VALUE OF FINANCIAL INSTRUMENTS The fair value of financial instruments has been estimated by the Company using available market information as of December 31, 2021 and 2020, and valuation methodologies considered appropriate. The estimates presented in the table below are not necessarily indicative of amounts the Company could realize in a current market exchange (in millions): December 31, 2021 December 31, 2020 Carrying Estimated Fair Carrying Estimated Fair Amount Value Amount Value Assets: Cash and cash equivalents $ 507 $ 507 $ 1,676 $ 1,676 Investments in equity securities 144 144 129 129 Available-for-sale debt securities 178 178 110 110 Trading securities 13 13 12 12 Liabilities: 6⅞% Senior Notes due 2022 — — 125 125 6¼% Senior Secured Notes due 2023 — — 95 99 8⅝% Senior Secured Notes due 2024 — — 1,025 1,080 6⅝% 1,434 1,517 1,427 1,543 8% 2,078 2,210 2,074 2,275 8% 692 758 692 760 5⅝% 1,819 2,011 1,809 2,048 6⅞% 759 758 758 618 6% 860 966 857 973 4¾% 1,090 1,108 — — 9⅞% Junior-Priority Secured Notes due 2023 — — 1,756 1,861 8⅛% Junior-Priority Secured Notes due 2024 — — 1,336 1,408 6⅞% 1,625 1,823 — — 6⅛% 1,352 1,431 — — ABL Facility and other debt 32 32 23 23 The carrying value of the Company’s long-term debt in the above table is presented net of unamortized deferred debt issuance costs. The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 8 . The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Cash and cash equivalents. The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months). Investments in equity securities. Estimated fair value is based on closing price as quoted in public markets. Available-for-sale debt securities. Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques. Trading securities. Estimated fair value is based on closing price as quoted in public markets. Senior Notes, Senior Secured Notes and Junior-Priority Secured Notes. Estimated fair value is based on the closing market price for these notes. ABL Facility and other debt. The carrying amount of the ABL Facility and all other debt approximates fair value due to the nature of these obligations.

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE	8. FAIR VALUE Fair Value Hierarchy Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). The inputs used to measure fair value are classified into the following fair value hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions. In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were no transfers between levels during the years ending December 31, 2021 or December 31, 2020. The following table sets forth, by level within the fair value hierarchy, the financial assets recorded at fair value on a recurring basis as of December 31, 2021 and 2020 (in millions): December 31, 2021 Level 1 Level 2 Level 3 Investments in equity securities $ 144 $ 144 $ — $ — Available-for-sale debt securities 178 — 178 — Trading securities 13 — 13 — Total assets $ 335 $ 144 $ 191 $ — December 31, 2020 Level 1 Level 2 Level 3 Investments in equity securities $ 129 $ 129 $ — $ — Available-for-sale debt securities 110 — 110 — Trading securities 12 — 12 — Total assets $ 251 $ 129 $ 122 $ — Investments in Equity Securities, Available-for-Sale Debt Securities and Trading Securities Investments in equity securities and trading securities classified as Level 1 are measured using quoted market prices. Level 2 available-for-sale debt securities and trading securities primarily consisted of bonds and notes issued by the United States government and its agencies and domestic and foreign corporations. The estimated fair values of these securities are determined using various valuation techniques, including a multi-dimensional relational model that incorporates standard observable inputs and assumptions such as benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids/offers and other pertinent reference data. Supplemental information regarding the Company’s available-for-sale debt securities (all of which had no withdrawal restrictions) is set forth in the table below (in millions): Gross Gross Estimated Amortized Unrealized Unrealized Fair Cost Gains Losses Values As of December 31, 2021: Government $ 83 $ 1 $ (1 ) $ 83 Corporate 62 — (1 ) 61 Mortgage and asset-backed securities 34 — — 34 Total available-for-sale debt securities $ 179 $ 1 $ (2 ) $ 178 Gross Gross Estimated Amortized Unrealized Unrealized Fair Cost Gains Losses Values As of December 31, 2020: Government $ 48 $ 2 $ — $ 50 Corporate 38 2 — 40 Mortgage and asset-backed securities 19 1 — 20 Total available-for-sale debt securities $ 105 $ 5 $ — $ 110 As of December 31, 2021 and 2020, investments with aggregate estimated fair values of approximately $125 million (281 investments) and $7 million (11 investments), respectively, generated the gross unrealized losses disclosed in the above table. At each reporting date, the Company performs an evaluation of impaired securities to determine if the unrealized losses are other-than-temporary. This evaluation considers a number of factors including, but not limited to, the length of time and extent to which the fair value has been less than cost, and management’s ability and intent to hold the securities until fair value recovers. Based on the results of this evaluation, management concluded that as of December 31, 2021, there were no other-than-temporary losses related to available-for-sale debt securities. The recent declines in value of the securities and/or length of time they have been below cost, as well as the Company’s ability and intent to hold the securities for a reasonable period of time sufficient for a projected recovery of fair value, have caused management to conclude that the securities, that have generated gross unrealized losses, were not other-than-temporarily impaired. Management will continue to monitor and evaluate the recoverability of the Company’s available-for-sale debt securities. The contractual maturities of debt-based securities held by the Company as of December 31, 2021 and 2020, excluding mutual fund holdings, are set forth in the table below (in millions). Expected maturities will differ from contractual maturities because the issuers of the debt securities may have the right to prepay their obligations without prepayment penalties. December 31, 2021 December 31, 2020 Amortized Estimated Amortized Estimated Cost Fair Values Cost Fair Values Within 1 year $ 8 $ 8 $ 3 $ 3 After 1 year and through year 5 61 61 26 27 After 5 years and through year 10 49 49 30 32 After 10 years 61 60 46 48 Gross realized gains and losses on sales of available-for-sale debt securities are summarized in the table below (in millions): Year Ended December 31, 2021 2020 2019 Realized gains $ 1 $ 2 $ — Realized losses (1 ) (1 ) — Other investment income, which includes interest and dividends, related to all investment securities were $5 million, $6 million and $7 million for the years ended December 31, 2021, 2020 and 2019, respectively. Net gains and losses recognized during the years ended December 31, 2021, 2020 and 2019 for investments in equity securities, which are broken out between investments sold during the year and investments held at the end of the year, are summarized in the table below (in millions): Year Ended December 31, 2021 2020 2019 Net gains and (losses), beginning of year $ 20 $ 9 $ 15 Less: Net gains and (losses) recognized during the year on equity securities sold during the year 13 14 2 Unrealized gains and (losses) recognized during the year on equity securities held, end of year $ 7 $ (5 ) $ 13

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
LEASES	9. LEASES The Company utilizes operating and finance leases for the use of certain hospitals, medical office buildings, and medical equipment. All lease agreements generally require the Company to pay maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Such costs are not included in the determination of the ROU asset or lease liability. Variable lease cost also includes escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other measures of cost inflation. Most leases include one or more options to renew the lease at the end of the initial term, with renewal terms that generally extend the lease at the then market rate of rental payment. Certain leases also include an option to buy the underlying asset at or a short time prior to the termination of the lease. All such options are at the Company’s discretion and are evaluated at the commencement of the lease, with only those that are reasonably certain of exercise included in determining the appropriate lease term. The components of lease cost and rent expense for the years ended December 31, 2021, 2020 and 2019 are as follows (in millions): Year Ended December 31, Lease Cost 2021 2020 2019 Operating lease cost: Operating lease cost $ 196 $ 203 $ 194 Short-term rent expense 92 104 114 Variable lease cost 25 26 18 Sublease income (5 ) (6 ) (5 ) Total operating lease cost $ 308 $ 327 $ 321 Finance lease cost: Amortization of ROU assets $ 9 $ 10 $ 12 Interest on finance lease liabilities 9 8 7 Total finance lease cost $ 18 $ 18 $ 19 Supplemental balance sheet information related to leases was as follows (in millions): Balance Sheet Classification December 31, 2021 December 31, 2020 Operating Leases: Operating Lease ROU Assets Other assets, net $ 668 $ 642 Finance Leases: Finance Lease ROU Assets Property and equipment Land and improvements $ 8 $ 8 Buildings and improvements 289 134 Equipment and fixtures 17 8 Property and equipment 314 150 Less accumulated depreciation and amortization (54 ) (46 ) Property and equipment, net $ 260 $ 104 Current finance lease liabilities Current maturities of long-term debt $ 8 $ 5 Long-term finance lease liabilities Long-term debt 233 74 Supplemental cash flow information related to leases for the years ended December 31, 2021, 2020 and 2019 are as follows (in millions): Year Ended December 31, Cash flow information 2021 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases (1) $ 197 $ 188 $ 167 Operating cash flows from finance leases 9 8 7 Financing cash flows from finance leases 4 7 9 ROU assets obtained in exchange for new finance lease liabilities 166 22 2 ROU assets obtained in exchange for new operating lease liabilities 143 150 122 Weighted-average remaining lease term: Operating leases 6 years 7 years 6 years Finance leases 30 years 19 years 20 years Weighted-average discount rate: Operating leases 8.1 % 9.0 % 9.1 % Finance leases 6.3 % 8.4 % 5.6 % (1) Included in the change in other operating assets and liabilities in the consolidated statements of cash flows. Commitments relating to noncancellable operating and finance leases and financing obligations for each of the next five years and thereafter are as follows (in millions): Financing Year Ending December 31, Operating Finance Obligations 2022 $ 194 $ 21 $ 12 2023 171 17 13 2024 123 16 13 2025 95 16 13 2026 75 16 13 Thereafter 236 525 89 Total minimum future payments 894 611 153 Less: Imputed interest (212 ) (370 ) 4 Total liabilities 682 241 157 Less: Current portion (147 ) (8 ) (2 ) Long-term liabilities $ 535 $ 233 $ 155 As of December 31, 2021, there were approximately $112 million of assets underlying approved but pending leases that have not yet commenced, primarily for leases of various real-estate and medical equipment.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2021
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	10. EMPLOYEE BENEFIT PLANS The Company maintains various benefit plans, including defined contribution plans, defined benefit plans and deferred compensation plans, for which certain of the Company’s subsidiaries are the plan sponsors. The CHS/Community Health Systems, Inc. Retirement Savings Plan is a defined contribution plan which covers the majority of the Company’s employees. Employees at locations whose employment is covered by collective bargaining agreements are generally eligible to participate in the CHS/Community Health Systems, Inc. Standard 401(k) Plan. Total expense to the Company under the 401(k) plans was $65 million, $74 million and $85 million for the years ended December 31, 2021, 2020 and 2019, respectively, and is recorded in salaries and benefits expense on the consolidated statements of income (loss). The Company maintains unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability for the deferred compensation plans was $175 million and $176 million as of December 31, 2021 and 2020, respectively, and is included in other long-term liabilities on the consolidated balance sheets. Assets designated to pay benefits under this plan are discussed below. The Company provides an unfunded Supplemental Executive Retirement Plan (“SERP”) for certain members of its executive management. The Company uses a December 31 measurement date for the benefit obligations and a January 1 measurement date for its net periodic costs for the SERP. Variances from actuarially assumed rates will result in increases or decreases in benefit obligations and net periodic cost in future periods. Benefits expense under the SERP was $11 million for the year ended December 31, 2021 and $7 million for both of the years ended December 31, 2020 and 2019. The accrued benefit liability for the SERP totaled $99 million and $89 million at December 31, 2021 and 2020, respectively, and is included in other long-term liabilities on the consolidated balance sheets. The weighted-average assumptions used in determining net periodic cost for the years ended December 31, 2021 and 2020 were discount rates of 2.7% and 3.1%, respectively, and an annual salary increase of 3.0% for both years ended December 31, 2021 and 2020. During 2021, certain members of executive management of the Company that were participants in the SERP retired and met the requirements for payout of their SERP retirement benefit. The SERP payout provisions require payment to the participant in an actuarially determined lump sum amount six months after the participant retires from the Company. There were no settlement losses during the years ended December 31, 2021, 2020 and 2019. The Company had assets of $248 million as of December 31, 2021, in a non-qualified plan trust generally designated to pay benefits of the deferred compensation plans and the SERP, consisting of equity securities of $81 million as of December 31, 2021, and company-owned life insurance contracts of $167 million as of December 31, 2021. The Company had assets of $243 million as of December 31, 2020, in a non-qualified plan trust generally designated to pay benefits of the deferred compensation plans and the SERP, consisting of equity securities of $95 million as of December 31, 2020, and company-owned life insurance contracts of $148 million as of December 31, 2020 . The Company maintains the CHS/Community Health Systems, Inc. Retirement Income Plan (“Pension Plan”), which is a defined benefit, non-contributory pension plan that covers certain employees at three of its formerly owned hospitals. The Pension Plan provides benefits to covered individuals satisfying certain age and service requirements. Employer contributions to the Pension Plan are in accordance with the minimum funding requirements of the Employee Retirement Income Security Act of 1974, as amended. The Company does not expect to make contributions to the Pension Plan in 2022. In September 2021, the lifetime obligation of the Pension Plan with respect to certain participants was transferred to a third-party insurer via an irrevocable annuity contract. The third-party insurer began paying benefits to the participants as of November 1, 2021. This action resulted in a partial plan settlement and recognition of a less than $1 million settlement charge during the year ended December 31, 2021. The Company uses a December 31 measurement date for the benefit obligations and a January 1 measurement date for its net periodic costs for the Pension Plan. Variances from actuarially assumed rates will result in increases or decreases in benefit obligations, net periodic cost and funding requirements in future periods. Benefits expense under the Pension Plan was less than $1 million during the year ended December 31, 2021, inclusive of the aforementioned partial plan settlement, and less than $1 million for each of the years ended December 31, 2020 and 2019. The accrued benefit liability for the Pension Plan totaled less than $1 million and $5 million at December 31, 2021 and 2020, respectively, and is included in other long-term liabilities on the consolidated balance sheets. The weighted-average assumptions used for determining the net periodic cost for the years ended December 31, 2021 and 2020 were discount rates of 2.5% and 3.2%, respectively, and the expected long-term rates of return on assets of 5.5% and 6.0%, respectively.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
STOCKHOLDERS' DEFICIT	11. STOCKHOLDERS’ DEFICIT Authorized capital shares of the Company include 400,000,000 shares of capital stock consisting of 300,000,000 shares of common stock and 100,000,000 shares of preferred stock. Each of the aforementioned classes of capital stock has a par value of $0.01 per share. Shares of preferred stock, none of which were outstanding as of December 31, 2021, may be issued in one or more series having such rights, preferences and other provisions as determined by the Board of Directors without approval by the holders of common stock. The Company is a holding company which operates through its subsidiaries. The Company’s ABL Facility and the indentures governing each series of the Company’s outstanding notes contain various covenants under which the assets of the subsidiaries of the Company are subject to certain restrictions relating to, among other matters, dividends and distributions, as referenced in the paragraph below. The ABL Facility and the indentures governing each series of the Company’s outstanding notes restrict the Company’s subsidiaries from, among other matters, paying dividends and making distributions to the Company, which thereby limits the Company’s ability to pay dividends and/or repurchase stock. As of December 31, 2021, under the most restrictive test in these agreements (and subject to certain exceptions), the Company has approximately $300 million of capacity to pay permitted dividends and/or repurchase shares of stock or make other restricted payments. The following schedule discloses the effects of changes in the Company’s ownership interest in its less-than-wholly-owned subsidiaries on Community Health Systems, Inc. stockholders’ deficit (in millions): Year Ended December 31, 2021 2020 2019 Net income (loss) attributable to Community Health Systems, Inc. stockholders $ 230 $ 511 $ (675 ) Transfers to the noncontrolling interests: Net increase in Community Health Systems, Inc. paid-in-capital for purchase of subsidiary partnership interests 17 3 3 Net transfers to the noncontrolling interests 17 3 3 Change to Community Health Systems, Inc. stockholders’ deficit from net income (loss) attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests $ 247 $ 514 $ (672 )

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings Per Share	12. EARNINGS PER SHARE The following table sets forth the components of the denominator for the computation of basic and diluted earnings per share for net income (loss) attributable to Community Health Systems, Inc. stockholders: Year Ended December 31, 2021 2020 2019 Weighted-average number of shares outstanding — basic 126,754,852 115,491,022 113,739,046 Effect of dilutive securities: Restricted stock awards 2,803,938 905,903 — Employee stock options 726,130 122,785 — Other equity-based awards 312,490 24,851 — Weighted-average number of shares outstanding — diluted 130,597,410 116,544,561 113,739,046 The Company generated a loss attributable to Community Health Systems, Inc. stockholders for the year ended December 31, 2019, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated income during the year ended December 31, 2019, the effect of restricted stock awards, employee stock options, and other equity-based awards on the diluted shares calculation would have been an increase in shares of 133,866. Year Ended December 31, 2021 2020 2019 Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive: Employee stock options and restricted stock awards 774,981 2,821,511 3,508,968

Equity Investments

Equity Investments	12 Months Ended
	Dec. 31, 2021
Equity Method Investments And Joint Ventures [Abstract]
Equity Investments	13. EQUITY INVESTMENTS On July 30, 2021, the Company sold its unconsolidated minority equity interests in Macon Healthcare, LLC, a joint venture with certain subsidiaries of HCA representing two $110 million On December 31, 2016, the Company sold 80% of its ownership interest in the legal entity that owned and operated its home care agency business. As part of the divestiture of its controlling interest in the home care agency business, the Company recorded an equity method investment representing its remaining 20% ownership. Since December 31, 2016 and primarily in conjunction with the divestiture of hospitals, the Company has divested of its remaining 20% ownership in certain home care agency businesses In March 2005, the Company began purchasing items, primarily medical supplies, medical equipment and pharmaceuticals, under an agreement with HealthTrust Purchasing Group, L.P. (“HealthTrust”), a group purchasing organization in which the Company is a noncontrolling partner. As of December 31, 2021, the Company had a 17.5% ownership interest in HealthTrust. The Company’s investment in all of its unconsolidated affiliates was $129 million and $190 million at December 31, 2021 and 2020, respectively, and is included in other assets, net in the accompanying consolidated balance sheets. Included in the Company’s results of operations is the Company’s equity in pre-tax earnings from its investments in unconsolidated affiliates, which was $22 million, $10 million and $15 million for the years ended December 31, 2021, 2020 and 2019, respectively.

Comprehensive Loss

Comprehensive Loss	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Comprehensive Loss	14. COMPREHENSIVE LOSS The following tables present information about items reclassified out of accumulated other comprehensive loss (“AOCL”) by component for the years ended December 31, 2021 and 2020 (in millions, net of tax): Change in Fair Value of Change in Available-for-Sale Unrecognized Debt Pension Cost Securities (1) Components AOCL (1) Balance as of December 31, 2020 $ 2 $ (15 ) $ (13 ) Other comprehensive (loss) income before reclassifications (1 ) 1 — Amounts reclassified from AOCL (4 ) 2 (2 ) Net current-period other comprehensive (loss) income (5 ) 3 (2 ) Balance as of December 31, 2021 $ (2 ) $ (12 ) $ (14 ) __________________________ (1) Totals may not add due to rounding. Change in Fair Value of Change in Change in Fair Available-for-Sale Unrecognized Value of Interest Debt Pension Cost Rate Swaps (1) Securities (1) Components AOCL Balance as of December 31, 2019 $ 2 $ (3 ) $ (8 ) $ (9 ) Other comprehensive (loss) income before reclassifications (1 ) 6 (1 ) 4 Amounts reclassified from AOCL — 2 (6 ) (8 ) Net current-period other comprehensive (loss) income (1 ) 4 (7 ) (4 ) Balance as of December 31, 2020 $ — $ 2 $ (15 ) $ (13 ) __________________________ (1) Totals may not add due to rounding. The following tables present a subtotal for each significant reclassification to net income (loss) out of AOCL and the line item affected in the accompanying consolidated statements of income (loss) for the years ended December 31, 2021 and 2020 (in millions): Amount reclassified from AOCL Affected line item in the Year Ended statement where net Details about AOCL components December 31, 2021 (loss) income is presented Amortization of defined benefit pension items Prior service costs $ (2 ) Salaries and benefits (2 ) Total before tax — Tax benefit $ (2 ) Net of tax Amount reclassified from AOCL Affected line item in the Year Ended statement where net Details about AOCL components December 31, 2020 income (loss) is presented Amortization of defined benefit pension items Prior service costs $ (1 ) Salaries and benefits Settlement losses recognized (3 ) Salaries and benefits (4 ) Total before tax 10 Tax benefit $ 6 Net of tax

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. COMMITMENTS AND CONTINGENCIES Construction and Other Capital Commitments. Pursuant to a hospital purchase agreement from the Company’s March 1, 2016 acquisition of Northwest Health – Starke, formerly known as Starke Hospital, the Company is committed to build a replacement facility in Knox, Indiana. Under the terms of such agreement, the construction of the replacement facility for Northwest Health - Starke is required to be completed within five years of the date the Company entered into a new lease with Starke County, Indiana, the hospital lessor, or in the event the Company does not enter into a new lease with Starke County, or is required to be completed by September 30, 2026. The Company has not entered into a new lease with the lessor for Northwest Health - Starke and currently anticipate completing construction of the Northwest Health - Starke replacement facility in 2026. Construction costs for the Northwest Health - Starke replacement facility are currently estimated to be approximately $15 million. Physician Recruiting Commitments. As part of its physician recruitment strategy, the Company provides income guarantee agreements to certain physicians who agree to relocate to its communities and commit to remain in practice there. Under such agreements, the Company is required to make payments to the physicians in excess of the amounts they earned in their practice up to the amount of the income guarantee. These income guarantee periods are typically for 12 months. Such payments are recoverable by the Company from physicians who do not fulfill their commitment period, which is typically three years, to the respective community. At December 31, 2021, the maximum potential amount of future payments under these guarantees in excess of the liability recorded is $10 million. Professional Liability Claims. As part of the Company’s business of providing healthcare services, it is subject to legal actions alleging liability on its part. The Company accrues for losses resulting from such liability claims, as well as loss adjustment expenses that are out-of-pocket and directly related to such liability claims. These direct out-of-pocket expenses include fees of outside counsel and experts. The Company does not accrue for costs that are part of corporate overhead, such as the costs of in-house legal and risk management departments. The losses resulting from professional liability claims primarily consist of estimates for known claims, as well as estimates for incurred but not reported claims. The estimates are based on specific claim facts, historical claim reporting and payment patterns, the nature and level of hospital operations and actuarially determined projections. The actuarially determined projections are based on the Company’s actual claim data, including historic reporting and payment patterns which have been gathered over an approximate 20-year period. As discussed below, since the Company purchases excess insurance on a claims-made basis that transfers risk to third-party insurers, the liability it accrues does include an amount for the losses covered by its excess insurance. The Company also records a receivable for the expected reimbursement of losses covered by excess insurance. Since the Company believes that the amount and timing of its future claims payments are reliably determinable, it discounts the amount accrued for losses resulting from professional liability claims using the risk-free interest rate corresponding to the timing of expected payments. The net present value of the projected payments was discounted using a weighted-average risk-free rate of 1.8% in both 2021 and 2020 and 2.6% in 2019. This liability is adjusted for new claims information in the period such information becomes known. The Company’s estimated liability for professional and general liability claims was $533 million and $602 million as of December 31, 2021 and 2020, respectively. The estimated undiscounted claims liability was $564 million and $629 million as of December 31, 2021 and 2020, respectively. The current portion of the liability for professional and general liability claims was $162 million and $177 million as of December 31, 2021 and 2020, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, with the long-term portion recorded in other long-term liabilities. Professional malpractice expense includes the losses resulting from professional liability claims and loss adjustment expense, as well as excess insurance premiums, and is presented within other operating expenses in the accompanying consolidated statements of income (loss). The Company’s processes for obtaining and analyzing claims and incident data are standardized across all of its businesses and have been consistent for many years. The Company monitors the outcomes of the medical care services that it provides and for each reported claim, the Company obtains various information concerning the facts and circumstances related to that claim. In addition, the Company routinely monitors current key statistics and volume indicators in its assessment of utilizing historical trends. The average lag period between claim occurrence and payment of a final settlement is between three and four years, although the facts and circumstances of individual claims could result in the timing of such payments being different from this average. Since claims are paid promptly after settlement with the claimant is reached, settled claims represent less than 1.0% of the total liability at the end of any period. For purposes of estimating its individual claim accruals, the Company utilizes specific claim information, including the nature of the claim, the expected claim amount, the year in which the claim occurred and the laws of the jurisdiction in which the claim occurred. Once the case accruals for known claims are determined, information is stratified by loss layers and retentions, accident years, reported years and geography. Several actuarial methods are used against this data to produce estimates of ultimate paid losses and reserves for incurred but not reported claims. Each of these methods uses company-specific historical claims data and other information. This company-specific data includes information regarding the Company’s business, including historical paid losses and loss adjustment expenses, historical and current case loss reserves, actual and projected hospital statistical data, a variety of hospital census information, employed physician information, professional liability retentions for each policy year, geographic information and other data. Based on these analyses the Company determines its estimate of the professional liability claims. The determination of management’s estimate, including the preparation of the reserve analysis that supports such estimate, involves subjective judgment of management. Changes in reserve data or the trends and factors that influence reserve data may signal fundamental shifts in the Company’s future claim development patterns or may simply reflect single-period anomalies. Even if a change reflects a fundamental shift, the full extent of the change may not become evident until years later. Moreover, since the Company’s methods and models use different types of data and the Company selects its liability from the results of all of these methods, it typically cannot quantify the precise impact of such factors on its estimates of the liability. Due to the Company’s standardized and consistent processes for handling claims and the long history and depth of company-specific data, the Company’s methodologies have produced reliably determinable estimates of ultimate paid losses. Management considers any changes in the amount and pattern of its historical paid losses up through the most recent reporting period to identify any fundamental shifts or trends in claim development experience in determining the estimate of professional liability claims. However, due to the subjective nature of this estimate and the impact that previously unforeseen shifts in actual claim experience can have, future estimates of professional liability could be adversely impacted when actual paid losses develop unexpectedly based on assumptions and settlement events that were not previously known or anticipated. During the year ended December 31, 2020, the Company incurred expenses in the amount of approximately $50 million related to the settlement of a professional liability claim for which the Company’s third-party insurers’ obligation to provide coverage to the Company in connection with the underlying loss was being litigated. In the ordinary course of business, the Company’s expense with respect to professional liability claims, which is actuarially determined, is limited to amounts not covered by third-party insurance policies, which typically provide coverage for professional liability claims. The subject of the litigation for the recovery of the full amount of the $50 million settlement was whether the claim was covered under the subject policies. This litigation was settled during the three months ended December 31, 2021, and in connection with this settlement, approximately $22 million was recovered from various third-party insurers related to their obligation to provide coverage for the professional liability claim. Aside from this matter, there were no significant changes in the Company’s estimate of the reserve for professional liability claims during the years ended December 31, 2021 and 2020. The Company is primarily self-insured for professional liability claims; however, the Company obtains excess insurance that transfers the risk of loss to a third-party insurer for claims in excess of the Company’s self-insured retentions. The Company’s excess insurance is underwritten on a claims-made basis. For claims reported prior to June 1, 2002, substantially all of the Company’s professional and general liability risks were subject to a less than $1 million per occurrence self-insured retention and for claims reported from June 1, 2002 through June 1, 2003, these self-insured retentions were $2 million per occurrence. Substantially all claims reported after June 1, 2003 and before June 1, 2005 are self-insured up to $4 million per claim. Substantially all claims reported on or after June 1, 2005 and before June 1, 2014 are self-insured up to $5 million per claim. Substantially all claims reported on or after June 1, 2014 and before June 1, 2018 are self-insured up to $10 million per claim. Substantially all claims reported on or after June 1, 2018 are self-insured up to $15 million per claim. Management, on occasion, has selectively increased the insured risk at certain hospitals based upon insurance pricing and other factors and may continue that practice in the future. totals up to $ 95 million per occurrence and in the aggregate for claims reported on or after June 1, 2003, up to $ 145 million per occurrence and in the aggregate for claims reported on or after January 1, 2008, up to $ 195 million per occurrence and in the aggregate for claims reported on or after June 1, 2010, and up to at least $ 215 million per occurrence and in the aggregate for claims reported on or after June 1, 2015. In addition, for integrated occurrence malpractice claims, there is an additional $ 50 million of excess coverage for claims reported on or after June 1, 2014 and an additional $ 75 million of excess coverage for claims reported on or after June 1, 2015 through June 1, 2020 . The $ 75 million in integrated occurrence coverage will also apply to claims reporte d between June 1, 2020 and June 1, 2022 for events that occurred prior to June 1, 2020 but which were not previously known or reported . For certain policy years prior to June 1, 2014, if the first aggregate layer of excess coverage becomes fully utilized, then the self-insured retention will increase to $ 10 million per claim for any subsequent claims in that policy year until the Company’s total aggregate coverage is met. Beginning June 1, 2018, this drop-down provision in the excess policies attaches over the $ 15 million per claim self-insured retention. Effective June 1, 2014, the hospitals acquired from HMA were insured on a claims-made basis as described above and through commercial insurance companies as described above for substantially all claims reported on or after June 1, 2014 except for physician-related claims with an occurrence date prior to June 1, 2014. Prior to June 1, 2014, the former HMA hospitals obtained insurance coverage through a wholly-owned captive insurance subsidiary and a risk retention group subsidiary which are domiciled in the Cayman Islands and South Carolina, respectively. Those insurance subsidiaries, which are collectively referred to as the “Insurance Subsidiaries,” provided (i) claims-made coverage to all of the former HMA hospitals and (ii) occurrence-basis coverage to most of the physicians employed by the former HMA hospitals. The employed physicians not covered by the Insurance Subsidiaries generally maintained claims-made policies with unrelated third party insurance companies. To mitigate the exposure of the program covering the former HMA hospitals and other healthcare facilities, the Insurance Subsidiaries bought claims-made reinsurance policies from unrelated third parties for claims above self-retention levels of $10 million or $15 million per claim, depending on the policy year. Legal Matters. The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period. With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters. In connection with the spin-off of Quorum Health Corporation (“QHC”), the Company agreed to indemnify QHC for certain liabilities relating to outcomes or events occurring prior to April 29, 2016, the closing date of the spin-off, including (i) certain claims and proceedings that were known to be outstanding at or prior to the consummation of the spin-off and involved multiple facilities and (ii) certain claims, proceedings and investigations by governmental authorities or private plaintiffs related to activities occurring at or related to QHC’s healthcare facilities prior to the closing date of the spin-off, but only to the extent, in the case of clause (ii), that such claims are covered by insurance policies maintained by the Company, including professional liability and employer practices. Notwithstanding the foregoing, the Company is not required to indemnify QHC in respect of any claims or proceedings arising out of or related to the business operations of Quorum Health Resources, LLC at any time or QHC’s compliance with the corporate integrity agreement. Subsequent to the spin-off of QHC, the Office of the Inspector General provided the Company with written assurance that it would look solely at QHC for compliance for its facilities under the Company’s corporate integrity agreement; however, the Office of the Inspector General declined to enter into a separate corporate integrity agreement with QHC. Summary of Recorded Amounts The table below presents a reconciliation of the beginning and ending liability balances (in millions) during the years ended December 31, 2021 and 2020, with respect to the Company’s determination of the contingencies of the Company in respect of which an accrual has been recorded. The l iability as of December 31, 2021 is comprised of individually insignificant amounts for various matters. Probable Contingencies Balance as of December 31, 2019 $ 68 Expense 14 Reserve for insured claim 11 Cash payments (82 ) Balance as of December 31, 2020 11 Expense 11 Reserve for insured claim (1 ) Cash payments (1 ) Balance as of December 31, 2021 $ 20 In accordance with applicable accounting guidance, the Company establishes a liability for litigation, regulatory and governmental matters for which, based on information currently available, the Company believes that a negative outcome is known or is probable and the amount of the loss is reasonably estimable. For all such matters (whether or not discussed in this contingencies footnote), such amounts have been recorded in other accrued liabilities on the consolidated balance sheets and are included in the table above. Due to the uncertainties and difficulty in predicting the ultimate resolution of these contingencies, the actual amount could differ from the estimated amount reflected as a liability on the consolidated balance sheets. In the aggregate, attorneys’ fees and other costs incurred but not included in the table above related to probable contingencies totaled less than $1 million, $3 million and $21 million during the years ended December 31, 2021, 2020 and 2019, respectively, and are included in other operating expenses in the accompanying consolidated statements of income (loss).

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	16. SUBSEQUENT EVENTS The Company has evaluated all material events occurring subsequent to the balance sheet date for events requiring disclosure or recognition in the consolidated financial statements. On February 4, 2022, CHS completed a private offering of $1.535 billion aggregate principal amount of 5¼% Senior Secured Notes due May 15, 2030 (the “5¼% Senior Secured Notes due 2030”). The proceeds of the offering were used to redeem the 6⅝% Senior Secured Notes due 2025 on February 4, 2022, and to pay related fees and expenses. The 5¼% Senior Secured Notes due 2030 bear interest at a rate of 5.250% per year payable semi-annually in arrears on May 15 and November 15, commencing on November 15, 2022. The 5¼% Senior Secured Notes due 2030 are unconditionally guaranteed on a senior-priority secured basis by each of CHS’ current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS. The 5¼% Senior Secured Notes due 2030 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 5¼% Senior Secured Notes due 2030. CHS is entitled, at its option, to redeem all or a portion of the 5¼% Senior Secured Notes due 2030 at any time prior to May 15, 2025, upon not less than 10 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 5¼% Senior Secured Notes due 2030 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 5¼% Senior Secured Notes due 2030. CHS may redeem up to 40% of the aggregate principal amount of the 5¼ At any time and from time to time on or after May 15, 2025, CHS may redeem the 5¼ amount set forth below plus accrued and unpaid interest, if any, on the 5¼% Senior Secured Notes due 2030 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the twelv e-month period beginning on May 15 of the years indicated below : Period Redemption Price May 15, 2025 to May 14, 2026 102.625 % May 15, 2026 to May 14, 2027 101.313 % May 15, 2027 to May 14, 2030 100.000 %

Condensed Financial Information

Condensed Financial Information of Parent	12 Months Ended
	Dec. 31, 2021
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Condensed Financial Information of Parent	17. CONDENSED FINANCIAL INFORMATION OF PARENT Parent Company Only Condensed Balance Sheets (In millions) December 31, 2021 2020 ASSETS Prepaid income taxes $ 94 $ 50 Total current assets 94 50 Deferred income taxes 53 59 Other assets, net — (3 ) Total assets $ 147 $ 106 LIABILITIES AND STOCKHOLDERS' DEFICIT Intercompany payable $ 1,326 $ 1,701 Deferred income taxes 192 29 Other long-term liabilities 1 1 Total liabilities 1,519 1,731 Community Health Systems, Inc. stockholders’ deficit: Preferred stock — — Common stock 1 1 Additional paid-in capital 2,118 2,094 Accumulated other comprehensive loss (14 ) (13 ) Accumulated deficit (3,477 ) (3,707 ) Total Community Health Systems, Inc. stockholders’ deficit (1,372 ) (1,625 ) Total liabilities and stockholders' deficit $ 147 $ 106 See note to condensed financial statements of Parent. Parent Company Only Condensed Statements of Income (Loss) (In millions) Year Ended December 31, 2021 2020 2019 Net operating revenues $ — $ — $ — Operating costs and expenses: Salaries and benefits — — — Supplies — — — Other operating expenses — — — Government and other legal settlements and related costs — — — Electronic health records incentive reimbursement — — — Lease cost and rent — — — Pandemic relief funds — — — Depreciation and amortization — — — Impairment and (gain) loss on sale of businesses, net — — — Total operating costs and expenses — — — Income from operations — — — Interest expense, net — — — Loss (gain) from early extinguishment of debt — — — Equity in earnings of unconsolidated affiliates (230 ) (511 ) 675 Income (loss) before income taxes 230 511 (675 ) (Benefit from) provision for income taxes — — — Net income (loss) 230 511 (675 ) Less: Net income attributable to noncontrolling interests — — — Net income (loss) attributable to Community Health Systems, Inc. stockholders $ 230 $ 511 $ (675 ) See note to condensed financial statements of Parent. Parent Company Only Condensed Statements of Comprehensive Income (Loss) (In millions) Year Ended December 31, 2021 2020 2019 (In millions) Net income (loss) $ 230 $ 511 $ (675 ) Equity in other comprehensive (loss) income of affiliates, net of income taxes: Net change in fair value of interest rate swaps, net of tax — (1 ) (3 ) Net change in fair value of available-for-sale debt securities, net of tax (5 ) 4 4 Amortization and recognition of unrecognized pension cost components, net of tax 3 (7 ) — Other comprehensive (loss) income (2 ) (4 ) 1 Comprehensive income (loss) 228 507 (674 ) Less: Comprehensive income attributable to noncontrolling interests — — — Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders $ 228 $ 507 $ (674 ) See note to condensed financial statements of Parent. Parent Company Only Condensed Statements of Cash Flows (In millions) Year Ended December 31, 2021 2020 2019 Cash flows from operating activities: Net cash used in operating activities $ (11 ) $ (12 ) $ (4 ) Cash flows from investing activities: Net cash provided by (used in) investing activities — — — Cash flows from financing activities: Repurchase of restricted stock shares for payroll tax withholding requirements (5 ) (1 ) (1 ) Changes in intercompany balances with affiliates, net 16 13 5 Net cash provided by financing activities 11 12 4 Net change in cash and cash equivalents — — — Cash and cash equivalents at beginning of period — — — Cash and cash equivalents at end of period $ — $ — $ — See note to condensed financial statements of Parent. 1. Basis of Presentation The Parent is a holding company and operates no business in its own name; all of the Company’s business operations are conducted through subsidiaries of the Parent. The Company’s outstanding indebtedness restricts the ability of subsidiaries to dividend or otherwise provide funds to the Parent. Accordingly, these financial statements have been presented on a “parent-only” basis. Under parent-only presentation, the Parent’s investments in its consolidated subsidiaries are presented under the equity method of accounting. These parent-only financial statements should be read in conjunction with consolidated financial statements of Community Health Systems, Inc.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Accounting	Business. Community Health Systems, Inc. is a holding company and operates no business in its own name. On a consolidated basis, Community Health Systems, Inc. and its subsidiaries (collectively the “Company”) own, lease and operate general acute care hospitals as well as outpatient facilities in communities across the country. As of December 31, 2021, the Company owned or leased 83 hospitals, including two stand-alone rehabilitation or psychiatric hospitals, licensed for 13,289 beds in 16 states. Throughout these notes to the consolidated financial statements, Community Health Systems, Inc. (the “Parent”) and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly-traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc. As of December 31, 2021, Indiana, Florida, Texas and Alabama represent the only areas of significant geographic concentration. Net operating revenues generated by the Company’s hospitals in Indiana, as a percentage of consolidated net operating revenues, were 16.4% in 2021, 15.0% in 2020 and 13.7% in 2019. Net operating revenues generated by the Company’s hospitals in Florida, as a percentage of consolidated net operating revenues, were 12.2% in 2021, 13.0% in 2020 and 14.3% in 2019. Net operating revenues generated by the Company’s hospitals in Texas, as a percentage of consolidated net operating revenues, were 11.0% in 2021 and 12.2% in both 2020 and 2019. Net operating revenues generated by the Company’s hospitals in Alabama, as a percentage of consolidated net operating revenues, were 13.0% in 2021, 12.1% in 2020 and 10.6% in 2019.
Use of Estimates	Use of Estimates . The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions.
Principles of Consolidation	Principles of Consolidation . The consolidated financial statements include the accounts of the Parent, its subsidiaries, all of which are controlled by the Parent through majority voting control, and variable interest entities for which the Company is the primary beneficiary. All intercompany accounts, profits and transactions have been eliminated. Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity to distinguish between the interests of the Parent and the interests of the noncontrolling owners. Revenues, expenses and income from these subsidiaries are included in the consolidated amounts as presented on the consolidated statements of income (loss), along with a net income measure that separately presents the amounts attributable to the controlling interests and the amounts attributable to the noncontrolling interests for each of the periods presented. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the consolidated balance sheets. Reclassifications . Certain prior period amounts have been reclassified to conform to the current period presentation within the consolidated statements of cash flows.
Reclassifications	Reclassifications . Certain prior period amounts have been reclassified to conform to the current period presentation within the consolidated statements of cash flows.
Cost of Revenue	Cost of Revenue . Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company would include the Company’s corporate office costs at its Franklin, Tennessee office which were collectively $222 million, $190 million and $184 million for the years ended December 31, 2021, 2020 and 2019, respectively. Included in these corporate office costs is stock-based compensation of $25 million, $13 million and $10 million for the years ended December 31, 2021, 2020 and 2019, respectively. Operating costs for the year ended December 31, 2021 reflect increased stock compensation expense and annual cash incentive compensation expense compared to the years ended December 31, 2020 and 2019.
Cash Equivalents	Cash Equivalents . The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents.
Supplies	Supplies. Supplies, principally medical supplies, are stated at the lower of cost (first-in, first-out basis) or market.
Marketable Securities	Marketable Securities. The Company’s marketable securities consist of debt securities that are classified as trading or available-for-sale and equity securities. Available-for-sale debt securities are reported at fair value as determined by quoted market prices, with unrealized gains and losses reported as a separate component of stockholders’ deficit. Trading securities are reported at fair value with unrealized gains and losses included in earnings. Other comprehensive loss, net of tax, included an unrealized loss of $5 million during the year ended December 31, 2021, and an unrealized gain of $4 million for both of the years ended December 31, 2020 and 2019 related to these available-for-sale debt securities.
Property and Equipment	Property and Equipment . Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the land and improvements (3 to 20 years), buildings and improvements (5 to 40 years) and equipment and fixtures (3 to 18 years). Costs capitalized as construction in progress were $225 million and $194 million at December 31, 2021 and 2020, respectively. Expenditures for renovations and other significant improvements are capitalized; however, maintenance and repairs which do not improve or extend the useful lives of the respective assets are charged to operations as incurred. Interest capitalized related to construction in progress was $13 million, $15 million and $20 million for the years ended December 31, The Company also leases certain facilities and equipment under finance leases (see Note 9). Such assets are amortized on a straight-line basis over the lesser of the term of the lease or the remaining useful lives of the applicable assets. During the year ended December 31, 2021, the Company had non-cash investing activity of $166 million related to certain facility and equipment additions that were financed through finance leases and other debt.
Goodwill	Goodwill. Goodwill represents the excess of the fair value of the consideration conveyed in the acquisition over the fair value of net assets acquired. Goodwill arising from business combinations is not amortized. Goodwill is required to be evaluated for impairment at the same time every year and when an event occurs or circumstances change such that it is more likely than not that impairment may exist. The Company performs its annual testing of impairment for goodwill in the fourth quarter of each year. There was no goodwill impairment charge during the years ended December 31, 2021, 2020 and 2019 as a result of the Company’s annual impairment evaluation.
Other Assets	Other Assets. Other assets consist of the insurance recovery receivable from excess insurance carriers related to the Company’s self-insured malpractice general liability and workers’ compensation insurance liability; costs to recruit physicians to the Company’s markets, which are deferred and expensed over the term of the respective physician recruitment contract, generally three years, and included in amortization expense; equity method investments; and capitalized internal-use software costs, which are expensed over the expected useful life, which is generally three years for routine software, and included in amortization expense.
Revenue Recognition	Revenue Recognition.
Net Operating Revenues	Net Operating Revenues Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing goods and services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these goods and services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the goods and services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and other patient price concessions. During each of the years ended December 31, 2021, 2020 and 2019, the impact of changes to the inputs used to determine the transaction price was considered immaterial. Currently, several states utilize supplemental reimbursement programs for the purpose of providing reimbursement to providers that is not specifically tied to an individual’s care, some of which offsets a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services (“CMS”) and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. Under these supplemental programs, the Company recognizes revenue and related expenses in the period in which amounts are estimable and payment is reasonably assured. Reimbursement under these programs is reflected in net operating revenues and fees, taxes or other program-related costs are reflected in other operating expenses. The Company’s net operating revenues during the years ended December 31, 2021, 2020 and 2019 have been presented in the following table based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in millions): Year Ended December 31, 2021 2020 2019 Medicare $ 2,650 $ 2,813 $ 3,331 Medicaid 1,671 1,578 1,736 Managed Care and other third-party payors 7,937 7,400 8,014 Self-pay 110 (2 ) 129 Total $ 12,368 $ 11,789 $ 13,210
Patient Accounts Receivable	Patient Accounts Receivable Patient accounts receivable are recorded at net realizable value based on certain assumptions determined by each payor. For third-party payors including Medicare, Medicaid, and Managed Care, the net realizable value is based on the estimated contractual reimbursement percentage, which is based on current contract prices or historical paid claims data by payor. For self-pay accounts receivable, which includes patients who are uninsured and the patient responsibility portion for patients with insurance, the net realizable value is determined using estimates of historical collection experience without regard to aging category. These estimates are adjusted for estimated conversions of patient responsibility portions, expected recoveries and any anticipated changes in trends. Patient accounts receivable can be impacted by the effectiveness of the Company’s collection efforts. Additionally, significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the net realizable value of accounts receivable. The Company also continually reviews the net realizable value of accounts receivable by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net revenue and admissions by payor classification, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables, the impact of recent acquisitions and dispositions and the impact of current economic and other events. Final settlements for some payors and programs are subject to adjustment based on administrative review and audit by third parties. As a result of these final settlements, the Company has recorded amounts due to third-party payors of $118 million and $98 million as of December 31, 2021 and 2020, respectively, and these amounts are included in accrued liabilities-other in the accompanying consolidated balance sheets. Amounts due from third-party payors were $114 million and $136 million as of December 31, 2021 and 2020, respectively, and are included in other current assets in the accompanying consolidated balance sheets. Substantially all Medicare and Medicaid cost reports are final settled through 2017.
Charity Care	Charity Care In the ordinary course of business, the Company renders services to patients who are financially unable to pay for hospital care. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges for those patients who are financially unable to pay and that otherwise do not qualify for reimbursement from a governmental program are not reported in net operating revenues, and are thus classified as charity care. The Company determines amounts that qualify for charity care based on the patient’s household income relative to the federal poverty level guidelines, as established by the federal government. These charity care services are estimated to be $1.1 billion, $1.0 billion and $540 million for the years ended December 31, 2021, 2020 and 2019, respectively, representing the value (at the Company’s standard charges) of these charity care services that are excluded from net operating revenues. The estimated cost incurred by the Company to provide these charity care services to patients who are unable to pay was approximately $123 million, $ 122
Leases	Leases. The right-of-use (“ROU”) asset recorded at commencement of the lease represents the right to use the underlying asset over the lease term in exchange for the lease payments. Leases with an initial term of 12 months or less that do not have an option to
Physician Income Guarantees	Physician Income Guarantees . The Company enters into physician recruiting agreements under which it supplements physician income to a minimum amount over a period of time, typically one year, while the physicians establish themselves in the community. As part of the agreements, the physicians are committed to practice in the community for a period of time, typically three years, which extends beyond their income guarantee period. The Company records an asset and liability for the estimated fair value of minimum revenue guarantees on new agreements and the asset is amortized over the life of each respective agreement. Adjustments to the ultimate value of the guarantee paid to physicians are recognized in the period that the change in estimate is identified. As of December 31, 2021 and 2020, the unamortized portion of these physician income guarantees was $13 million and $16 million, respectively, and is recorded in other assets in the consolidated balance sheets.
Concentrations of Credit Risk	Concentrations of Credit Risk . The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company’s facilities and non-governmental third-party payors, Medicare represents the only significant concentration of credit risk from payors. Accounts receivable, net of contractual allowances, from Medicare was $211 million and $232 million at December 31, 2021 and 2020, respectively, representing 5% and 6% of consolidated net accounts receivable at December 31, 2021 and 2020, respectively.
Accounting for the Impairment or Disposal of Long-Lived Assets	Accounting for the Impairment or Disposal of Long-Lived Assets. During the year ended December 31, 2021, the Company recorded a net loss on disposal of approximately $24 million, of which (i) approximately $ 29 million was recorded to adjust the carrying value of long-lived assets at several hospitals that were sold at a sales price below carrying value, (ii) approximately $3 million was recorded related to divestiture related expenses, and (iii) approximately $8 million of gain was recorded related to the disposal of the Company’s majority interest in a surgery center that was sold on January 1, 2021. Approximately $5 million of goodwill was allocated to facilities disposed of during the year ended December 31, 2021. During the year ended December 31, 2020, the Company recorded a total combined net impairment charge and loss on disposal of approximately $48 million, of which (i) 59 was recorded to reduce the carrying value of closed hospitals and certain hospitals that have been sold or deemed held for sale based on the difference between the carrying value of the hospital disposal groups compared to estimated fair value less costs to sell 74 was recorded primarily to adjust the carrying value of other long-lived assets at several underperforming hospitals or where the Company was in discussions with potential buyers for divestiture at a sales price that indicated a fair value below carrying value 3 1 The impairment charge was 89 110
Income Taxes	Income Taxes. The Company accounts for income taxes under the asset and liability method, in which deferred income tax assets and liabilities are recognized for the tax consequences of “temporary differences” by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred taxes of a change in tax rates is recognized in the consolidated statements of income (loss) during the period in which the tax rate change becomes law.
Comprehensive Loss	Comprehensive Loss . Comprehensive loss is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.
Segment Reporting	Segment Reporting . A public company is required to report annual and interim financial and descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet the criteria established by U.S. GAAP. The Company operates a single operating segment represented by hospital operations (which includes the Company's acute care hospitals and related healthcare entities that provide inpatient and outpatient healthcare services).
COVID-19 Pandemic	COVID-19 Pandemic. COVID-19, a disease caused by a novel strain of coronavirus, materially affected the Company’s results of operations during 2020 and continued to affect the Company’s results of operations during the year ended December 31, 2021. Federal and state governments have passed legislation, promulgated regulations and taken other administrative actions intended to assist healthcare providers in providing care to COVID-19 and other patients during the public health emergency. Sources of relief include the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), the Paycheck Protection Program and Health Care Enhancement Act (the “PPPHCE Act”), the Consolidated Appropriations Act, 2021 (the “CAA”), and the American Rescue Plan Act of 2021 (the “ARPA”). Together, these stimulus laws authorize over $186 billion in funding to be distributed to hospitals and other healthcare providers through the Public Health and Social Services Emergency Fund (the “PHSSEF” or “Provider Relief Fund”). In addition to the relief funding, the CARES Act provided for an expansion of the Medicare Accelerated and Advance Payment Program whereby inpatient acute care hospitals and other eligible providers were able to request accelerated payment of up to 100% of their Medicare payment amount for a six-month Providers are required to repay accelerated payments beginning one year after the payment was issued. Repayments occur through withholding of future Medicare fee-for-service payments. Various state and local programs also exist to provide relief, either independently or through distribution of monies received via the CARES Act and other enacted federal legislation. The Company’s accounting policies for the recognition of these stimulus monies are as follows: Pandemic Relief Funds Through December 31, 2021, net of amounts that have been repaid to the respective federal, state, or local agency, the Company received approximately $763 million in payments through the PHSSEF and various state and local programs on a cumulative basis since their enactment. Of the net amount received through December 31, 2021, approximately $705 million was received during the year ended December 31, 2020 and the remainder was received during the year ended December 31, 2021. The recognition of amounts received is conditioned upon the provision of care for individuals with possible or actual cases of COVID-19 after January 31, 2020, certification that payment will be used to prevent, prepare for and respond to coronavirus (such amounts shall reimburse the recipient only for healthcare-related expenses or lost revenues, as defined by the U.S. Department of Health and Human Services Agency (“ The Company’s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met is updated each reporting period and considers, among other things, the requirements set forth in the CARES Act and subsequent relief legislation, responses to all applicable frequently asked questions and other interpretive guidance issued by HHS, including the various Post-Payment Notices of Reporting Requirements, the Company’s expenses incurred attributable to the coronavirus, the Company’s results of operations during such period as compared to the Company’s 2020 budget, and the allocation of general and targeted fund distribution payments among subsidiaries of the Company during such period. The HHS guidance, specifically the various Post-Payment Notices of Reporting Requirements and frequently asked questions, set forth the allowable methods for quantifying eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to coronavirus that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. The use of funds calculation takes into account expenses attributable to each respective entity, which for the Company primarily relate to incremental labor and supply costs, as well as lost revenues. The deadlines for using and required timelines for reporting on the use of funds depend on the dates of receipt of the funds. Pandemic relief funds of approximately $148 million and $601 million were recognized during the years ended December 31, 2021 and 2020, respectively. Amounts received through the PHSSEF or state and local programs that have not yet been recognized or otherwise have not been refunded to HHS or the various state and local agencies as of December 31, 2021, total approximately $14 million and are reflected within accrued liabilities-other in the consolidated balance sheets. Such unrecognized amounts may either be returned to HHS or the respective state or local agency, as applicable, or may be recognized in future periods if the underlying conditions for recognition are reasonably assured of having been met. HHS’ interpretation of the underlying terms and conditions of such PHSSEF payments, including auditing and reporting requirements, continues to evolve. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such PHSSEF payments may result in changes in the Company’s estimate of amounts for which the terms and conditions are reasonably assured of being met, and any such changes may be material. Additionally, any such changes may result in the Company’s inability to recognize additional PHSSEF payments or may result in the derecognition of amounts previously recognized, which (in any such case) may be material. Medicare Acceler ated Payments With respect to the Medicare Accelerated and Advanced Payment Program, the Company received Medicare accelerated payments of approximately $1.2 billion in April 2020. No additional Medicare accelerated payments have been received by the Company since such time. In addition, because CMS is no longer accepting new applications for accelerated payments, the Company does not expect to receive additional Medicare accelerated payments. CMS began recouping Medicare accelerated payments in April 2021. As of December 31, 2021, all Medicare accelerated payments received by the Company have been recouped or repaid to CMS or assumed by buyers related to hospitals the Company divested. Approximately $1.1 billion and $77 million of Medicare accelerated payments received by the Company were recouped or repaid to CMS or assumed by buyers related to hospitals the Company divested during the years ended December 31, 2021 and 2020, respectively .
New Accounting Pronouncements	New Accounting Pronouncements . In November 2021, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2021-10, “Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance.” This ASU provides specific authoritative guidance for the disclosure of government assistance including the nature of assistance received, the accounting for and presentation of assistance received and the significant terms and conditions, including commitments and contingences. This ASU is effective for all entities for financial statements issued for annual periods beginning after December 15, 2021 and may be early adopted. The Company early adopted this ASU beginning with this Annual Report on Form 10-K (“Form 10-K”) for the year ended December 31, 2021. The Company has evaluated all other recently issued, but not yet effective, ASUs and does not expect the eventual adoption of these ASUs to have a material impact on its consolidated financial position or results of operations.
Acquisitions	Acquisitions The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded when identified. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired.
Fair Value of Financial Instruments	The carrying value of the Company’s long-term debt in the above table is presented net of unamortized deferred debt issuance costs. The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 8 . The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Cash and cash equivalents. The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months). Investments in equity securities. Estimated fair value is based on closing price as quoted in public markets. Available-for-sale debt securities. Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques. Trading securities. Estimated fair value is based on closing price as quoted in public markets. Senior Notes, Senior Secured Notes and Junior-Priority Secured Notes. Estimated fair value is based on the closing market price for these notes. ABL Facility and other debt. The carrying amount of the ABL Facility and all other debt approximates fair value due to the nature of these obligations.
Fair Value	Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). The inputs used to measure fair value are classified into the following fair value hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions.
Legal Matters	Legal Matters. The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period. With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Net Operating Revenues	The Company’s net operating revenues during the years ended December 31, 2021, 2020 and 2019 have been presented in the following table based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in millions): Year Ended December 31, 2021 2020 2019 Medicare $ 2,650 $ 2,813 $ 3,331 Medicaid 1,671 1,578 1,736 Managed Care and other third-party payors 7,937 7,400 8,014 Self-pay 110 (2 ) 129 Total $ 12,368 $ 11,789 $ 13,210

Accounting for Stock-Based Co_2

Accounting for Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-based Compensation Expense	The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions): Year Ended December 31, 2021 2020 2019 Effect on income (loss) before income taxes $ (25 ) $ (13 ) $ (10 ) Effect on net income (loss) $ (20 ) $ (10 ) $ (8 )
Schedule of Share-based Payment Awards, Stock Options, Valuation Assumptions	The fair value of stock options was estimated using the Black Scholes option pricing model with the following assumptions and weighted-average fair values during the years ended December 31, 2021, 2020 and 2019: Year Ended December 31, 2021 2020 2019 Expected volatility 84.3% - 88.9% 73.5% 68.4 % Expected dividends — — — Expected term 3.0 - 6.0 years 6.0 years 5.6 years Risk-free interest rate 0.3% - 0.9% 1.0% 2.6 %
Schedule of Share-based Compensation, Stock Options, Activity	Options outstanding and exercisable under the 2009 Plan as of December 31, 2021, and changes during each of the years in the three-year period prior to December 31, 2021, were as follows (in millions, except share and per share data): Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value as of December 31, 2021 Outstanding at December 31, 2018 624,938 $ 31.21 Granted 658,500 4.95 Exercised — — Forfeited and cancelled (173,304 ) 23.04 Outstanding at December 31, 2019 1,110,134 16.90 Granted 946,500 4.93 Exercised (18,166 ) 4.99 Forfeited and cancelled (220,943 ) 33.52 Outstanding at December 31, 2020 1,817,525 8.77 Granted 749,250 8.81 Exercised (65,499 ) 5.03 Forfeited and cancelled (199,523 ) 33.14 Outstanding at December 31, 2021 2,301,753 $ 6.77 8.0 years $ 16 Exercisable at December 31, 2021 730,828 $ 6.76 6.8 years $ 5
Schedule of Share-based Compensation, Restricted Stock, Activity	Restricted stock outstanding under the 2009 Plan as of December 31, 2021, and changes during each of the years in the three-year period prior to December 31, 2021, were as follows: Shares Weighted- Average Grant Date Fair Value Unvested at December 31, 2018 3,308,907 $ 7.00 Granted 1,989,000 4.94 Vested (1,160,667 ) 8.89 Forfeited (279,838 ) 5.60 Unvested at December 31, 2019 3,857,402 5.47 Granted 2,205,500 4.90 Vested (1,123,329 ) 5.84 Forfeited (383,838 ) 8.58 Unvested at December 31, 2020 4,555,735 4.84 Granted 2,929,250 8.16 Vested (2,312,328 ) 4.68 Forfeited (177,343 ) 6.33 Unvested at December 31, 2021 4,995,314 6.30
Schedule of Share-based Compensation, Restricted Stock Units, Activity	RSUs outstanding under the 2009 Plan as of December 31, 2021, and changes during each of the years in the three-year period prior to December 31, 2021, were as follows: Shares Weighted- Average Grant Date Fair Value Unvested at December 31, 2018 397,906 $ 6.17 Granted 306,612 4.99 Vested (162,942 ) 7.42 Forfeited — — Unvested at December 31, 2019 541,576 5.13 Granted 310,347 4.93 Vested (238,184 ) 5.47 Forfeited — — Unvested at December 31, 2020 613,739 4.89 Granted 173,664 8.81 Vested (300,805 ) 5.09 Forfeited — — Unvested at December 31, 2021 486,598 6.17

Acquisitions and Divestitures (

Acquisitions and Divestitures (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Divestitures	The following table provides a summary of hospitals that the Company divested during the years ended December 31, 2021, 2020 and 2019. Hospital Buyer City, State Licensed Beds Effective Date 2021 Divestitures: Lea Regional Medical Center Covenant Health System Hobbs, NM 84 January 1, 2021 Tennova Healthcare - Tullahoma Vanderbilt University Medical Center Tullahoma, TN 135 January 1, 2021 Tennova Healthcare - Shelbyville Vanderbilt University Medical Center Shelbyville, TN 60 January 1, 2021 Northwest Mississippi Medical Center Delta Health System Clarksdale, MS 181 February 1, 2021 AllianceHealth Midwest SSM Health Care of Oklahoma, Inc. Midwest City, OK 255 April 1, 2021 2020 Divestitures: Berwick Hospital Center Fayette Holdings, Inc. Berwick, PA 90 December 1, 2020 Brownwood Regional Medical Center Hendrick Health System Brownwood, TX 188 October 27, 2020 Abilene Regional Medical Center Hendrick Health System Abilene, TX 231 October 27, 2020 San Angelo Community Medical Center Shannon Health System San Angelo, TX 171 October 24, 2020 Bayfront Health St. Petersburg Orlando Health, Inc. St. Petersburg, FL 480 October 1, 2020 Hill Regional Hospital AHRK Holdings, LLC Hillsboro, TX 25 August 1, 2020 St. Cloud Regional Medical Center Orlando Health, Inc. St. Cloud, FL 84 July 1, 2020 Northern Louisiana Medical Center Allegiance Health Management, Inc. Ruston, LA 130 July 1, 2020 Shands Live Oak Regional Medical Center HCA Live Oak, FL 25 May 1, 2020 Shands Starke Regional Medical Center HCA Starke, FL 49 May 1, 2020 Southside Regional Medical Center Bon Secours Mercy Health System Petersburg, VA 300 January 1, 2020 Southampton Memorial Hospital Bon Secours Mercy Health System Franklin, VA 105 January 1, 2020 Southern Virginia Regional Medical Center Bon Secours Mercy Health System Emporia, VA 80 January 1, 2020 2019 Divestitures: Bluefield Regional Medical Center Princeton Community Hospital Association Bluefield, WV 92 October 1, 2019 Lake Wales Medical Center Adventist Health System Lake Wales, FL 160 September 1, 2019 Heart of Florida Regional Medical Center Adventist Health System Davenport, FL 193 September 1, 2019 College Station Medical Center St. Joseph Regional Health Center College Station, TX 167 August 1, 2019 Tennova Healthcare - Lebanon Vanderbilt University Medical Center Lebanon, TN 245 August 1, 2019 Chester Regional Medical Center Medical University Hospital Authority Chester, SC 82 March 1, 2019 Carolinas Hospital System - Florence Medical University Hospital Authority Florence, SC 396 March 1, 2019 Springs Memorial Hospital Medical University Hospital Authority Lancaster, SC 225 March 1, 2019 Carolinas Hospital System - Marion Medical University Hospital Authority Mullins, SC 124 March 1, 2019 Memorial Hospital of Salem County Community Healthcare Associates, LLC Salem, NJ 126 January 31, 2019 Mary Black Health System - Spartanburg Spartanburg Regional Healthcare System Spartanburg, SC 207 January 1, 2019 Mary Black Health System - Gaffney Spartanburg Regional Healthcare System Gaffney, SC 125 January 1, 2019
Schedule of Balance Sheet Items Classified as Held for Sale	The following table discloses amounts included in the consolidated balance sheets for the hospitals classified as held for sale as of December 31, 2020 (in millions). Other assets, net primarily includes the net property and equipment for hospitals held for sale. No hospitals were classified as held for sale as of December 31, 2021 and no divestitures or potential divestitures meet the criteria for reporting as a discontinued operation as of December 31, 2021, 2020, or 2019. December 31, 2020 Other current assets $ 12 Other assets, net 11 Accrued liabilities 16
Hospitals Included in Continuing Operations [Member]
Schedule Of Operating Results Included In Consolidated Statement Of Income	Summary financial results of these hospitals for the periods included in the accompanying consolidated statements of income (loss) are as follows (in millions): Year Ended December 31, 2021 2020 2019 (Loss) income before income taxes $ (36 ) $ 83 $ (61 ) Less: Loss attributable to noncontrolling interests — (6 ) (8 ) (Loss) income from operations before income taxes attributable to Community Health Systems, Inc. stockholders $ (36 ) $ 89 $ (53 )

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows (in millions): Balance, beginning balance 2021 2020 Goodwill $ 7,033 $ 7,142 Accumulated impairment losses (2,814 ) (2,814 ) 4,219 4,328 Goodwill acquired as part of acquisitions during current year 5 1 Goodwill allocated to hospitals divested or held for sale (5 ) (110 ) Balance, end of year Goodwill 7,033 7,033 Accumulated impairment losses (2,814 ) (2,814 ) $ 4,219 $ 4,219

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Provision for (Benefit from) Income Taxes	The provision for (benefit from) income taxes consists of the following (in millions): Year Ended December 31, 2021 2020 2019 Current: Federal $ (46 ) $ (1 ) $ (38 ) State 6 3 (5 ) (40 ) 2 (43 ) Deferred: Federal 161 (162 ) 179 State 10 (25 ) 24 171 (187 ) 203 Total provision for (benefit from) income taxes for income (loss) $ 131 $ (185 ) $ 160
Schedule of Reconciliation between the Statutory Federal Income Tax Rate and the Effective Tax Rate	The following table reconciles the differences between the statutory federal income tax rate and the effective tax rate (dollars in millions): Year Ended December 31, 2021 2020 2019 Amount % Amount % Amount % Provision for (benefit from) income taxes at statutory federal rate $ 105 21.0 % $ 89 21.0 % $ (90 ) 21.0 % State income taxes, net of federal income tax benefit 44 8.7 (15 ) (3.6 ) (104 ) 24.3 Net income attributable to noncontrolling interests (29 ) (5.8 ) (20 ) (4.7 ) (18 ) 4.2 Change in valuation allowance 33 6.8 (267 ) (63.2 ) 340 (79.2 ) Nondeductible goodwill — — 41 9.8 11 (2.6 ) Amended return adjustments (22 ) (4.4 ) — — — — Nondeductible loss on divestiture — — (15 ) (3.4 ) 15 (3.5 ) Other — — 2 0.3 6 (1.4 ) Provision for (benefit from) income taxes and effective tax rate for income (loss) $ 131 26.3 % $ (185 ) (43.8 )% $ 160 (37.2 )%
Schedule of Components of Deferred Income Taxes	Deferred income taxes are based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities under the provisions of the enacted tax laws. Deferred income taxes as of December 31, 2021 and 2020 consist of (in millions): December 31, 2021 2020 Assets Liabilities Assets Liabilities Net operating loss and credit carryforwards $ 833 $ — $ 873 $ — Property and equipment — 343 — 300 Self-insurance liabilities 49 — 58 — Prepaid expenses — 30 — 29 Intangibles — 144 — 127 Investments in unconsolidated affiliates — 58 — 57 Other liabilities — 9 — 9 IRC Section 481(a) - mixed service cost — — — 106 Long-term debt and interest 48 — 154 — Accounts receivable 22 — 52 — IRC Section 163(j) interest limitation 329 — 108 — Accrued vacation 22 — 22 — Accrued bonus 31 — 32 — Other comprehensive income 5 — 6 — Right-of-use assets — 137 — 150 Right-of-use liability 142 — 155 — Stock-based compensation 4 — 4 — Deferred compensation 64 — 69 — IRC Section 481(a) Adjustments — 191 — — Other 38 — 57 — Total 1,587 912 1,590 778 Valuation allowance (814 ) — (781 ) — Total deferred income taxes $ 773 $ 912 $ 809 $ 778
Schedule of Reconciliation of the Total Amount of Unrecognized Tax Benefit	The following is a tabular reconciliation of the total amount of unrecognized tax benefit for the years ended December 31, 2021, 2020 and 2019 (in millions): Year Ended December 31, 2021 2020 2019 Unrecognized tax benefit, beginning of year $ 45 $ 26 $ 29 Gross increases — tax positions in current period 5 19 10 Reductions — tax positions in prior period (8 ) — — Settlements — — (13 ) Unrecognized tax benefit, end of year $ 42 $ 45 $ 26

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Instrument [Line Items]
Schedule of Debt	Long-term debt, net of unamortized debt issuance costs and discounts or premiums, consists of the following (in millions): December 31, 2021 2020 6⅞ $ — $ 126 6¼ — 95 8⅝ — 1,033 6⅝ 1,462 1,462 8% Senior Secured Notes due 2026 2,101 2,101 8% Senior Secured Notes due 2027 700 700 5⅝ 1,900 1,900 6⅞ 767 767 6% Senior Secured Notes due 2029 900 900 4¾ 1,095 — 9⅞ — 1,769 8⅛ — 1,348 6⅞ 1,775 — 6⅛ 1,440 — ABL Facility — — Finance lease and financing obligations 398 239 Other 37 26 Less: Unamortized deferred debt issuance costs and note premium (435 ) (250 ) Total debt 12,140 12,216 Less: Current maturities (31 ) (123 ) Total long-term debt $ 12,109 $ 12,093
Schedule of Maturities of Long-term Debt	As of December 31, 2021, the scheduled maturities of long-term debt outstanding, including finance lease and financing obligations for each of the next four years and thereafter are as follows (in millions): Year Ending December 31, Amount 2022 $ 31 2023 14 2024 10 2025 1,471 2026 2,109 Thereafter 8,940 Total maturities 12,575 Less: Deferred debt issuance costs (421 ) Plus: Unamortized note premium (14 ) Total long-term debt $ 12,140
Senior Notes at 6.875%, Due 2022 | Senior Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	CHS was entitled, at its option, to redeem all or a portion of the 6⅞% Senior Notes due 2022 upon not less than 30 nor more than 60 days’ notice, at a redemption price of 100% (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed prior to the maturity date.
Senior Secured Notes at 6.25%, Due 2023 | Senior Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	CHS had the option to redeem some or all of the 6¼% Senior Secured Notes due 2023 at any time on or after March 31, 2020 upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price March 31, 2020 to March 30, 2021 103.125 % March 31, 2021 to March 30, 2022 101.563 % March 31, 2022 to March 30, 2023 100.000 %
Junior-Priority Secured Notes at 9.875% Due 2023 | Junior-Priority Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	After June 30, 2020, CHS was entitled, at its option, to redeem all or a portion of the 9⅞% Junior-Priority Secured Notes due 2023 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price June 30, 2020 to June 29, 2021 107.406 % June 30, 2021 to June 29, 2022 103.703 % June 30, 2022 to June 29, 2023 100.000 %
Junior-Priority Secured Notes at 8.125% Due 2024 | Junior-Priority Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	After June 30, 2021, CHS was entitled, at its option, to redeem all or a portion of the 8⅛% Junior-Priority Secured Notes due 2024 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price June 30, 2021 to June 29, 2022 104.063 % June 30, 2022 to June 29, 2023 102.031 % June 30, 2023 to June 29, 2024 100.000 %
Senior Secured Notes at 8.625%, Due 2024 | Senior Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	After January 15, 2021, CHS was entitled, at its option, to redeem all or a portion of the 8⅝% Senior Secured Notes due 2024 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price January 15, 2021 to January 14, 2022 104.313 % January 15, 2022 to January 14, 2023 102.156 % January 15, 2023 to January 14, 2024 100.000 %
Senior Secured Notes at 6.625% Due 2025 | Senior Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	After February 15, 2022, CHS is entitled, at its option, to redeem some or all of the 6⅝% Senior Secured Notes at a redemption price equal to the percentage of principal amount below plus accrued and unpaid interest, if any, to, but excluding the applicable redemption date, if redeemed during the twelve-month period beginning on February 15 of the years set forth below: Period Redemption Price February 15, 2022 to February 14, 2023 103.313 % February 15, 2023 to February 14, 2024 101.656 % February 15, 2024 to February 14, 2025 100.000 %
Senior Secured Notes at 8%, Due 2026 | Senior Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	After March 15, 2022, CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Secured Notes due 2026 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price March 15, 2022 to March 14, 2023 104.000 % March 15, 2023 to March 14, 2024 102.000 % March 15, 2024 to March 14, 2026 100.000 %
Senior Secured Notes at 8% Due 2027 | Senior Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	CHS may redeem some or all of the 8% Senior Secured Notes due 2027 at any time on or after December 15, 2022 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price December 15, 2022 to December 14, 2023 104.000 % December 15, 2023 to December 14, 2024 102.000 % December 15, 2024 to December 14, 2027 100.000 %
5⅝% Senior Secured Notes due 2027 | Senior Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	At any time and from time to time on or after December 15, 2023, CHS may redeem the 5⅝% Senior Secured Notes due 2027 in whole or in part, upon not less than 15 no more than 60 days’ prior written notice at a redemption price equal to the percentage of principal amount set forth below plus accrued and unpaid interest, if any, on the 5⅝% Senior Secured Notes due 2027 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the twelve-month period beginning on December 15 of the years indicated below: Period Redemption Price December 15, 2023 to December 14, 2024 102.813 % December 15, 2024 to December 14, 2025 101.406 % December 15, 2025 to December 14, 2027 100.000 %
Senior Notes at 6.875% Due 2028 | Senior Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	CHS may redeem some or all of the 6⅞% Senior Notes due 2028 at any time on or after April 1, 2023 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: Period Redemption Price April 1, 2023 to March 31, 2024 103.438 % April 1, 2024 to March 31, 2025 101.719 % April 1, 2025 to March 31, 2028 100.000 %
6% Senior Secured Notes due 2029 | Senior Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	At any time and from time to time on or after January 15, 2024, CHS may redeem the 6% Senior Secured Notes due 2029 in whole or in part, upon not less than 15 nor more than 60 days’ prior written notice at a redemption price equal to the percentage of principal amount set forth below plus accrued and unpaid interest, if any, on the 6% Senior Secured Notes due 2029 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the twelve-month period beginning on January 15 of the years indicated below: Period Redemption Price January 15, 2024 to January 14, 2025 103.000 % January 15, 2025 to January 14, 2026 101.500 % January 15, 2026 to January14, 2029 100.000 %
Senior Secured Notes at 4.75% due 2031 | Senior Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	At any time and from time to time on or after February 15, 2026, CHS may redeem the 4¾ Period Redemption Price February 15, 2026 to February 14, 2027 102.375 % February 15, 2027 to February 14, 2028 101.583 % February 15, 2028 to February 14, 2029 100.792 % February 15, 2029 to February 14, 2031 100.000 %
Junior-Priority Secured Notes at 6.875% Due 2029 | Senior Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	At any time and from time to time on or after April 15, 2024, CHS may redeem the 6⅞ Period Redemption Price April 15, 2024 to April 14, 2025 103.438 % April 15, 2025 to April 14, 2026 101.719 % April 15, 2026 to April 14, 2029 100.000 %
Junior-Priority Secured Notes at 6.125% Due 2030 | Senior Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	At any time and from time to time on or after April 1, 2025, CHS may redeem the 6⅛% Period Redemption Price April 1, 2025 to March 31, 2026 103.063 % April 1, 2026 to March 31, 2027 101.531 % April 1, 2027 to March 31, 2030 100.000 %

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping	The fair value of financial instruments has been estimated by the Company using available market information as of December 31, 2021 and 2020, and valuation methodologies considered appropriate. The estimates presented in the table below are not necessarily indicative of amounts the Company could realize in a current market exchange (in millions): December 31, 2021 December 31, 2020 Carrying Estimated Fair Carrying Estimated Fair Amount Value Amount Value Assets: Cash and cash equivalents $ 507 $ 507 $ 1,676 $ 1,676 Investments in equity securities 144 144 129 129 Available-for-sale debt securities 178 178 110 110 Trading securities 13 13 12 12 Liabilities: 6⅞% Senior Notes due 2022 — — 125 125 6¼% Senior Secured Notes due 2023 — — 95 99 8⅝% Senior Secured Notes due 2024 — — 1,025 1,080 6⅝% 1,434 1,517 1,427 1,543 8% 2,078 2,210 2,074 2,275 8% 692 758 692 760 5⅝% 1,819 2,011 1,809 2,048 6⅞% 759 758 758 618 6% 860 966 857 973 4¾% 1,090 1,108 — — 9⅞% Junior-Priority Secured Notes due 2023 — — 1,756 1,861 8⅛% Junior-Priority Secured Notes due 2024 — — 1,336 1,408 6⅞% 1,625 1,823 — — 6⅛% 1,352 1,431 — — ABL Facility and other debt 32 32 23 23

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets Measured on Recurring Basis	The following table sets forth, by level within the fair value hierarchy, the financial assets recorded at fair value on a recurring basis as of December 31, 2021 and 2020 (in millions): December 31, 2021 Level 1 Level 2 Level 3 Investments in equity securities $ 144 $ 144 $ — $ — Available-for-sale debt securities 178 — 178 — Trading securities 13 — 13 — Total assets $ 335 $ 144 $ 191 $ — December 31, 2020 Level 1 Level 2 Level 3 Investments in equity securities $ 129 $ 129 $ — $ — Available-for-sale debt securities 110 — 110 — Trading securities 12 — 12 — Total assets $ 251 $ 129 $ 122 $ —
Supplemental Information Regarding Available-for-Sale Debt Securities	Supplemental information regarding the Company’s available-for-sale debt securities (all of which had no withdrawal restrictions) is set forth in the table below (in millions): Gross Gross Estimated Amortized Unrealized Unrealized Fair Cost Gains Losses Values As of December 31, 2021: Government $ 83 $ 1 $ (1 ) $ 83 Corporate 62 — (1 ) 61 Mortgage and asset-backed securities 34 — — 34 Total available-for-sale debt securities $ 179 $ 1 $ (2 ) $ 178 Gross Gross Estimated Amortized Unrealized Unrealized Fair Cost Gains Losses Values As of December 31, 2020: Government $ 48 $ 2 $ — $ 50 Corporate 38 2 — 40 Mortgage and asset-backed securities 19 1 — 20 Total available-for-sale debt securities $ 105 $ 5 $ — $ 110
Contractual Maturities of Debt Securities	The contractual maturities of debt-based securities held by the Company as of December 31, 2021 and 2020, excluding mutual fund holdings, are set forth in the table below (in millions). Expected maturities will differ from contractual maturities because the issuers of the debt securities may have the right to prepay their obligations without prepayment penalties. December 31, 2021 December 31, 2020 Amortized Estimated Amortized Estimated Cost Fair Values Cost Fair Values Within 1 year $ 8 $ 8 $ 3 $ 3 After 1 year and through year 5 61 61 26 27 After 5 years and through year 10 49 49 30 32 After 10 years 61 60 46 48
Gross Realized Gains and Losses and Investment Income on Available-for-Sale Debt Securities	Gross realized gains and losses on sales of available-for-sale debt securities are summarized in the table below (in millions): Year Ended December 31, 2021 2020 2019 Realized gains $ 1 $ 2 $ — Realized losses (1 ) (1 ) —
Net Gains and Losses Recognized for Investments in Equity Securities	Net gains and losses recognized during the years ended December 31, 2021, 2020 and 2019 for investments in equity securities, which are broken out between investments sold during the year and investments held at the end of the year, are summarized in the table below (in millions): Year Ended December 31, 2021 2020 2019 Net gains and (losses), beginning of year $ 20 $ 9 $ 15 Less: Net gains and (losses) recognized during the year on equity securities sold during the year 13 14 2 Unrealized gains and (losses) recognized during the year on equity securities held, end of year $ 7 $ (5 ) $ 13

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Components of Lease Cost and Rent Expense	The components of lease cost and rent expense for the years ended December 31, 2021, 2020 and 2019 are as follows (in millions): Year Ended December 31, Lease Cost 2021 2020 2019 Operating lease cost: Operating lease cost $ 196 $ 203 $ 194 Short-term rent expense 92 104 114 Variable lease cost 25 26 18 Sublease income (5 ) (6 ) (5 ) Total operating lease cost $ 308 $ 327 $ 321 Finance lease cost: Amortization of ROU assets $ 9 $ 10 $ 12 Interest on finance lease liabilities 9 8 7 Total finance lease cost $ 18 $ 18 $ 19
Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases was as follows (in millions): Balance Sheet Classification December 31, 2021 December 31, 2020 Operating Leases: Operating Lease ROU Assets Other assets, net $ 668 $ 642 Finance Leases: Finance Lease ROU Assets Property and equipment Land and improvements $ 8 $ 8 Buildings and improvements 289 134 Equipment and fixtures 17 8 Property and equipment 314 150 Less accumulated depreciation and amortization (54 ) (46 ) Property and equipment, net $ 260 $ 104 Current finance lease liabilities Current maturities of long-term debt $ 8 $ 5 Long-term finance lease liabilities Long-term debt 233 74
Supplemental Cash Flow and Other Information Related to Leases	Supplemental cash flow information related to leases for the years ended December 31, 2021, 2020 and 2019 are as follows (in millions): Year Ended December 31, Cash flow information 2021 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases (1) $ 197 $ 188 $ 167 Operating cash flows from finance leases 9 8 7 Financing cash flows from finance leases 4 7 9 ROU assets obtained in exchange for new finance lease liabilities 166 22 2 ROU assets obtained in exchange for new operating lease liabilities 143 150 122 Weighted-average remaining lease term: Operating leases 6 years 7 years 6 years Finance leases 30 years 19 years 20 years Weighted-average discount rate: Operating leases 8.1 % 9.0 % 9.1 % Finance leases 6.3 % 8.4 % 5.6 % (1) Included in the change in other operating assets and liabilities in the consolidated statements of cash flows.
Commitments Relating To Noncancellable Operating And Finance Leases And Financing Obligations	Commitments relating to noncancellable operating and finance leases and financing obligations for each of the next five years and thereafter are as follows (in millions): Financing Year Ending December 31, Operating Finance Obligations 2022 $ 194 $ 21 $ 12 2023 171 17 13 2024 123 16 13 2025 95 16 13 2026 75 16 13 Thereafter 236 525 89 Total minimum future payments 894 611 153 Less: Imputed interest (212 ) (370 ) 4 Total liabilities 682 241 157 Less: Current portion (147 ) (8 ) (2 ) Long-term liabilities $ 535 $ 233 $ 155

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Impact of Noncontrolling Interest to Stockholders' Deficit	The following schedule discloses the effects of changes in the Company’s ownership interest in its less-than-wholly-owned subsidiaries on Community Health Systems, Inc. stockholders’ deficit (in millions): Year Ended December 31, 2021 2020 2019 Net income (loss) attributable to Community Health Systems, Inc. stockholders $ 230 $ 511 $ (675 ) Transfers to the noncontrolling interests: Net increase in Community Health Systems, Inc. paid-in-capital for purchase of subsidiary partnership interests 17 3 3 Net transfers to the noncontrolling interests 17 3 3 Change to Community Health Systems, Inc. stockholders’ deficit from net income (loss) attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests $ 247 $ 514 $ (672 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Components of Denominator for Computation of Basic and Diluted Earnings Per Share	The following table sets forth the components of the denominator for the computation of basic and diluted earnings per share for net income (loss) attributable to Community Health Systems, Inc. stockholders: Year Ended December 31, 2021 2020 2019 Weighted-average number of shares outstanding — basic 126,754,852 115,491,022 113,739,046 Effect of dilutive securities: Restricted stock awards 2,803,938 905,903 — Employee stock options 726,130 122,785 — Other equity-based awards 312,490 24,851 — Weighted-average number of shares outstanding — diluted 130,597,410 116,544,561 113,739,046
Schedule of Antidilutive Securities	The Company generated a loss attributable to Community Health Systems, Inc. stockholders for the year ended December 31, 2019, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated income during the year ended December 31, 2019, the effect of restricted stock awards, employee stock options, and other equity-based awards on the diluted shares calculation would have been an increase in shares of 133,866. Year Ended December 31, 2021 2020 2019 Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive: Employee stock options and restricted stock awards 774,981 2,821,511 3,508,968

Comprehensive Loss (Tables)

Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Income (Loss) ("AOCL") by Component	The following tables present information about items reclassified out of accumulated other comprehensive loss (“AOCL”) by component for the years ended December 31, 2021 and 2020 (in millions, net of tax): Change in Fair Value of Change in Available-for-Sale Unrecognized Debt Pension Cost Securities (1) Components AOCL (1) Balance as of December 31, 2020 $ 2 $ (15 ) $ (13 ) Other comprehensive (loss) income before reclassifications (1 ) 1 — Amounts reclassified from AOCL (4 ) 2 (2 ) Net current-period other comprehensive (loss) income (5 ) 3 (2 ) Balance as of December 31, 2021 $ (2 ) $ (12 ) $ (14 ) __________________________ (1) Totals may not add due to rounding. Change in Fair Value of Change in Change in Fair Available-for-Sale Unrecognized Value of Interest Debt Pension Cost Rate Swaps (1) Securities (1) Components AOCL Balance as of December 31, 2019 $ 2 $ (3 ) $ (8 ) $ (9 ) Other comprehensive (loss) income before reclassifications (1 ) 6 (1 ) 4 Amounts reclassified from AOCL — 2 (6 ) (8 ) Net current-period other comprehensive (loss) income (1 ) 4 (7 ) (4 ) Balance as of December 31, 2020 $ — $ 2 $ (15 ) $ (13 ) __________________________ (1) Totals may not add due to rounding.
Schedule of Amounts Reclassified Out of AOCL (Loss)	The following tables present a subtotal for each significant reclassification to net income (loss) out of AOCL and the line item affected in the accompanying consolidated statements of income (loss) for the years ended December 31, 2021 and 2020 (in millions): Amount reclassified from AOCL Affected line item in the Year Ended statement where net Details about AOCL components December 31, 2021 (loss) income is presented Amortization of defined benefit pension items Prior service costs $ (2 ) Salaries and benefits (2 ) Total before tax — Tax benefit $ (2 ) Net of tax Amount reclassified from AOCL Affected line item in the Year Ended statement where net Details about AOCL components December 31, 2020 income (loss) is presented Amortization of defined benefit pension items Prior service costs $ (1 ) Salaries and benefits Settlement losses recognized (3 ) Salaries and benefits (4 ) Total before tax 10 Tax benefit $ 6 Net of tax

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Schedule of Reconciliation of the Beginning and Ending Liability Balances in Connection with Probable Contingencies	The table below presents a reconciliation of the beginning and ending liability balances (in millions) during the years ended December 31, 2021 and 2020, with respect to the Company’s determination of the contingencies of the Company in respect of which an accrual has been recorded. The l iability as of December 31, 2021 is comprised of individually insignificant amounts for various matters. Probable Contingencies Balance as of December 31, 2019 $ 68 Expense 14 Reserve for insured claim 11 Cash payments (82 ) Balance as of December 31, 2020 11 Expense 11 Reserve for insured claim (1 ) Cash payments (1 ) Balance as of December 31, 2021 $ 20

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2021
Senior Secured Notes at 5.25%, Due 2030 | Senior Secured Notes
Schedule of Early Redemption Prices on Notes	At any time and from time to time on or after May 15, 2025, CHS may redeem the 5¼ amount set forth below plus accrued and unpaid interest, if any, on the 5¼% Senior Secured Notes due 2030 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the twelv e-month period beginning on May 15 of the years indicated below : Period Redemption Price May 15, 2025 to May 14, 2026 102.625 % May 15, 2026 to May 14, 2027 101.313 % May 15, 2027 to May 14, 2030 100.000 %

Condensed Financial Informati_2

Condensed Financial Information of Parent (Tables)	12 Months Ended
	Dec. 31, 2021
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Condensed Balance Sheets	Parent Company Only Condensed Balance Sheets (In millions) December 31, 2021 2020 ASSETS Prepaid income taxes $ 94 $ 50 Total current assets 94 50 Deferred income taxes 53 59 Other assets, net — (3 ) Total assets $ 147 $ 106 LIABILITIES AND STOCKHOLDERS' DEFICIT Intercompany payable $ 1,326 $ 1,701 Deferred income taxes 192 29 Other long-term liabilities 1 1 Total liabilities 1,519 1,731 Community Health Systems, Inc. stockholders’ deficit: Preferred stock — — Common stock 1 1 Additional paid-in capital 2,118 2,094 Accumulated other comprehensive loss (14 ) (13 ) Accumulated deficit (3,477 ) (3,707 ) Total Community Health Systems, Inc. stockholders’ deficit (1,372 ) (1,625 ) Total liabilities and stockholders' deficit $ 147 $ 106 See note to condensed financial statements of Parent.
Condensed Statements of Income (Loss)	Parent Company Only Condensed Statements of Income (Loss) (In millions) Year Ended December 31, 2021 2020 2019 Net operating revenues $ — $ — $ — Operating costs and expenses: Salaries and benefits — — — Supplies — — — Other operating expenses — — — Government and other legal settlements and related costs — — — Electronic health records incentive reimbursement — — — Lease cost and rent — — — Pandemic relief funds — — — Depreciation and amortization — — — Impairment and (gain) loss on sale of businesses, net — — — Total operating costs and expenses — — — Income from operations — — — Interest expense, net — — — Loss (gain) from early extinguishment of debt — — — Equity in earnings of unconsolidated affiliates (230 ) (511 ) 675 Income (loss) before income taxes 230 511 (675 ) (Benefit from) provision for income taxes — — — Net income (loss) 230 511 (675 ) Less: Net income attributable to noncontrolling interests — — — Net income (loss) attributable to Community Health Systems, Inc. stockholders $ 230 $ 511 $ (675 ) See note to condensed financial statements of Parent.
Condensed Statements of Comprehensive Income (Loss)	Parent Company Only Condensed Statements of Comprehensive Income (Loss) (In millions) Year Ended December 31, 2021 2020 2019 (In millions) Net income (loss) $ 230 $ 511 $ (675 ) Equity in other comprehensive (loss) income of affiliates, net of income taxes: Net change in fair value of interest rate swaps, net of tax — (1 ) (3 ) Net change in fair value of available-for-sale debt securities, net of tax (5 ) 4 4 Amortization and recognition of unrecognized pension cost components, net of tax 3 (7 ) — Other comprehensive (loss) income (2 ) (4 ) 1 Comprehensive income (loss) 228 507 (674 ) Less: Comprehensive income attributable to noncontrolling interests — — — Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders $ 228 $ 507 $ (674 ) See note to condensed financial statements of Parent.
Condensed Statement of Cash Flows	Parent Company Only Condensed Statements of Cash Flows (In millions) Year Ended December 31, 2021 2020 2019 Cash flows from operating activities: Net cash used in operating activities $ (11 ) $ (12 ) $ (4 ) Cash flows from investing activities: Net cash provided by (used in) investing activities — — — Cash flows from financing activities: Repurchase of restricted stock shares for payroll tax withholding requirements (5 ) (1 ) (1 ) Changes in intercompany balances with affiliates, net 16 13 5 Net cash provided by financing activities 11 12 4 Net change in cash and cash equivalents — — — Cash and cash equivalents at beginning of period — — — Cash and cash equivalents at end of period $ — $ — $ — See note to condensed financial statements of Parent.

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Additional Information (Details)	Oct. 27, 2020Item	Sep. 30, 2020USD ($)	Jul. 01, 2020Item	Jan. 01, 2020Item	Apr. 30, 2020USD ($)	Oct. 27, 2020USD ($)	Dec. 31, 2021USD ($)ItemState	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Business Description [Abstract]
Number of hospitals owned and leased by the Company | Item							83
Number of stand alone rehabilitation or psychiatric hospitals | Item							2
Number of licensed beds | Item							13,289
Number of states in which entity operates | State							16
Cost of Revenue, Policy [Abstract]
Corporate Office Costs							$ 222,000,000	$ 190,000,000	$ 184,000,000
Stock-based compensation expense							25,000,000	13,000,000	10,000,000
Marketable Securities, Policy [Abstract]
Net change in fair value of available-for-sale debt securities, net of tax							(5,000,000)	4,000,000	4,000,000
Property and Equipment, Policy [Abstract]
Construction in Progress, Gross							225,000,000	194,000,000
Interest Costs Capitalized							13,000,000	15,000,000	20,000,000
Purchases of property and equipment and internal-use software accrued in accounts payable							105,000,000	100,000,000
Goodwill, Policy [Abstract]
Impairment of goodwill							0	0	0
Third Party Reimbursement [Abstract]
Amounts due to third party payors							118,000,000	98,000,000
Amounts due from third party payors							114,000,000	136,000,000
Net Operating Revenues, Policy [Abstract]
Charity care services charges excluded from net operating revenues							1,100,000,000	1,000,000,000	540,000,000
Value of charity care services at the Company's standard charges included in contractual allowances							123,000,000	122,000,000	66,000,000
Concentration of Credit Risk, Policy [Abstract]
Accounts receivable, net of contractual allowances							2,062,000,000	1,927,000,000
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business							24,000,000	(48,000,000)
Goodwill allocated to hospital disposal group held for sale							5,000,000	110,000,000
Impairment of long-lived assets sold							29,000,000
Divestiture related expenses							$ 3,000,000
New Accounting Pronouncements, Policy [Abstract]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]							true
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]							true
CARES Act
Medicare Accelerated Payments [Abstract]
Medicare accelerated payments received under the Cares Act					$ 1,200,000,000
Medicare accelerated payments, recouped subject to the aforementioned repayment terms							$ 1,100,000,000	77,000,000
CARES Act | Paycheck Protection Program, Health Care Enhancement Act And the American Rescue Plan Act of 2021
COVID-19 Pandemic [Abstract]
Percentage of maximum accelerated payment							100.00%
Medicare accelerated and advance payment program period							6 months
Public Health and Social Services Emergency Fund (the "PHSSEF") | CARES Act | Paycheck Protection Program, Health Care Enhancement Act And the American Rescue Plan Act of 2021
COVID-19 Pandemic [Abstract]
CARES Act and PPPHCE Act of 2020 Aid, amount							$ 186,000,000,000
Public Health and Social Services Emergency Fund (the "PHSSEF") | CARES Act | Paycheck Protection Program and Health Care Enhancement Act
CARES Act and PPPHCE Act Funds [Abstract]
Payments through the PHSSEF and various state and local programs							763,000,000	705,000,000
Public Health and Social Services Emergency Fund (the "PHSSEF") | CARES Act | Paycheck Protection Program and Health Care Enhancement Act | Accrued Liabilities - Other
CARES Act and PPPHCE Act Funds [Abstract]
Payments through the PHSSEF and various state and local programs								14,000,000
Public Health and Social Services Emergency Fund (the "PHSSEF") | CARES Act | Paycheck Protection Program and Health Care Enhancement Act | Operating Costs and Expenses
CARES Act and PPPHCE Act Funds [Abstract]
Payments through the PHSSEF and various state and local programs							148,000,000	601,000,000
Hospitals Closed
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business		$ (3,000,000)
Shared Service Center
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business								(1,000,000)
Hospitals Sold or Deemed Held for Sale
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business						$ 89,000,000	8,000,000	(59,000,000)
Number of hospitals sold | Item	2		1	3
Adjustment for Carrying Value of Other Long-Lived Assets at Underperforming Hospitals
Accounting for the Impairment or Disposal of Long-Lived Assets
Impairment of long-lived assets held for sale								74,000,000
Medicare
Concentration of Credit Risk, Policy [Abstract]
Accounts receivable, net of contractual allowances							$ 211,000,000	$ 232,000,000
Accounts receivable net of contractual allowances, percent							5.00%	6.00%
Physician Recruitment Contracts
Other Assets, Policy [Abstract]
Term of Physician Recruitment Contract							3 years
Physician Income Guarantees, Policy [Abstract]
Physicians recruitment agreement period							1 year
Term of Physician Recruitment Contract							3 years
Finite-lived intangible assets, net							$ 13,000,000		$ 16,000,000
Capitalized Internal Use Software, Significant System Conversions
Other Assets, Policy [Abstract]
Finite-Lived Intangible Assets, Weighted-Average Useful Life							3 years
Capitalized Internal Use Software Except Significant System Conversions
Other Assets, Policy [Abstract]
Finite-Lived Intangible Assets, Weighted-Average Useful Life							3 years
Maximum
Physician Income Guarantees, Policy [Abstract]
Finite-lived intangible assets, net							$ 1,000,000	$ 1,000,000
Land Improvements | Minimum
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life							3 years
Land Improvements | Maximum
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life							20 years
Building and Building Improvements | Minimum
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life							5 years
Building and Building Improvements | Maximum
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life							40 years
Equipment and Fixtures | Minimum
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life							3 years
Equipment and Fixtures | Maximum
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life							18 years
Certain Facility
Property and Equipment, Policy [Abstract]
Non-cash investing activity through capital leases							$ 166,000,000
Geographic Concentration Risk | Indiana | Sales Revenue, Net
Business Description [Abstract]
Concentration Risk, Percentage							16.40%	15.00%	13.70%
Geographic Concentration Risk | Florida | Sales Revenue, Net
Business Description [Abstract]
Concentration Risk, Percentage							12.20%	13.00%	14.30%
Geographic Concentration Risk | Texas | Sales Revenue, Net
Business Description [Abstract]
Concentration Risk, Percentage							11.00%	12.20%	12.20%
Geographic Concentration Risk | Alabama | Sales Revenue, Net
Business Description [Abstract]
Concentration Risk, Percentage							13.00%	12.10%	10.60%

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Schedule of Net Operating Revenues (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	$ 12,368	$ 11,789	$ 13,210
Medicare
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	2,650	2,813	3,331
Medicaid
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	1,671	1,578	1,736
Managed Care and Other Third Party Payors
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	7,937	7,400	8,014
Self-Pay
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	$ 110	$ (2)	$ 129

Accounting for Stock-Based Co_3

Accounting for Stock-Based Compensation - Additional Information (Details)	Mar. 01, 2021USD ($)Directorshares	Mar. 01, 2020USD ($)Directorshares	Mar. 01, 2019USD ($)shares	Dec. 31, 2021USD ($)Item$ / sharesshares	Dec. 31, 2020USD ($)Item$ / sharesshares	Dec. 31, 2019Item$ / sharesshares	Dec. 31, 2018USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation, unrecognized compensation costs on nonvested awards				$ 27,000,000
Employee service share-based compensation total compensation cost not yet recognized, period for recognition				22 months
Employee service share-based compensation, nonvested awards, modifications to awards | Item				0	0	0
Share Price | $ / shares				$ 13.31
Aggregate intrinsic value of options exercised							$ 0
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value of options exercised				$ 1,000,000	$ 1,000,000
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation total compensation cost not yet recognized, period for recognition				22 months
Employee service share-based compensation, unrecognized compensation costs on nonvested stock options				$ 4,000,000
Share-based compensation arrangement by share-based payment award, options, grants in period | shares				749,250	946,500	658,500
Weighted-average grant date fair value of stock options | $ / shares				$ 6.22	$ 3.17	$ 3.05
Restricted Stock and Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation total compensation cost not yet recognized, period for recognition				22 months
Employee service share-based compensation, unrecognized compensation costs on nonvested awards other than options				$ 23,000,000
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, number of shares received by each director | shares				173,664	310,347	306,612
Number of directors elected to defer the receipt of RSUs granted | Director	4	5
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement award vesting rights				one-third increments on each of the first three anniversaries of the award date
Share-based compensation, number of shares received by each director | shares				2,929,250	2,205,500	1,989,000
Plan 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement award vesting rights				one-third increments on each of the first three anniversaries of the award date
Contractual term of option granted				10 years
Unissued common stock reserved for grants | shares				12,522,282
Plan 2009 | Restricted Stock Units (RSUs) | Non-management Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, number of shares received by each director | shares	19,296	34,483	34,068
Fair value of units granted	$ 170,000	$ 170,000	$ 170,000
Performance-Based Awards Granted On Or After March 1, 2017 | Restricted Stock Performance Based Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by payment award, performance objective measurement period				3 years
Performance Based Awards Granted On Or After March12018 | Restricted Stock Performance Based Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement award vesting rights, percentage				200.00%

Accounting for Stock-Based Co_4

Accounting for Stock-Based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Effect on income (loss) before income taxes	$ (25)	$ (13)	$ (10)
Effect on net income (loss)	$ (20)	$ (10)	$ (8)

Accounting for Stock-Based Co_5

Accounting for Stock-Based Compensation - Schedule of Share-based Payment Awards, Stock Options, Valuation Assumptions (Details) - Employee Stock Option	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		73.50%	68.40%
Expected volatility, minimum	84.30%
Expected volatility, maximum	88.90%
Expected term		6 years	5 years 7 months 6 days
Risk-free interest rate		1.00%	2.60%
Risk-free interest rate, minimum	0.30%
Risk-free interest rate, maximum	0.90%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years

Accounting for Stock-Based Co_6

Accounting for Stock-Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details) - Employee Stock Option - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Shares	1,817,525	1,110,134	624,938
Granted, Shares	749,250	946,500	658,500
Exercised, Shares	(65,499)	(18,166)
Forfeited and cancelled, Shares	(199,523)	(220,943)	(173,304)
Ending Balance, Shares	2,301,753	1,817,525	1,110,134
Exercisable, Shares	730,828
Beginning of Period, Weighted Average Exercise Price	$ 8.77	$ 16.90	$ 31.21
Granted, Weighted Average Exercise Price	8.81	4.93	4.95
Exercised, Weighted Average Exercise Price	5.03	4.99
Forfeited and Cancelled, Weighted Average Exercise Price	33.14	33.52	23.04
End of Period, Weighted Average Exercise Price	6.77	$ 8.77	$ 16.90
Exercisable, Weighted Average Exercise Price	$ 6.76
Weighted Average Remaining Contractual Term	8 years
Exercisable, Weighted Average Remaining Contractual Term	6 years 9 months 18 days
Outstanding, Aggregate Intrinsic Value as of December 31, 2021	$ 16
Exercisable, Aggregate Intrinsic Value as of December 31, 2021	$ 5

Accounting for Stock-Based Co_7

Accounting for Stock-Based Compensation - Schedule of Share-based Compensation, Restricted Stock, Activity (Details) - Restricted Stock - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Unvested Shares	4,555,735	3,857,402	3,308,907
Granted, Shares	2,929,250	2,205,500	1,989,000
Vested, Shares	(2,312,328)	(1,123,329)	(1,160,667)
Forfeited, Shares	(177,343)	(383,838)	(279,838)
Ending Balance, Unvested Shares	4,995,314	4,555,735	3,857,402
Beginning of Period, Weighted Average Grant Date Fair Value	$ 4.84	$ 5.47	$ 7
Granted, Weighted Average Grant Date Fair Value	8.16	4.90	4.94
Vested, Weighted Average Grant Date Fair Value	4.68	5.84	8.89
Forfeited, Weighted Average Grant Date Fair Value	6.33	8.58	5.60
End of Period, Weighted Average Grant Date Fair Value	$ 6.30	$ 4.84	$ 5.47

Accounting for Stock-Based Co_8

Accounting for Stock-Based Compensation - Schedule of Share-based Compensation, Restricted Stock Units, Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Unvested Shares	613,739	541,576	397,906
Granted, Shares	173,664	310,347	306,612
Vested, Shares	(300,805)	(238,184)	(162,942)
Ending Balance, Unvested Shares	486,598	613,739	541,576
Beginning of Period, Weighted Average Grant Date Fair Value	$ 4.89	$ 5.13	$ 6.17
Granted, Weighted Average Grant Date Fair Value	8.81	4.93	4.99
Vested, Weighted Average Grant Date Fair Value	5.09	5.47	7.42
End of Period, Weighted Average Grant Date Fair Value	$ 6.17	$ 4.89	$ 5.13

Acquisitions and Divestitures -

Acquisitions and Divestitures - Acquisitions - Additional Information (Details)	Jun. 01, 2019USD ($)Item	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Acquisitions and Divestitures [Line Items]
Goodwill		$ 4,219,000,000	$ 4,219,000,000	$ 4,328,000,000
Northwest Mississippi Medical Center [Member]
Acquisitions and Divestitures [Line Items]
Business acquisition number of licensed beds | Item	181
Business acquisition cash paid for operating assets	$ 2,000,000
Business acquisition liabilities assumed	9,000,000
Business acquisition, cost of acquired entity, purchase price	$ 11,000,000
Goodwill				0
Physician Practices Clinics and Other Ancillary Businesses
Acquisitions and Divestitures [Line Items]
Business acquisition, cost of acquired entity, purchase price		$ 3,000,000	$ 1,000,000	8,000,000
Purchase price allocation, property and equipment				4,000,000
Business acquisition, purchase price allocation, intangible assets, other than goodwill				$ 4,000,000

Acquisitions and Divestitures_2

Acquisitions and Divestitures - Schedule of Divestitures (Details) - Item	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2019
Lea Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	84
Effective Date	Jan. 1, 2021
Tennova Healthcare - Tullahoma
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	135
Effective Date	Jan. 1, 2021
Tennova Healthcare - Shelbyville
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	60
Effective Date	Jan. 1, 2021
Northwest Mississippi Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	181
Effective Date	Feb. 1, 2021
Alliance Health Midwest
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	255
Effective Date	Apr. 1, 2021
Berwick Hospital Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	90
Effective Date	Dec. 1, 2020
Brownwood Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	188
Effective Date	Oct. 27, 2020
Abilene Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	231
Effective Date	Oct. 27, 2020
San Angelo Community Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	171
Effective Date	Oct. 24, 2020
Bayfront Health St. Petersburg
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	480
Effective Date	Oct. 1, 2020
Hill Regional Hospital
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	25
Effective Date	Aug. 1, 2020
St. Cloud Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	84
Effective Date	Jul. 1, 2020
Northern Louisiana Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	130
Effective Date	Jul. 1, 2020
Shands Live Oak Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	25
Effective Date	May 1, 2020
Shands Starke Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	49
Effective Date	May 1, 2020
Southside Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	300
Effective Date	Jan. 1, 2020
Southampton Memorial Hospital
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	105
Effective Date	Jan. 1, 2020
Southern Virginia Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	80
Effective Date	Jan. 1, 2020
Bluefield Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		92
Effective Date		Oct. 1, 2019
Lake Wales Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		160
Effective Date		Sep. 1, 2019
Heart of Florida Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		193
Effective Date		Sep. 1, 2019
College Station Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		167
Effective Date		Aug. 1, 2019
Tennova Healthcare - Lebanon
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		245
Effective Date		Aug. 1, 2019
Chester Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		82
Effective Date		Mar. 1, 2019
Carolinas Hospital System - Florence
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		396
Effective Date		Mar. 1, 2019
Springs Memorial Hospital
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		225
Effective Date		Mar. 1, 2019
Carolinas Hospital System - Marion
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		124
Effective Date		Mar. 1, 2019
Memorial Hospital of Salem County
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		126
Effective Date		Jan. 31, 2019
Mary Black Health System - Spartanburg
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		207
Effective Date		Jan. 1, 2019
Mary Black Health System - Gaffney
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		125
Effective Date		Jan. 1, 2019

Acquisitions and Divestitures_3

Acquisitions and Divestitures - Schedule of Balance Sheet Items Classified as Held for Sale (Details) $ in Millions	Dec. 31, 2020USD ($)
Acquisitions And Divestitures [Abstract]
Other current assets	$ 12
Other assets, net	11
Accrued liabilities	$ 16

Acquisitions and Divestitures_4

Acquisitions and Divestitures - Schedule of Net Operating Revenues and Loss and Assets and Liabilities Classified as Discontinued Operations) (Details) - Hospitals Included in Continuing Operations [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups
(Loss) income before income taxes	$ (36)	$ 83	$ (61)
Less: Loss attributable to noncontrolling interests		(6)	(8)
(Loss) income from operations before income taxes attributable to Community Health Systems, Inc. stockholders	$ (36)	$ 89	$ (53)

Acquisitions and Divestitures_5

Acquisitions and Divestitures - Divestitures - Additional Information (Details) $ in Millions	Nov. 30, 2020Item	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2020Item
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment and (gain) loss on sale of businesses, net		$ 24	$ 48	$ 138
Hospitals Included in Continuing Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment and (gain) loss on sale of businesses, net		$ 29	(80)	$ (5)
Biloxi Mississippi To Memorial Properties Inc
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds | Item	153
Agreement date	Oct. 12, 2020
Biloxi Mississippi To Memorial Properties Inc | Merit Health Biloxi
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership Interest percentage by parent	50.00%
Shands Lake Shore Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge recorded on the sale or closure of hospitals			$ 3
Shands Lake Shore Regional Medical Center | Lake City Florida
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds | Item					99

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill [Roll Forward]
Goodwill	$ 7,033	$ 7,033	$ 7,142
Accumulated impairment losses	(2,814)	(2,814)	(2,814)
Goodwill, total	4,219	4,219	$ 4,328
Goodwill acquired as part of acquisitions during current year	5	1
Goodwill allocated to hospitals divested or held for sale	$ (5)	$ (110)

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Goodwill - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	$ 4,219,000,000	$ 4,219,000,000	$ 4,328,000,000
Impairment of goodwill	$ 0	$ 0	$ 0

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Intangible Assets - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired during the year	$ 0
Finite-lived intangible assets, gross	1,000,000	$ 1,000,000
Net, intangible asset not subject to amortization	54,000,000	53,000,000
Gross carrying amount of capitalized software	992,000,000	1,100,000,000
Capitalized computer software, net	215,000,000	251,000,000
Capitalized computer software, development stage costs	79,000,000
Finite-Lived Intangible Assets, Except Capitalized Internal-Use Software
Finite Lived Intangible Assets [Line Items]
Amortization expense	$ 1,000,000	1,000,000	$ 1,000,000
Capitalized Internal Use Software, Significant System Conversions
Finite Lived Intangible Assets [Line Items]
Weighted-average amortization period	3 years
Capitalized Internal Use Software
Finite Lived Intangible Assets [Line Items]
Amortization expense	$ 108,000,000	123,000,000	$ 121,000,000
Amortization expense for 2022	90,000,000
Acquired finite-lived intangible asset, residual value	0
Amortization expense for 2023	62,000,000
Amortization expense for 2024	40,000,000
Amortization expense for 2025	9,000,000
Amortization expense for 2026	7,000,000
Amortization expense thereafter	7,000,000
Maximum
Finite Lived Intangible Assets [Line Items]
Finite-Lived intangible assets, net	1,000,000	$ 1,000,000
Maximum | Finite-Lived Intangible Assets, Except Capitalized Internal-Use Software
Finite Lived Intangible Assets [Line Items]
Amortization expense for 2022	$ 1,000,000

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision for (Benefit from) Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current:
Federal	$ (46)	$ (1)	$ (38)
State	6	3	(5)
Total, Current	(40)	2	(43)
Deferred:
Federal	161	(162)	179
State	10	(25)	24
Total, Deferred	171	(187)	203
Total provision for (benefit from) income taxes for income (loss)	$ 131	$ (185)	$ 160

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation between the Statutory Federal Income Tax Rate and the Effective Tax Rate (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Differences between the statutory federal income tax rate and the effective tax rate
Provision for (benefit from) income taxes at statutory federal rate, Amount	$ 105	$ 89	$ (90)
State income taxes, net of federal income tax benefit, Amount	44	(15)	(104)
Net income attributable to noncontrolling interests, Amount	(29)	(20)	(18)
Change in valuation allowance, Amount	33	(267)	340
Nondeductible goodwill, Amount		41	11
Amended return adjustments, Amount	(22)
Nondeductible loss on divestiture, Amount		(15)	15
Other, Amount		2	6
Total provision for (benefit from) income taxes for income (loss)	$ 131	$ (185)	$ 160
Provision for (benefit from) income taxes at statutory federal rate, Percentage	21.00%	21.00%	21.00%
State income taxes, net of federal income tax benefit, Percentage	8.70%	(3.60%)	24.30%
Net income attributable to noncontrolling interests, Percentage	(5.80%)	(4.70%)	4.20%
Change in valuation allowance, Percentage	6.80%	(63.20%)	(79.20%)
Nondeductible goodwill, Percentage		9.80%	(2.60%)
Amended return adjustments, Percentage	(4.40%)
Nondeductible loss on divestiture, Percentage		(3.40%)	(3.50%)
Other, Percentage		0.30%	(1.40%)
Provision for (benefit from) income taxes and effective tax rate for income (loss), Percentage	26.30%	(43.80%)	(37.20%)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes [Line Items]
Effective income tax rate	26.30%	(43.80%)	(37.20%)
Operating loss carryforwards, valuation allowance	$ 814,000,000
Income tax (payments) refunds, net	$ (4,000,000)	$ (2,000,000)	$ 3,000,000
Minimum
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Jan. 1, 2022
Maximum
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2041
Unrecognized benefit that would affect the effective tax rate	$ 1,000,000
Amount of interest and penalties included in liabilities for uncertain tax positions	1,000,000
Federal
Income Taxes [Line Items]
Net operating loss and credit carryforwards	763,000,000
Operating loss carryforwards expected to be utilized	195,000,000
Valuation allowance increase (decrease)	$ 64,000,000	(265,000,000)
Federal | Tax Year 2018
Income Taxes [Line Items]
Open tax year	2018
State and Local Jurisdiction
Income Taxes [Line Items]
Net operating loss and credit carryforwards	$ 9,400,000,000
Operating loss carryforwards expected to be utilized	638,000,000
Valuation allowance increase (decrease)	$ (31,000,000)	$ (2,000,000)

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Income Taxes (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Assets
Net operating loss and credit carryforwards	$ 833	$ 873
Self-insurance liabilities	49	58
Long-term debt and interest	48	154
Accounts receivable	22	52
IRC Section 163(j) interest limitation	329	108
Accrued vacation	22	22
Accrued bonus	31	32
Other comprehensive income	5	6
Right-of-use liability	142	155
Stock-based compensation	4	4
Deferred compensation	64	69
Other		57
Total	1,587	1,590
Valuation allowance	(814)	(781)
Total Deferred Income Tax Assets, Net	773	809
Liabilities
Property and equipment	343	300
Prepaid expenses	30	29
Intangibles	144	127
Investments in unconsolidated affiliates	58	57
Other liabilities	9	9
IRC Section 481(a) - mixed service cost		106
Right-of-use assets	137	150
IRC Section 481(a) Adjustments	191
Total Deferred Income Tax Liabilities, Gross	$ 912	$ 778

Income Taxes - Schedule of Re_2

Income Taxes - Schedule of Reconciliation of the Total Amount of Unrecognized Tax Benefit (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Unrecognized tax benefit, beginning of year	$ 45	$ 26	$ 29
Gross increases — tax positions in current period	5	19	10
Reductions — tax positions in prior period	(8)
Settlements			(13)
Unrecognized tax benefit, end of year	$ 42	$ 45	$ 26

Long-Term Debt - Schedule of De

Long-Term Debt - Schedule of Debt (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt and lease obligations	$ 12,140	$ 12,216
Less: Unamortized deferred debt issuance costs and note premium	(435)	(250)
Less: Current maturities	(31)	(123)
Total long-term debt	12,109	12,093
Senior Secured Notes | Senior Secured Notes at 4.750% due 2031
Debt Instrument [Line Items]
Debt and lease obligations	1,095
Senior Secured Notes | Senior Secured Notes at 6.25%, Due 2023
Debt Instrument [Line Items]
Debt and lease obligations		95
Senior Secured Notes | Senior Secured Notes at 8.625%, Due 2024
Debt Instrument [Line Items]
Debt and lease obligations		1,033
Senior Secured Notes | Senior Secured Notes at 6.625% Due 2025
Debt Instrument [Line Items]
Debt and lease obligations	1,462	1,462
Senior Secured Notes | Senior Secured Notes at 8%, Due 2026
Debt Instrument [Line Items]
Debt and lease obligations	2,101	2,101
Senior Secured Notes | Senior Secured Notes at 8% Due 2027
Debt Instrument [Line Items]
Debt and lease obligations	700	700
Senior Secured Notes | 5⅝% Senior Secured Notes due 2027
Debt Instrument [Line Items]
Debt and lease obligations	1,900	1,900
Senior Secured Notes | 6% Senior Secured Notes due 2029
Debt Instrument [Line Items]
Debt and lease obligations	900	900
Senior Notes | Senior Notes at 6.875%, Due 2022
Debt Instrument [Line Items]
Debt and lease obligations		126
Senior Notes | Senior Notes at 6.875% Due 2028
Debt Instrument [Line Items]
Debt and lease obligations	767	767
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 9.875% Due 2023
Debt Instrument [Line Items]
Debt and lease obligations		1,769
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 6.875% Due 2029
Debt Instrument [Line Items]
Debt and lease obligations	1,775
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 8.125% Due 2024
Debt Instrument [Line Items]
Debt and lease obligations		1,348
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 6.125% Due 2030
Debt Instrument [Line Items]
Debt and lease obligations	1,440
Finance Lease and Financing Obligations
Debt Instrument [Line Items]
Debt and lease obligations	398	239
Other
Debt Instrument [Line Items]
Debt and lease obligations	$ 37	$ 26

Long-Term Debt - Schedule of _2

Long-Term Debt - Schedule of Debt (Parenthetical) (Details)	May 19, 2021	Feb. 09, 2021	Feb. 02, 2021	Dec. 31, 2021	Dec. 31, 2020	Nov. 19, 2019	Jun. 23, 2019	Mar. 06, 2019	Jun. 22, 2018	Jan. 27, 2014
Senior Secured Notes at 8% Due 2027
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage						8.00%
Senior Notes | Senior Notes at 6.875%, Due 2022
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				6.875%	6.875%					6.875%
Debt instrument, maturity year				2022	2022
Senior Notes | Senior Notes at 6.875% Due 2028
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				6.875%	6.875%
Debt instrument, maturity year				2028	2028
Senior Secured Notes | Senior Secured Notes at 8.625%, Due 2024
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		8.625%		8.625%	8.625%
Debt instrument, maturity year		2024		2024	2024
Senior Secured Notes | Senior Secured Notes at 6.25%, Due 2023
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				6.25%	6.25%
Debt instrument, maturity year				2023	2023
Senior Secured Notes | Senior Secured Notes at 6.625% Due 2025
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				6.625%	6.625%
Debt instrument, maturity year				2025	2025
Senior Secured Notes | Senior Secured Notes at 8% Due 2027
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				8.00%	8.00%	8.00%
Debt instrument, maturity year				2027	2027
Senior Secured Notes | 5⅝% Senior Secured Notes due 2027
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				5.625%	5.625%
Debt instrument, maturity year				2027	2027
Senior Secured Notes | Senior Secured Notes at 8%, Due 2026
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				8.00%	8.00%			8.00%
Debt instrument, maturity year				2026	2026
Senior Secured Notes | 6% Senior Secured Notes due 2029
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				6.00%	6.00%
Debt instrument, maturity year				2029	2029
Senior Secured Notes | Senior Secured Notes at 4.750% due 2031
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		4.75%		4.75%	4.75%
Debt instrument, maturity year		2031		2031	2031
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 9.875% Due 2023
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage			9.875%	9.875%	9.875%		9.875%		11.00%
Debt instrument, maturity year			2023	2023	2023
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 8.125% Due 2024
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				8.125%	8.125%
Debt instrument, maturity year				2024	2024
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 6.875% Due 2029
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage			6.875%	6.875%	6.875%
Debt instrument, maturity year			2029	2029	2029
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 6.125% Due 2030
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	6.125%			6.125%	6.125%
Debt instrument, maturity year	2030			2030	2030

Long-Term Debt - 6.875% Senior

Long-Term Debt - 6.875% Senior Notes, Due 2022 - Additional Information (Details) - USD ($)	Nov. 19, 2019	Jun. 22, 2018	Jan. 27, 2014	Dec. 31, 2020	Dec. 31, 2021	Dec. 07, 2020
Debt Instrument [Line Items]
Long-term debt outstanding					$ 12,140,000,000
Senior Notes at 6.875%, Due 2022
Debt Instrument [Line Items]
Extinguishment of debt amount	$ 2,400,000,000			$ 34,000,000
Junior-Priority Secured Notes at 8.125% Due 2024
Debt Instrument [Line Items]
Debt instrument aggregate principal amount		$ 276,000,000
Senior Secured Notes at 8% Due 2027
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 700,000,000
Debt instrument stated interest rate	8.00%
Senior Notes | Senior Notes at 6.875%, Due 2022
Debt Instrument [Line Items]
Debt instrument, offering date				Jan. 27, 2014
Debt instrument aggregate principal amount			$ 3,000,000,000
Debt instrument stated interest rate			6.875%	6.875%	6.875%
Extinguishment of debt amount		$ 368,000,000
Long-term debt outstanding	$ 231,000,000
Extinguishment of debt amount via tender offer				$ 72,000,000
Tender offer commencement date				Oct. 30, 2020
Tender offer expiration date				Nov. 30, 2020
Senior Notes | Senior Notes at 6.875%, Due 2022 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Minimum period notice for redemption of debt			30 days
Maximum period notice for redemption of debt			60 days
Debt instrument redemption price percentage			100.00%
Senior Notes | Senior Notes at 6.875%, Due 2028
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 1,700,000,000					$ 700,000,000
Debt instrument stated interest rate	6.875%
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Extinguishment of debt amount				$ 226,000,000
Extinguishment of debt amount via tender offer				$ 7,000,000
Tender offer commencement date				Oct. 30, 2020
Tender offer expiration date				Nov. 30, 2020
Senior Notes | Senior Notes at 6.875%, Due 2028 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage	106.875%

Long-Term Debt - 6.25% Senior S

Long-Term Debt - 6.25% Senior Secured Notes, Due 2023 - Additional Information (Details) - USD ($)	Jan. 28, 2021	Dec. 28, 2020	Feb. 06, 2020	May 12, 2017	Mar. 16, 2017	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Issuance of long-term debt						$ 4,310,000,000	$ 4,262,000,000	$ 3,042,000,000
Senior Secured Notes | Senior Secured Notes at 6.25%, Due 2023
Debt Instrument [Line Items]
Debt instrument, offering date						Mar. 16, 2017
Debt instrument aggregate principal amount				$ 3,100,000,000	$ 2,200,000,000
Extinguishment of debt amount	$ 95,000,000	$ 2,579,000,000	$ 426,000,000
Issuance of long-term debt				900,000,000
Debt instrument stated interest rate					6.25%
Senior Secured Notes | Senior Secured Notes at 6.25%, Due 2023 | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Minimum period notice for redemption of debt					30 days
Maximum period notice for redemption of debt					60 days
Debt instrument redemption price percentage					100.00%
Debt instrument redemption description						plus a “make-whole” premium, as described in the indenture governing the 6¼% Senior Secured Notes due 2023.
Senior Secured Notes | Senior Secured Notes at 6.25%, Due 2023 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage					106.25%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount					40.00%
Senior Secured Notes | Senior Secured Notes at 5.125% Due 2018
Debt Instrument [Line Items]
Extinguishment of debt amount					$ 700,000,000
Senior Secured Notes | 5⅝% Senior Secured Notes due 2027
Debt Instrument [Line Items]
Debt instrument, offering date						Dec. 28, 2020
Debt instrument aggregate principal amount		$ 1,900,000,000
Debt instrument stated interest rate						5.625%	5.625%
Minimum period notice for redemption of debt		15 days
Maximum period notice for redemption of debt		60 days
Debt instrument redemption description						plus a “make-whole” premium, as described in the indenture governing the 5⅝% Senior Secured Notes due 2027.
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount		40.00%
Senior Secured Notes | 5⅝% Senior Secured Notes due 2027 | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument redemption price percentage		100.00%				102.813%
Senior Secured Notes | 5⅝% Senior Secured Notes due 2027 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage		105.625%				101.406%
Secured Debt | Credit Facility, Term Loan F
Debt Instrument [Line Items]
Extinguishment of debt amount					$ 1,445,000,000
Secured Debt | Credit Facility, Term Loan A
Debt Instrument [Line Items]
Extinguishment of debt amount				$ 713,000,000
Senior Notes | 6% Senior Secured Notes due 2029
Debt Instrument [Line Items]
Debt instrument aggregate principal amount		$ 900,000,000
Debt instrument stated interest rate		6.00%
Minimum period notice for redemption of debt		15 days
Maximum period notice for redemption of debt		60 days
Debt instrument redemption description						plus a “make-whole” premium, as described in the indenture governing the 6% Senior Secured Notes due 2029.
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount		40.00%
Senior Notes | 6% Senior Secured Notes due 2029 | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument redemption price percentage		100.00%
Senior Notes | 6% Senior Secured Notes due 2029 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage		106.00%

Long-Term Debt - Schedule of Ea

Long-Term Debt - Schedule of Early Redemption Prices on 6.25% Senior Secured Notes due 2023 (Details) - Senior Secured Notes at 6.25%, Due 2023 - Senior Secured Notes	12 Months Ended
	Dec. 31, 2021
Debt Instrument, Redemption, Period Three
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	103.125%
Debt Instrument, Redemption Period, Start Date	Mar. 31, 2020
Debt Instrument, Redemption Period, End Date	Mar. 31, 2021
Debt Instrument, Redemption, Period Four
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	101.563%
Debt Instrument, Redemption Period, Start Date	Mar. 31, 2021
Debt Instrument, Redemption Period, End Date	Mar. 30, 2022
Debt Instrument, Redemption, Period Five
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Mar. 31, 2022
Debt Instrument, Redemption Period, End Date	Mar. 30, 2023

Long-Term Debt - 9.875% Junior-

Long-Term Debt - 9.875% Junior-Priority Secured Notes, Due 2023 - Additional Information (Details) - Junior-Priority Secured Notes - USD ($) $ in Millions	Feb. 02, 2021	Jun. 29, 2020	Jun. 22, 2018	Dec. 31, 2021	Dec. 31, 2020	Jun. 23, 2019
Junior-Priority Secured Notes at 9.875% Due 2023
Debt Instrument [Line Items]
Debt instrument, offering date				Jun. 22, 2018
Debt instrument aggregate principal amount			$ 1,770
Debt instrument stated interest rate	9.875%		11.00%	9.875%	9.875%	9.875%
Debt instrument redemption description				plus a “make-whole” premium, as described in the indenture governing the 9⅞% Junior-Priority Secured Notes due 2023.
Extinguishment of debt amount				$ 2
Tender offer commencement date				Oct. 30, 2020
Tender offer expiration date				Nov. 30, 2020
Junior-Priority Secured Notes at 9.875% Due 2023 | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument redemption price percentage		109.875%	100.00%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount		40.00%
Junior-Priority Secured Notes at 9.875% Due 2023 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Minimum period notice for redemption of debt			15 days
Maximum period notice for redemption of debt			60 days
Junior-Priority Secured Notes at 6.875% Due 2029
Debt Instrument [Line Items]
Debt instrument, offering date	Feb. 2, 2021
Debt instrument aggregate principal amount	$ 1,775
Debt instrument stated interest rate	6.875%			6.875%	6.875%
Debt instrument redemption price percentage	100.00%
Debt instrument redemption description	plus a “make-whole” premium, as described in the indenture governing the 6⅞% Junior-Priority Secured Notes due 2029
Junior-Priority Secured Notes at 6.875% Due 2029 | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument redemption price percentage	103.438%
Junior-Priority Secured Notes at 6.875% Due 2029 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage	101.719%

Long-Term Debt - Schedule of _3

Long-Term Debt - Schedule of Early Redemption Prices on Junior-Priority Secured Notes due 2023 (Details) - Junior-Priority Secured Notes at 9.875% Due 2023 - Junior-Priority Secured Notes	12 Months Ended
	Dec. 31, 2021
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	107.406%
Debt Instrument, Redemption Period, Start Date	Jun. 30, 2020
Debt Instrument, Redemption Period, End Date	Jun. 29, 2021
Debt Instrument, Redemption, Period Four
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.703%
Debt Instrument, Redemption Period, Start Date	Jun. 30, 2021
Debt Instrument, Redemption Period, End Date	Jun. 29, 2022
Debt Instrument, Redemption, Period Five
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Jun. 30, 2022
Debt Instrument, Redemption Period, End Date	Jun. 29, 2023

Long-Term Debt - 8.125% Junior-

Long-Term Debt - 8.125% Junior-Priority Secured Notes Due 2024 - Additional Information (Details) - USD ($)	May 19, 2021	Nov. 19, 2019	Jun. 22, 2018	Jan. 27, 2014	Dec. 31, 2021	Dec. 31, 2020
Junior-Priority Secured Notes at 8.125% Due 2024
Debt Instrument [Line Items]
Debt instrument aggregate principal amount			$ 276,000,000
Senior Notes at 6.875%, Due 2022
Debt Instrument [Line Items]
Extinguishment of debt amount		$ 2,400,000,000				$ 34,000,000
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 8.125% Due 2024
Debt Instrument [Line Items]
Debt instrument, offering date	May 19, 2021				Jun. 22, 2018
Extinguishment of debt amount					$ 1,000,000
Debt instrument stated interest rate	6.125%		8.125%
Debt instrument redemption description					plus a “make-whole” premium, as described in the indenture governing the 8⅛% Junior-Priority Secured Notes due 2024.
Minimum period notice for redemption of debt			15 days
Maximum period notice for redemption of debt			60 days
Extinguishment of debt amount via tender offer					$ 6,000,000
Tender offer commencement date					Oct. 30, 2020
Tender offer expiration date					Nov. 30, 2020
Debt instrument, maturity year	2030
Debt instrument, frequency of periodic payment					On May 19, 2021, CHS redeemed the remaining principal amount of the 8⅛% Junior-Priority Secured Notes due 2024 using proceeds from the issuance of the 6⅛% Junior-Priority Secured Notes due 2030 on May 19, 2021.
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 8.125% Due 2024 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage			108.125%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount			40.00%
Junior Priority Secured Notes Two | Junior-Priority Secured Notes at 8.125% Due 2024
Debt Instrument [Line Items]
Debt instrument aggregate principal amount			$ 1,355,000,000
Debt instrument redemption price percentage					100.00%
Junior Priority Secured Notes One | Junior-Priority Secured Notes at 8.125% Due 2024
Debt Instrument [Line Items]
Debt instrument aggregate principal amount			1,079,000,000
Senior Notes | Senior Notes at 6.875%, Due 2022
Debt Instrument [Line Items]
Debt instrument, offering date						Jan. 27, 2014
Debt instrument aggregate principal amount				$ 3,000,000,000
Extinguishment of debt amount			$ 368,000,000
Debt instrument stated interest rate				6.875%	6.875%	6.875%
Extinguishment of debt amount via tender offer						$ 72,000,000
Tender offer commencement date						Oct. 30, 2020
Tender offer expiration date						Nov. 30, 2020
Debt instrument, maturity year					2022	2022
Senior Notes | Senior Notes at 6.875%, Due 2022 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage				100.00%
Minimum period notice for redemption of debt				30 days
Maximum period notice for redemption of debt				60 days

Long-Term Debt - Schedule of _4

Long-Term Debt - Schedule of Early Redemption Prices on 8.125% Junior-Priority Secured Notes due 2024 (Details) - Junior-Priority Secured Notes at 8.125% Due 2024 - Junior-Priority Secured Notes	12 Months Ended
	Dec. 31, 2021
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	104.063%
Debt Instrument, Redemption Period, Start Date	Jun. 30, 2021
Debt Instrument, Redemption Period, End Date	Jun. 29, 2022
Debt Instrument, Redemption, Period Four
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	102.031%
Debt Instrument, Redemption Period, Start Date	Jun. 30, 2022
Debt Instrument, Redemption Period, End Date	Jun. 29, 2023
Debt Instrument, Redemption, Period Five
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Jun. 30, 2023
Debt Instrument, Redemption Period, End Date	Jun. 29, 2024

Long-Term Debt - 8.625% Senior

Long-Term Debt - 8.625% Senior Secured Notes Due 2024 - Additional Information (Details) - Senior Secured Notes - USD ($)	Feb. 09, 2021	Jul. 06, 2018	Dec. 31, 2021	Dec. 31, 2020
Senior Secured Notes at 8.625%, Due 2024
Debt Instrument [Line Items]
Debt instrument, offering date			Jul. 6, 2018
Debt instrument aggregate principal amount		$ 1,033,000,000
Debt instrument stated interest rate		8.625%
Debt instrument, maturity date			Jan. 15, 2024
Debt instrument redemption description			plus a “make-whole” premium, as described in the indenture governing the 8⅝% Senior Secured Notes due 2024.
Debt instrument redemption price percentage		108.625%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount		40.00%
Minimum period notice for redemption of debt		15 days
Maximum period notice for redemption of debt		60 days
Senior Secured Notes at 8.625%, Due 2024 | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument redemption price percentage		100.00%
Senior Secured Notes at 4.750% due 2031
Debt Instrument [Line Items]
Debt instrument, offering date	Feb. 9, 2021
Debt instrument aggregate principal amount	$ 1,095,000,000
Debt instrument stated interest rate	4.75%		4.75%	4.75%
Debt instrument, maturity date	Feb. 15, 2031
Debt instrument redemption description			The 4¾% Senior Secured Notes due 2031 bear interest at a rate of 4.750% per year payable semi-annually in arrears on February 15 and August 15, commencing on August 15, 2021.

Long-Term Debt - Schedule of _5

Long-Term Debt - Schedule of Early Redemption Prices on 8.625% Senior Secured Notes due 2024 (Details) - Senior Secured Notes at 8.625%, Due 2024 - Senior Secured Notes	Jul. 06, 2018	Dec. 31, 2021
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	108.625%
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage		104.313%
Debt Instrument, Redemption Period, Start Date		Jan. 15, 2021
Debt Instrument, Redemption Period, End Date		Jan. 14, 2022
Debt Instrument, Redemption, Period Four
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage		102.156%
Debt Instrument, Redemption Period, Start Date		Jan. 15, 2022
Debt Instrument, Redemption Period, End Date		Jan. 14, 2023
Debt Instrument, Redemption, Period Five
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage		100.00%
Debt Instrument, Redemption Period, Start Date		Jan. 15, 2023
Debt Instrument, Redemption Period, End Date		Jan. 14, 2024

Long-Term Debt - 6.625% Senior

Long-Term Debt - 6.625% Senior Secured Notes, Due 2025 - Additional Information (Details) - USD ($)	Feb. 04, 2022	Feb. 06, 2020	Dec. 31, 2021
Senior Secured Notes at 6.625% Due 2025 | Senior Secured Notes
Debt Instrument [Line Items]
Debt instrument, offering date			Feb. 6, 2020
Debt instrument aggregate principal amount		$ 1,462,000,000
Debt instrument stated interest rate		6.625%
Debt instrument, maturity date			Feb. 15, 2025
Debt instrument redemption price percentage			100.00%
Senior Secured Notes at 6.625% Due 2025 | Senior Secured Notes | Subsequent Event
Debt Instrument [Line Items]
Debt instrument, offering date	Feb. 4, 2022
Debt instrument aggregate principal amount	$ 1,535,000,000
Debt instrument stated interest rate	5.25%
Debt instrument, maturity date	May 15, 2030
Senior Secured Notes at 6.25%, Due 2023
Debt Instrument [Line Items]
Extinguishment of debt amount		$ 426,000,000

Long-Term Debt - Schedule of _6

Long-Term Debt - Schedule of Early Redemption Prices on 6.625% Senior Secured Notes due 2025 (Details) - Senior Secured Notes at 6.625% Due 2025 - Senior Secured Notes	12 Months Ended
	Dec. 31, 2021
Debt Instrument, Redemption, Period One
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.313%
Debt Instrument, Redemption Period, Start Date	Feb. 15, 2022
Debt Instrument, Redemption Period, End Date	Feb. 14, 2023
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.656%
Debt Instrument, Redemption Period, Start Date	Feb. 15, 2023
Debt Instrument, Redemption Period, End Date	Feb. 14, 2024
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Feb. 15, 2024
Debt Instrument, Redemption Period, End Date	Feb. 14, 2025

Long-Term Debt - 8% Senior Secu

Long-Term Debt - 8% Senior Secured Notes, Due 2026 - Additional Information (Details) - USD ($)	Nov. 19, 2019	Mar. 06, 2019	Dec. 31, 2021	Dec. 31, 2020
Senior Secured Notes at 8%, Due 2026
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 500,000,000
Credit Facility, Term Loan H
Debt Instrument [Line Items]
Extinguishment of debt amount		$ 1,557,000,000
Senior Secured Notes | Senior Secured Notes at 8%, Due 2026
Debt Instrument [Line Items]
Debt instrument, offering date			Mar. 6, 2019
Debt instrument aggregate principal amount	2,101,000,000	$ 1,601,000,000
Debt instrument stated interest rate		8.00%	8.00%	8.00%
Debt instrument redemption price percentage		108.00%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount		40.00%
Debt instrument redemption description			plus a “make-whole” premium, as described in the indenture governing the 8% Senior Secured Notes due 2026.
Senior Secured Notes | Senior Notes at 7.125%, Due 2020
Debt Instrument [Line Items]
Extinguishment of debt amount	$ 121,000,000

Long-Term Debt - Schedule of _7

Long-Term Debt - Schedule of Early Redemption Prices on 8% Senior Secured Notes due 2026 (Details) - Senior Secured Notes at 8%, Due 2026 - Senior Secured Notes	Mar. 06, 2019	Dec. 31, 2021
Debt Instrument Redemption Price Percentage	108.00%
Debt Instrument, Redemption, Period One
Debt Instrument Redemption Price Percentage		104.00%
Debt Instrument, Redemption Period, Start Date		Mar. 15, 2022
Debt Instrument, Redemption Period, End Date		Mar. 14, 2023
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption Price Percentage		102.00%
Debt Instrument, Redemption Period, Start Date		Mar. 15, 2023
Debt Instrument, Redemption Period, End Date		Mar. 14, 2024
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption Price Percentage		100.00%
Debt Instrument, Redemption Period, Start Date		Mar. 15, 2024
Debt Instrument, Redemption Period, End Date		Mar. 14, 2026

Long-Term Debt - 8% Senior Se_2

Long-Term Debt - 8% Senior Secured Notes, Due 2027 - Additional Information (Details) - Senior Secured Notes at 8% Due 2027 - USD ($)	Nov. 19, 2019	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 700,000,000
Debt instrument stated interest rate	8.00%
Senior Secured Notes
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 700,000,000
Debt instrument stated interest rate	8.00%	8.00%	8.00%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Debt instrument redemption description		plus a “make-whole” premium, as described in the indenture governing the 8% Senior Secured Notes due 2027.
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Senior Secured Notes | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage	108.00%	102.00%
Senior Secured Notes | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument redemption price percentage	100.00%	104.00%

Long-Term Debt - Schedule of _8

Long-Term Debt - Schedule of Early Redemption Prices on 8% Senior Secured Notes due 2027 (Details) - Senior Secured Notes at 8% Due 2027 - Senior Secured Notes	Nov. 19, 2019	Dec. 31, 2021
Debt Instrument, Redemption, Period One
Debt Instrument Redemption Price Percentage	100.00%	104.00%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2022
Debt Instrument, Redemption Period, End Date		Dec. 14, 2023
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption Price Percentage	108.00%	102.00%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2023
Debt Instrument, Redemption Period, End Date		Dec. 14, 2024
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption Price Percentage		100.00%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2024
Debt Instrument, Redemption Period, End Date		Dec. 14, 2027

Long-Term Debt - 5.625% Senior

Long-Term Debt - 5.625% Senior Secured Notes, Due 2027 - Additional Information (Details) - Senior Secured Notes - USD ($)	Dec. 28, 2020	Dec. 31, 2021
5⅝% Senior Secured Notes due 2027
Debt Instrument [Line Items]
Debt instrument, offering date		Dec. 28, 2020
Debt instrument, maturity date		Mar. 15, 2027
Debt instrument aggregate principal amount	$ 1,900,000,000
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Debt instrument redemption description		plus a “make-whole” premium, as described in the indenture governing the 5⅝% Senior Secured Notes due 2027.
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
5⅝% Senior Secured Notes due 2027 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage	105.625%	101.406%
5⅝% Senior Secured Notes due 2027 | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument redemption price percentage	100.00%	102.813%
Senior Secured Notes at 6.25%, Due 2023
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 2,579,000,000

Long-Term Debt - Schedule of _9

Long-Term Debt - Schedule of Early Redemption Prices on 5.625% Senior Secured Notes Due 2027 (Details) - 5⅝% Senior Secured Notes due 2027 - Senior Secured Notes	Dec. 28, 2020	Dec. 31, 2021
Debt Instrument, Redemption, Period One
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%	102.813%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2023
Debt Instrument, Redemption Period, End Date		Dec. 14, 2024
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	105.625%	101.406%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2024
Debt Instrument, Redemption Period, End Date		Dec. 14, 2025
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage		100.00%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2025
Debt Instrument, Redemption Period, End Date		Dec. 14, 2027

Long-Term Debt - 6.875% Senio_2

Long-Term Debt - 6.875% Senior Notes, Due 2028 - Additional Information (Details) - USD ($) shares in Millions	Dec. 07, 2020	Nov. 19, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Gain (loss) on early extinguishment of debt			$ (79,000,000)	$ 317,000,000	$ (54,000,000)
Senior Notes | Senior Notes at 6.875%, Due 2028
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 700,000,000	$ 1,700,000,000
Debt instrument stated interest rate		6.875%
Cash proceeds received in exchange offer		$ 0
Debt instrument, maturity date		Apr. 1, 2028
Minimum period notice for redemption of debt		15 days
Maximum period notice for redemption of debt		60 days
Debt instrument redemption description			plus a “make-whole” premium, as described in the indenture governing the 6⅞% Senior Notes due 2028.
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount		40.00%
Aggregate consideration from debt instrument exchanged for cash	$ 400,000,000
Debt instrument converted into shares of common stock	10
Gain (loss) on early extinguishment of debt	$ 205,000,000
Extinguishment of debt amount				226,000,000
Extinguishment of debt amount via tender offer				$ 7,000,000
Tender offer commencement date				Oct. 30, 2020
Tender offer expiration date				Nov. 30, 2020
Senior Notes | Senior Notes at 6.875%, Due 2028 | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument redemption price percentage		100.00%
Senior Notes | Senior Notes at 6.875%, Due 2028 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage		106.875%

Long-Term Debt - Schedule of_10

Long-Term Debt - Schedule of Early Redemption Prices on 6.875% Senior Notes Due 2028 (Details) - Senior Notes at 6.875%, Due 2028 - Senior Notes	12 Months Ended
	Dec. 31, 2021
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption Price Percentage	103.438%
Debt Instrument, Redemption Period, Start Date	Apr. 1, 2023
Debt Instrument, Redemption Period, End Date	Mar. 31, 2024
Debt Instrument, Redemption, Period Four
Debt Instrument Redemption Price Percentage	101.719%
Debt Instrument, Redemption Period, Start Date	Apr. 1, 2024
Debt Instrument, Redemption Period, End Date	Mar. 31, 2025
Debt Instrument, Redemption, Period Five
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Apr. 1, 2025
Debt Instrument, Redemption Period, End Date	Mar. 31, 2028

Long-Term Debt - 6% Senior Secu

Long-Term Debt - 6% Senior Secured Notes, Due 2029 - Additional Information - (Details) - Senior Notes - USD ($)	Dec. 28, 2020	Dec. 31, 2021
6% Senior Secured Notes due 2029
Debt instrument aggregate principal amount	$ 900,000,000
Debt instrument, maturity date	Jan. 15, 2029
Debt instrument stated interest rate	6.00%
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Debt instrument redemption description		plus a “make-whole” premium, as described in the indenture governing the 6% Senior Secured Notes due 2029.
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
6% Senior Secured Notes due 2029 | Debt Instrument, Redemption, Period One
Debt instrument redemption price percentage	100.00%
6% Senior Secured Notes due 2029 | Debt Instrument, Redemption, Period Two
Debt instrument redemption price percentage	106.00%
6% Senior Secured Notes due 2029 and 5.625% Senior Secured Notes due 2027
Debt instrument, repurchase amount	$ 2,579,000,000

Long-Term Debt - Schedule of_11

Long-Term Debt - Schedule of Early Redemption Prices on 6.0% Senior Notes Due 2029 (Details) - 6% Senior Secured Notes due 2029 - Senior Secured Notes	12 Months Ended
	Dec. 31, 2021
Debt Instrument, Redemption, Period One
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.00%
Debt Instrument, Redemption Period, Start Date	Jan. 15, 2024
Debt Instrument, Redemption Period, End Date	Jan. 14, 2025
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.50%
Debt Instrument, Redemption Period, Start Date	Jan. 15, 2025
Debt Instrument, Redemption Period, End Date	Jan. 14, 2026
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Jan. 15, 2026
Debt Instrument, Redemption Period, End Date	Jan. 14, 2029

Long-Term Debt - 4.750% Senior

Long-Term Debt - 4.750% Senior Secured Notes, Due 2031 - Additional Information (Details) - Senior Secured Notes - USD ($) $ in Millions	Feb. 09, 2021	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument Redemption Period Six
Debt Instrument [Line Items]
Debt instrument stated interest rate	4.75%
Debt instrument, maturity year	2031
Debt instrument redemption description	plus a “make-whole” premium, as described in the indenture governing the 4¾% Senior Secured Notes due 2031
Debt instrument optional redemption date	Feb. 15, 2026
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Debt instrument redemption price percentage	100.00%
Senior Secured Notes at 4.750% due 2031
Debt Instrument [Line Items]
Debt instrument, offering date	Feb. 9, 2021
Debt instrument aggregate principal amount	$ 1,095
Debt instrument stated interest rate	4.75%	4.75%	4.75%
Debt instrument, maturity date	Feb. 15, 2031
Debt instrument, maturity year	2031	2031	2031
Debt instrument redemption description		The 4¾% Senior Secured Notes due 2031 bear interest at a rate of 4.750% per year payable semi-annually in arrears on February 15 and August 15, commencing on August 15, 2021.
Debt instrument optional redemption date	Feb. 15, 2026
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Senior Secured Notes at 4.750% due 2031 | Redeem up to 40% Principal Amount Prior to February 15, 2024
Debt Instrument [Line Items]
Debt instrument stated interest rate	4.75%
Debt instrument, maturity year	2031
Debt instrument optional redemption date	Feb. 15, 2024
Debt instrument redemption price percentage	104.75%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Senior Secured Notes at 4.750% due 2031 | Redeem up to 10% Principal Amount Prior to February 15, 2026
Debt Instrument [Line Items]
Debt instrument redemption description	plus accrued and unpaid interest, if any. In addition, any time prior to February 15, 2026, but not more than once during each twelve-month period
Debt instrument redemption price percentage	103.00%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	10.00%
Senior Secured Notes at 8.625%, Due 2024
Debt Instrument [Line Items]
Debt instrument stated interest rate	8.625%	8.625%	8.625%
Debt instrument, maturity year	2024	2024	2024
Debt instrument redemption date	Feb. 9, 2021

Long-Term Debt - Schedule of_12

Long-Term Debt - Schedule of Early Redemption Prices on 4.750% Senior Notes Due 2031 (Details) - Senior Secured Notes - Senior Secured Notes at 4.750% due 2031	12 Months Ended
	Dec. 31, 2021
Debt Instrument, Redemption, Period One
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	102.375%
Debt Instrument, Redemption Period, Start Date	Feb. 15, 2026
Debt Instrument, Redemption Period, End Date	Feb. 14, 2027
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.583%
Debt Instrument, Redemption Period, Start Date	Feb. 15, 2027
Debt Instrument, Redemption Period, End Date	Feb. 14, 2028
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.792%
Debt Instrument, Redemption Period, Start Date	Feb. 15, 2028
Debt Instrument, Redemption Period, End Date	Feb. 14, 2029
Debt Instrument, Redemption, Period Four
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Feb. 15, 2029
Debt Instrument, Redemption Period, End Date	Feb. 14, 2031

Long-Term Debt - 6.875% Senio_3

Long-Term Debt - 6.875% Senior Secured Notes, Due 2029 - Additional Information (Details) - Junior-Priority Secured Notes - USD ($) $ in Millions	Feb. 02, 2021	Dec. 31, 2021	Dec. 31, 2020	Jun. 23, 2019	Jun. 22, 2018
Junior-Priority Secured Notes at 6.875% Due 2029
Debt Instrument [Line Items]
Debt instrument, offering date	Feb. 2, 2021
Debt instrument aggregate principal amount	$ 1,775
Debt instrument stated interest rate	6.875%	6.875%	6.875%
Debt instrument, maturity date	Apr. 15, 2029
Debt instrument, maturity year	2029	2029	2029
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Debt instrument redemption price percentage	100.00%
Debt instrument optional redemption date	Apr. 15, 2024
Debt instrument redemption description	plus a “make-whole” premium, as described in the indenture governing the 6⅞% Junior-Priority Secured Notes due 2029
Junior-Priority Secured Notes at 6.875% Due 2029 | Debt Instrument, Redemption, Period Five
Debt Instrument [Line Items]
Debt instrument redemption price percentage	106.875%
Debt instrument optional redemption date	Apr. 15, 2024
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Junior-Priority Secured Notes at 9.875% Due 2023
Debt Instrument [Line Items]
Debt instrument, offering date		Jun. 22, 2018
Debt instrument aggregate principal amount					$ 1,770
Debt instrument stated interest rate	9.875%	9.875%	9.875%	9.875%	11.00%
Debt instrument, maturity year	2023	2023	2023
Debt instrument redemption description		plus a “make-whole” premium, as described in the indenture governing the 9⅞% Junior-Priority Secured Notes due 2023.
Junior-Priority Secured Notes at 9.875% Due 2023 | Debt Instrument, Redemption, Period Five
Debt Instrument [Line Items]
Debt instrument redemption price percentage		100.00%

Long-Term Debt - Schedule of_13

Long-Term Debt - Schedule of Early Redemption Prices 6.875% Junior-Priority Secured Notes due 2029 (Details) - Junior-Priority Secured Notes at 6.875% Due 2029 - Junior-Priority Secured Notes	Feb. 02, 2021
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption, Period One
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.438%
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2024
Debt Instrument, Redemption Period, End Date	Apr. 14, 2025
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.719%
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2025
Debt Instrument, Redemption Period, End Date	Apr. 14, 2026
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2026
Debt Instrument, Redemption Period, End Date	Apr. 14, 2029

Long-Term Debt - 6.125% Junior-

Long-Term Debt - 6.125% Junior-Priority Secured Notes, Due 2030 - Additional Information (Details) - Junior-Priority Secured Notes - Junior-Priority Secured Notes at 6.125% Due 2030 - USD ($) $ in Millions	May 19, 2021	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt instrument, offering date	May 19, 2021
Debt instrument aggregate principal amount	$ 1,440
Debt instrument stated interest rate	6.125%	6.125%	6.125%
Debt instrument, maturity date	Apr. 1, 2030
Debt instrument, maturity year	2030	2030	2030
Debt instrument, frequency of periodic payment		The 6⅛% Junior-Priority Secured Notes due 2030 bear interest at a rate of 6.125% per year payable semi-annually in arrears on April 1 and October 1, commencing on October 1, 2021
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Debt instrument redemption price percentage	100.00%
Debt instrument optional redemption date	Apr. 1, 2025
Debt instrument redemption description		plus a “make-whole” premium, as described in the indenture governing the 6⅛% Junior-Priority Secured Notes due 2030.
Redeem up to 40% Principal Amount Prior to May 15, 2024
Debt Instrument [Line Items]
Debt instrument redemption price percentage	106.125%
Debt instrument optional redemption date	May 15, 2024
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%

Long-Term Debt - Schedule of_14

Long-Term Debt - Schedule of Early Redemption Prices 6.125% Junior-Priority Secured Notes due 2030 (Details) - Junior-Priority Secured Notes at 6.125% Due 2030 - Junior-Priority Secured Notes	May 19, 2021
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption, Period One
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.063%
Debt Instrument, Redemption Period, Start Date	Apr. 1, 2025
Debt Instrument, Redemption Period, End Date	Mar. 31, 2026
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.531%
Debt Instrument, Redemption Period, Start Date	Apr. 1, 2026
Debt Instrument, Redemption Period, End Date	Mar. 31, 2027
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Apr. 1, 2027
Debt Instrument, Redemption Period, End Date	Mar. 31, 2030

Long-Term Debt - ABL Facility -

Long-Term Debt - ABL Facility - Additional Information (Details) - USD ($)	Nov. 22, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Gain (loss) on early extinguishment of debt		$ (79,000,000)	$ 317,000,000	$ (54,000,000)
After-tax gain (loss) from extinguishment of debt		(116,000,000)	352,000,000	(42,000,000)
Interest paid on borrowings		778,000,000	$ 1,039,000,000	$ 1,011,000,000
Amended and Restated ABL Credit Agreement
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 1,000,000,000	1,000,000,000
Line of credit facility, excess availability		897,000,000
Line of credit outstanding amount		0
Aggregate principal amount for springing maturity	350,000,000
Amended and Restated ABL Credit Agreement | ABL Facility Customary Covenants
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 95,000,000
Debt instrument variable interest rate	10.00%
Amended and Restated ABL Credit Agreement | Minimum
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage	0.25%
Amended and Restated ABL Credit Agreement | Maximum
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage	0.375%
Amended and Restated ABL Credit Agreement | Base Rate
Debt Instrument [Line Items]
Percentage of the maximum commitment of excess availability, one	0.75%
Percentage of the maximum commitment of excess availability, two	1.00%
Percentage of the maximum commitment of excess availability, three	1.25%
Amended and Restated ABL Credit Agreement | Federal Reserve’s Secured Overnight Financing Rate
Debt Instrument [Line Items]
Percentage of the maximum commitment of excess availability, one	1.75%
Percentage of the maximum commitment of excess availability, two	2.00%
Percentage of the maximum commitment of excess availability, three	2.25%
Letter of Credit | Amended and Restated ABL Credit Agreement
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 200,000,000
Line of credit outstanding amount		$ 103,000,000

Long-Term Debt - Schedule of Ma

Long-Term Debt - Schedule of Maturities of Long-Term Debt (Details) $ in Millions	Dec. 31, 2021USD ($)
Debt Disclosure [Abstract]
2022	$ 31
2023	14
2024	10
2025	1,471
2026	2,109
Thereafter	8,940
Total maturities	12,575
Less: Deferred debt issuance costs	(421)
Plus: Unamortized note premium	(14)
Total long-term debt	$ 12,140

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Assets:
Available-for-sale debt securities	$ 178	$ 110
Carrying Amount
Assets:
Cash and cash equivalents	507	1,676
Investments in equity securities	144	129
Available-for-sale debt securities	178	110
Trading securities	13	12
Carrying Amount | Senior Secured Notes | Senior Secured Notes at 6.25%, Due 2023
Liabilities:
Notes payable, fair value disclosure		95
Carrying Amount | Senior Secured Notes | Senior Secured Notes at 8.625%, Due 2024
Liabilities:
Notes payable, fair value disclosure		1,025
Carrying Amount | Senior Secured Notes | Senior Secured Notes at 6.625% Due 2025
Liabilities:
Notes payable, fair value disclosure	1,434	1,427
Carrying Amount | Senior Secured Notes | Senior Secured Notes at 8%, Due 2026
Liabilities:
Notes payable, fair value disclosure	2,078	2,074
Carrying Amount | Senior Secured Notes | Senior Secured Notes at 8% Due 2027
Liabilities:
Notes payable, fair value disclosure	692	692
Carrying Amount | Senior Secured Notes | Senior Secured Notes at 5.625% due 2027
Liabilities:
Notes payable, fair value disclosure	1,819	1,809
Carrying Amount | Senior Secured Notes | Senior Notes at 6% Due 2029
Liabilities:
Notes payable, fair value disclosure	860	857
Carrying Amount | Senior Secured Notes | Senior Secured Notes at 4.750% due 2031
Liabilities:
Notes payable, fair value disclosure	1,090
Carrying Amount | Senior Notes | Senior Notes at 6.875%, Due 2022
Liabilities:
Notes payable, fair value disclosure		125
Carrying Amount | Senior Notes | Senior Notes at 6.875% Due 2028
Liabilities:
Notes payable, fair value disclosure	759	758
Carrying Amount | Junior-Priority Secured Notes | Junior-Priority Secured Notes at 9.875% Due 2023
Liabilities:
Notes payable, fair value disclosure		1,756
Carrying Amount | Junior-Priority Secured Notes | Junior-Priority Secured Notes at 8.125% Due 2024
Liabilities:
Notes payable, fair value disclosure		1,336
Carrying Amount | Junior-Priority Secured Notes | Junior-Priority Secured Notes at 6.875% Due 2029
Liabilities:
Notes payable, fair value disclosure	1,625
Carrying Amount | Junior-Priority Secured Notes | Junior-Priority Secured Notes at 6.125% Due 2030
Liabilities:
Notes payable, fair value disclosure	1,352
Carrying Amount | ABL Facility and Other Debt
Liabilities:
Notes payable, fair value disclosure	32	23
Estimated Fair Value
Assets:
Cash and cash equivalents	507	1,676
Investments in equity securities	144	129
Available-for-sale debt securities	178	110
Trading securities	13	12
Estimated Fair Value | Senior Secured Notes | Senior Secured Notes at 6.25%, Due 2023
Liabilities:
Notes payable, fair value disclosure		99
Estimated Fair Value | Senior Secured Notes | Senior Secured Notes at 8.625%, Due 2024
Liabilities:
Notes payable, fair value disclosure		1,080
Estimated Fair Value | Senior Secured Notes | Senior Secured Notes at 6.625% Due 2025
Liabilities:
Notes payable, fair value disclosure	1,517	1,543
Estimated Fair Value | Senior Secured Notes | Senior Secured Notes at 8%, Due 2026
Liabilities:
Notes payable, fair value disclosure	2,210	2,275
Estimated Fair Value | Senior Secured Notes | Senior Secured Notes at 8% Due 2027
Liabilities:
Notes payable, fair value disclosure	758	760
Estimated Fair Value | Senior Secured Notes | Senior Notes at 6% Due 2029
Liabilities:
Notes payable, fair value disclosure	966	973
Estimated Fair Value | Senior Secured Notes | Senior Secured Notes at 4.750% due 2031
Liabilities:
Notes payable, fair value disclosure	1,108
Estimated Fair Value | Senior Notes | Senior Notes at 6.875%, Due 2022
Liabilities:
Notes payable, fair value disclosure		125
Estimated Fair Value | Senior Notes | Senior Secured Notes at 5.625% due 2027
Liabilities:
Notes payable, fair value disclosure	2,011	2,048
Estimated Fair Value | Senior Notes | Senior Notes at 6.875% Due 2028
Liabilities:
Notes payable, fair value disclosure	758	618
Estimated Fair Value | Junior-Priority Secured Notes | Junior-Priority Secured Notes at 9.875% Due 2023
Liabilities:
Notes payable, fair value disclosure		1,861
Estimated Fair Value | Junior-Priority Secured Notes | Junior-Priority Secured Notes at 8.125% Due 2024
Liabilities:
Notes payable, fair value disclosure		1,408
Estimated Fair Value | Junior-Priority Secured Notes | Junior-Priority Secured Notes at 6.875% Due 2029
Liabilities:
Notes payable, fair value disclosure	1,823
Estimated Fair Value | Junior-Priority Secured Notes | Junior-Priority Secured Notes at 6.125% Due 2030
Liabilities:
Notes payable, fair value disclosure	1,431
Estimated Fair Value | ABL Facility and Other Debt
Liabilities:
Notes payable, fair value disclosure	$ 32	$ 23

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping (Parenthetical) (Details)	May 19, 2021	Feb. 09, 2021	Feb. 02, 2021	Dec. 31, 2021	Dec. 31, 2020	Nov. 19, 2019	Jun. 23, 2019	Mar. 06, 2019	Jun. 22, 2018	Jan. 27, 2014
Senior Secured Notes at 8% Due 2027
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate						8.00%
Senior Notes | Senior Notes at 6.875%, Due 2022
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate				6.875%	6.875%					6.875%
Debt instrument maturity year				2022	2022
Senior Notes | Senior Notes at 6.875% Due 2028
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate				6.875%	6.875%
Debt instrument maturity year				2028	2028
Senior Secured Notes | Senior Secured Notes at 6.25%, Due 2023
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate				6.25%	6.25%
Debt instrument maturity year				2023	2023
Senior Secured Notes | Senior Secured Notes at 8.625%, Due 2024
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate		8.625%		8.625%	8.625%
Debt instrument maturity year		2024		2024	2024
Senior Secured Notes | Senior Secured Notes at 6.625% Due 2025
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate				6.625%	6.625%
Debt instrument maturity year				2025	2025
Senior Secured Notes | Senior Secured Notes at 8%, Due 2026
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate				8.00%	8.00%			8.00%
Debt instrument maturity year				2026	2026
Senior Secured Notes | Senior Secured Notes at 8% Due 2027
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate				8.00%	8.00%	8.00%
Debt instrument maturity year				2027	2027
Senior Secured Notes | Senior Secured Notes at 5.625% due 2027
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate				5.625%	5.625%
Debt instrument maturity year				2027	2027
Senior Secured Notes | Senior Notes at 6% Due 2029
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate				6.00%	6.00%
Debt instrument maturity year				2029	2029
Senior Secured Notes | Senior Secured Notes at 4.750% due 2031
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate		4.75%		4.75%	4.75%
Debt instrument maturity year		2031		2031	2031
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 9.875% Due 2023
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate			9.875%	9.875%	9.875%		9.875%		11.00%
Debt instrument maturity year			2023	2023	2023
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 8.125% Due 2024
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate				8.125%	8.125%
Debt instrument maturity year				2024	2024
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 6.875% Due 2029
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate			6.875%	6.875%	6.875%
Debt instrument maturity year			2029	2029	2029
Junior-Priority Secured Notes | Junior-Priority Secured Notes at 6.125% Due 2030
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument stated interest rate	6.125%			6.125%	6.125%
Debt instrument maturity year	2030			2030	2030

Fair Value - Additional Informa

Fair Value - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021USD ($)Item	Dec. 31, 2020USD ($)Item	Dec. 31, 2019USD ($)
Fair Value Disclosures [Line Items]
Fair value, assets, level 1 to level 2 transfers, amount	$ 0	$ 0
Fair value, assets, level 2 to level 1 transfers, amount	0	0
Fair value, liabilities, level 1 to level 2 transfers, amount	0	0
Fair value, liabilities, level 2 to level 1 transfers, amount	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	$ 125,000,000	$ 7,000,000
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions | Item	281	11
Other Investment Income
Fair Value Disclosures [Line Items]
Investment Income, Interest and Dividend	$ 5,000,000	$ 6,000,000	$ 7,000,000
Available-for-sale Securities
Fair Value Disclosures [Line Items]
Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held	$ 0

Fair Value - Schedule of Fair V

Fair Value - Schedule of Fair Value, Assets Measured on Recurring Basis (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale debt securities	$ 178	$ 110
Fair Value, Measurements, Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments in equity securities	144	129
Available-for-sale debt securities	178	110
Trading securities	13	12
Total assets	335	251
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments in equity securities	144	129
Total assets	144	129
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale debt securities	178	110
Trading securities	13	12
Total assets	$ 191	$ 122

Fair Value - Supplemental Infor

Fair Value - Supplemental Information Regarding Available-for-Sale Debt Securities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 179	$ 105
Gross Unrealized Gains	1	5
Gross Unrealized Losses	(2)
Estimated Fair Value	178	110
Government
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	83	48
Gross Unrealized Gains	1	2
Gross Unrealized Losses	(1)
Estimated Fair Value	83	50
Corporate
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	62	38
Gross Unrealized Gains		2
Gross Unrealized Losses	(1)
Estimated Fair Value	61	40
Mortgage and Asset-Backed Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	34	19
Gross Unrealized Gains		1
Estimated Fair Value	$ 34	$ 20

Fair Value - Contractual Maturi

Fair Value - Contractual Maturities of Debt Securities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Within 1 year, Amortized Cost	$ 8	$ 3
After 1 year and through year 5, Amortized Cost	61	26
After 5 years and through year 10, Amortized Cost	49	30
After 10 years, Amortized Cost	61	46
Within 1 year, Fair Value	8	3
After 1 year and through year 5, Fair Value	61	27
After 5 years and through year 10, Fair Value	49	32
After 10 years, Fair Value	$ 60	$ 48

Fair Value - Gross Realized Gai

Fair Value - Gross Realized Gains and Losses and Investment Income on Available-for-Sale Debt Securities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Realized gains	$ 1	$ 2
Realized losses	$ (1)	$ (1)

Fair Value - Net Gains and Loss

Fair Value - Net Gains and Losses Recognized for Investments in Equity Securities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Equity Securities, FV-NI, Realized Gain (Loss)	$ 20	$ 9	$ 15
Available-for-sale Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Equity Securities, FV-NI, Realized Gain (Loss)	13	14	2
Held-to-maturity Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Equity Securities, FV-NI, Unrealized Gain (Loss)	$ 7	$ (5)	$ 13

Leases - Components of Lease Co

Leases - Components of Lease Cost and Rent Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease cost	$ 196	$ 203	$ 194
Short-term rent expense	92	104	114
Variable lease cost	25	26	18
Sublease income	(5)	(6)	(5)
Total operating lease cost	308	327	321
Finance lease cost:
Amortization of ROU assets	9	10	12
Interest on finance lease liabilities	9	8	7
Total finance lease cost	$ 18	$ 18	$ 19

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Operating Leases:
Operating Lease ROU Assets	$ 668	$ 642
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	us-gaap:OtherAssets	us-gaap:OtherAssets
Finance Leases:
Property and equipment	$ 9,757	$ 9,352
Less accumulated depreciation and amortization	(4,204)	(4,030)
Property and equipment, net	5,553	5,322
Current finance lease liabilities	$ 8	$ 5
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	us-gaap:DebtCurrent	us-gaap:DebtCurrent
Long-term finance lease liabilities	$ 233	$ 74
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term debt	Long-term debt
Finance Lease ROU Assets
Finance Leases:
Property and equipment	$ 314	$ 150
Less accumulated depreciation and amortization	(54)	(46)
Property and equipment, net	260	104
Finance Lease ROU Assets | Land and Improvements
Finance Leases:
Property and equipment	8	8
Finance Lease ROU Assets | Building and Building Improvements
Finance Leases:
Property and equipment	289	134
Finance Lease ROU Assets | Equipment and Fixtures
Finance Leases:
Property and equipment	$ 17	$ 8

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases	$ 197	$ 188	$ 167
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases	9	8	7
Cash paid for amounts included in the measurement of lease liabilities: Financing cash flows from finance leases	4	7	9
ROU assets obtained in exchange for new finance lease liabilities	166	22	2
ROU assets obtained in exchange for new operating lease liabilities	$ 143	$ 150	$ 122
Weighted-average remaining lease term: Operating leases	6 years	7 years	6 years
Weighted-average remaining lease term: Finance leases	30 years	19 years	20 years
Weighted-average discount rate: Operating leases	8.10%	9.00%	9.10%
Weighted-average discount rate: Finance leases	6.30%	8.40%	5.60%

Leases - Commitments Relating t

Leases - Commitments Relating to Noncancellable Lease Obligations (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Operating Leases
2022	$ 194
2023	171
2024	123
2025	95
2026	75
Thereafter	236
Total minimum future payments	894
Less: Imputed interest	(212)
Total liabilities	682
Less: Current portion	(147)	$ (142)
Long-term liabilities	535	524
Finance Leases
2022	21
2023	17
2024	16
2025	16
2026	16
Thereafter	525
Total minimum future payments	611
Less: Imputed interest	(370)
Total liabilities	241
Less: Current portion	(8)	(5)
Long-term liabilities	233	$ 74
Financing Obligations
2022	12
2023	13
2024	13
2025	13
2026	13
Thereafter	89
Total minimum future payments	153
Less: Imputed interest	4
Total liabilities	157
Less: Current portion	(2)
Long-term liabilities	$ 155

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	Dec. 31, 2021USD ($)
Leases [Abstract]
Operating lease right of use asset pending leases that have not yet commenced	$ 112

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Cost Recognized	$ 65,000,000	$ 74,000,000	$ 85,000,000
Liability for deferred compensation plans	175,000,000	176,000,000
Defined benefit plan, noncash settlement loss	$ 0	0	0
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued benefits liabilities		$ 5,000,000
Defined benefit plans and other post-retirement plans, weighted-average assumptions to determine net periodic cost, discount rates	2.50%	3.20%
Expected long-term rates of return on assets	5.50%	6.00%
Pension Plans, Defined Benefit [Member] | Maximum
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost		$ 1,000,000	1,000,000
Accrued benefits liabilities	$ 1,000,000
Settlement charge	1,000,000
Deferred Compensation Plans Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Liability for deferred compensation plans	81,000,000	95,000,000
Deferred Compensation Company-Owned Life Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Liability for deferred compensation plans	167,000,000	148,000,000
Trust for Benefit of Employees [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan assets designated to pay benefits of the deferred compensation plans	248,000,000	243,000,000
Supplemental Employee Retirement Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost	11,000,000	7,000,000	$ 7,000,000
Accrued benefits liabilities	$ 99,000,000	$ 89,000,000
Defined benefit plans and other post-retirement plans, weighted-average assumptions to determine net periodic cost, discount rates	2.70%	3.10%
Defined benefit plans and other post-retirement plans, weighted-average assumptions to determine net periodic cost, rate of compensation increase	3.00%	3.00%

Stockholders' Deficit - Additio

Stockholders' Deficit - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Capital stock, shares authorized	400,000,000
Common stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares authorized	100,000,000	100,000,000
Common stock, par value per share	$ 0.01	$ 0.01
Preferred stock, par value per share	$ 0.01	$ 0.01
Preferred stock, shares outstanding	0
Amount available for dividend payments, stock repurchases at period end	$ 300

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Impact of Noncontrolling Interest to Stockholders' Deficit (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Net income (loss) attributable to Community Health Systems,Inc. stockholders	$ 230	$ 511	$ (675)
Net increase (decrease) in Community Health Systems,Inc. paid-in-capital for purchase of subsidiary partnership interests	17	3	3
Net transfers to the noncontrolling interests	17	3	3
Change to Community Health Systems, Inc. stockholders' deficit from net income (loss) attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests	$ 247	$ 514	$ (672)

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Components of Denominator for Computation of Basic and Diluted Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Effect of dilutive securities:
Weighted-average number of shares outstanding — basic	126,754,852	115,491,022	113,739,046
Restricted stock awards	2,803,938	905,903
Employee stock options	726,130	122,785
Other equity-based awards	312,490	24,851
Weighted-average number of shares outstanding — diluted	130,597,410	116,544,561	113,739,046

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Details)	12 Months Ended
	Dec. 31, 2019shares
Earnings Per Share [Abstract]
Increase in number of shares to diluted shares calculation if income would have been generated	133,866

Earnings Per Share - Schedule_2

Earnings Per Share - Schedule of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Employee stock options and restricted stock awards excluded from computation of earnings per share amount	774,981	2,821,511	3,508,968

Equity Investments - Additional

Equity Investments - Additional Information (Details) $ in Millions	Jul. 30, 2021USD ($)Hospital	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2016	Dec. 31, 2021USD ($)
Schedule Of Equity Method Investments [Line Items]
Proceeds from sale of unconsolidated minority equity interests		$ 110
Equity method investment		129	$ 190			$ 129
Equity in earnings of unconsolidated affiliates		$ 22	$ 10	$ 15
HealthTrust [Member]
Schedule Of Equity Method Investments [Line Items]
Equity method investment ownership percentage		17.50%				17.50%
Two Hospitals in Macon Georgia
Schedule Of Equity Method Investments [Line Items]
Disposal date		Jul. 30, 2021
Number of hospitals sold | Hospital	2
Percentage of ownership interest sold	38.00%
Proceeds from sale of unconsolidated minority equity interests	$ 110
Pre tax gain on sale of investments		$ 39
Home Care [Member]
Schedule Of Equity Method Investments [Line Items]
Disposal date		Dec. 31, 2016
Percentage of ownership interest sold					80.00%	20.00%
Equity method investment ownership percentage					80.00%

Comprehensive Loss - Schedule o

Comprehensive Loss - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) ("AOCL") by Component (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income Loss [Line Items]
AOCL, Beginning Balance	$ (13)	$ (9)
Other comprehensive (loss) income before reclassifications		4
Amounts reclassified from AOCL	(2)	(8)
Other comprehensive (loss) income	(2)	(4)	$ 1
AOCL, Ending Balance	(14)	(13)	(9)
Change in Fair Value of Available for Sale Debt Securities
Accumulated Other Comprehensive Income Loss [Line Items]
AOCL, Beginning Balance	2	(3)
Other comprehensive (loss) income before reclassifications	(1)	6
Amounts reclassified from AOCL	(4)	2
Other comprehensive (loss) income	(5)	4
AOCL, Ending Balance	(2)	2	(3)
Change in Unrecognized Pension Cost Components
Accumulated Other Comprehensive Income Loss [Line Items]
AOCL, Beginning Balance	(15)	(8)
Other comprehensive (loss) income before reclassifications	1	(1)
Amounts reclassified from AOCL	2	(6)
Other comprehensive (loss) income	3	(7)
AOCL, Ending Balance	$ (12)	(15)	(8)
Change in Fair Value of Interest Rate Swaps [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
AOCL, Beginning Balance		2
Other comprehensive (loss) income before reclassifications		(1)
Other comprehensive (loss) income		$ (1)
AOCL, Ending Balance			$ 2

Comprehensive Loss - Schedule_2

Comprehensive Loss - Schedule of Amounts Reclassified Out of AOCL (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Reclassification, net of tax	$ 2	$ 8
Pension Plans, Defined Benefit [Member]
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Reclassification, Total before tax	(2)	(4)
Tax benefit		10
Reclassification, net of tax	(2)	6
Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member] | Pension Plans, Defined Benefit [Member]
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Reclassification, Total before tax	$ (2)	(1)
Accumulated Defined Benefit Plans Adjustment, Net Transition Attributable to Parent [Member] | Pension Plans, Defined Benefit [Member]
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Reclassification, Total before tax		$ (3)

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	Jun. 01, 2018	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Commitments And Contingencies [Line Items]
Physician recruiting commitment, physician income guarantee period			12 months
Physician recruiting commitment, period of recoverability of physician income guarantee for noncommitment			3 years
Physician recruiting commitment, maximum potential future payments in excess of liability recorded		$ 10,000,000	$ 10,000,000
Malpractice loss contingency, historical claims period used by actuary to estimate liability	20 years
Malpractice Loss Contingency, Discount Rate			1.80%	1.80%	2.60%
Malpractice Loss Contingency, Accrual, Discounted		533,000,000	$ 533,000,000	$ 602,000,000
Malpractice Loss Contingency, Accrual, Undiscounted		564,000,000	564,000,000	629,000,000
Malpractice Loss Contingency, Accrual, Discounted, Current		162,000,000	162,000,000	177,000,000
Expenses related to settlement of professional liability claim				50,000,000
Recovery of full settlement amount				50,000,000
Recovery from third-party insurers of professional liability claim		22,000,000
Change in estimate reserve for professional liability claims			0	0
Pending Litigation [Member] | Litigation Matters Where Negative Outcome Is Reasonably Possible [Member]
Commitments And Contingencies [Line Items]
Attorneys' fees and other costs incurred			1,000,000	$ 3,000,000	$ 21,000,000
Professional and general liability self-insured claims reported prior to June 1, 2002, per occurrence [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			1,000,000
Professional and general liability self-insured reported from June 1, 2002 through June 1, 2003, per occurrence [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			2,000,000
Professional and general liability self-insured reported from June 1, 2003 and before June 1, 2005, per occurrence [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			4,000,000
Professional and general liability self-insured claims reported on or after June 1, 2005, per occurrence [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			5,000,000
Professional and general liability claims reported on or after June 1, 2014 [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			10,000,000
Professional and general liability claims reported on or after June 1, 2003 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident			95,000,000
Professional and general liability claims incurred and reported after January 1, 2008 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident			145,000,000
Professional and general liability claims incurred and reported after June 1, 2010 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident			195,000,000
Professional and general liability claims reported on or after June 1, 2015 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident			215,000,000
Integrated occurrence claims reported on or after June 1, 2014 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Annual Coverage Limit			50,000,000
Integrated occurrence claims reported on or after June 1, 2015 through June 1, 2020 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Annual Coverage Limit			75,000,000
Integrated occurrence claims reported between June 1,2020 and June 1,2022 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Annual Coverage Limit			75,000,000
Professional and general liability self-insured claims under certain policy terms until Company total aggregate coverage is met if first aggregate layer becomes fully utilized [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			$ 10,000,000
Maximum
Commitments And Contingencies [Line Items]
Malpractice loss contingency, average lag period from occurrence to settlement			4 years
Malpractice loss contingency, settled claims as percent of total liability			1.00%
Malpractice loss contingency, self-insured retention			$ 15,000,000
Maximum | Professional And General Liability Claims Incurred And Reported On Or After June 1, 2008 [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			$ 15,000,000
Minimum
Commitments And Contingencies [Line Items]
Malpractice loss contingency, average lag period from occurrence to settlement			3 years
Malpractice loss contingency, self-insured retention			$ 10,000,000
Minimum | Professional and general liability self-insured claims under certain policy terms until Company total aggregate coverage is met if first aggregate layer becomes fully utilized [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			$ 15,000,000
Northwest Health – Starke [Member]
Commitments And Contingencies [Line Items]
Capital commitment, future period after acquisition for completing open capital improvement projects date			Sep. 30, 2026
Capital commitment, post-acquisition estimated cost of replacement hospital		$ 15,000,000	$ 15,000,000
Northwest Health – Starke [Member] | Maximum
Commitments And Contingencies [Line Items]
Capital commitment, future period after acquisition for completing open capital improvement projects			5 years

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Reconciliation of the Beginning and Ending Liability Balances in Connection with Probable Contingencies (Details) - Pending Litigation [Member] - Other Probable Contingencies [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Loss Contingency Accrual [Roll Forward]
Beginning Balance	$ 11	$ 68
Expense	11	14
Reserve for insured claim	(1)	11
Cash payments	(1)	(82)
Ending Balance	$ 20	$ 11

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Senior Secured Notes - Senior Secured Notes at 5.25%, Due 2030 - USD ($)	Feb. 04, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Debt instrument, offering date		Feb. 4, 2022
Debt instrument, maturity date		May 15, 2030
Debt instrument redemption description		plus a “make-whole” premium, as described in the indenture governing the 5¼% Senior Secured Notes due 2030.
Redeem up to 40% Principal Amount Prior to May 15, 2025
Subsequent Event [Line Items]
Debt instrument redemption description		plus accrued and unpaid interest, if any. In addition, any time prior to May 15, 2025, but not more than once during each twelve-month period
Redeem up to 10% Principal Amount Prior to May 15, 2025
Subsequent Event [Line Items]
Debt instrument redemption description		plus accrued and unpaid interest, if any
Redeem up to 40% Principal Amount Prior to May 15, 2024
Subsequent Event [Line Items]
Debt instrument redemption description		plus accrued and unpaid interest, if any, on the 5¼% Senior Secured Notes due 2030 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the twelve-month period beginning on May 15 of the years indicated below
Subsequent Event
Subsequent Event [Line Items]
Debt instrument aggregate principal amount	$ 1,535,000,000
Debt instrument stated interest rate	5.25%
Debt instrument redemption price percentage	100.00%
Minimum period notice for redemption of debt	10 days
Maximum period notice for redemption of debt	60 days
Debt instrument, maturity year	2030
Subsequent Event | Redeem up to 40% Principal Amount Prior to May 15, 2025
Subsequent Event [Line Items]
Debt instrument redemption price percentage	105.25%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Debt instrument optional redemption date	May 15, 2025
Subsequent Event | Redeem up to 10% Principal Amount Prior to May 15, 2025
Subsequent Event [Line Items]
Debt instrument stated interest rate	103.00%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	10.00%
Subsequent Event | Redeem up to 40% Principal Amount Prior to May 15, 2024
Subsequent Event [Line Items]
Debt instrument stated interest rate	5.25%
Debt instrument, maturity year	2030
Debt instrument optional redemption date	May 15, 2025
Minimum period notice for redemption of debt	10 days
Maximum period notice for redemption of debt	60 days

Subsequent Events - Schedule of

Subsequent Events - Schedule of Early Redemption Prices on 5.25% Senior Secured Notes due 2030 (Details) - Subsequent Event - Senior Secured Notes at 5.25%, Due 2030 - Senior Secured Notes	Feb. 04, 2022
Subsequent Event [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption, Period Three
Subsequent Event [Line Items]
Debt Instrument Redemption Price Percentage	102.625%
Debt Instrument, Redemption Period, Start Date	May 15, 2025
Debt Instrument, Redemption Period, End Date	May 14, 2026
Debt Instrument, Redemption, Period Four
Subsequent Event [Line Items]
Debt Instrument Redemption Price Percentage	101.313%
Debt Instrument, Redemption Period, Start Date	May 15, 2026
Debt Instrument, Redemption Period, End Date	May 14, 2027
Debt Instrument, Redemption, Period Five
Subsequent Event [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	May 15, 2027
Debt Instrument, Redemption Period, End Date	May 14, 2030

Condensed Financial Informati_3

Condensed Financial Information of Parent - Condensed Balance Sheets (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
ASSETS
Prepaid income taxes	$ 94	$ 50
Total current assets	3,479	4,510
Deferred income taxes	53	59
Other assets, net	1,913	1,896
Total assets	15,217	16,006
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Deferred income taxes	192	29
Other long-term liabilities	827	1,599
Total liabilities	16,027	17,060
Community Health Systems, Inc. stockholders’ deficit:
Preferred stock
Common stock	1	1
Additional paid-in capital	2,118	2,094
Accumulated other comprehensive loss	(14)	(13)	$ (9)
Accumulated deficit	(3,477)	(3,707)
Total Community Health Systems, Inc. stockholders’ deficit	(1,372)	(1,625)
Total liabilities and stockholders' deficit	15,217	16,006
Parent Company
ASSETS
Prepaid income taxes	94	50
Total current assets	94	50
Deferred income taxes	53	59
Other assets, net		(3)
Total assets	147	106
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Intercompany payable	1,326	1,701
Deferred income taxes	192	29
Other long-term liabilities	1	1
Total liabilities	1,519	1,731
Community Health Systems, Inc. stockholders’ deficit:
Preferred stock
Common stock	1	1
Additional paid-in capital	2,118	2,094
Accumulated other comprehensive loss	(14)	(13)
Accumulated deficit	(3,477)	(3,707)
Total Community Health Systems, Inc. stockholders’ deficit	(1,372)	(1,625)
Total liabilities and stockholders' deficit	$ 147	$ 106

Condensed Financial Informati_4

Condensed Financial Information of Parent - Condensed Statement of Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Condensed Income Statements Captions [Line Items]
Net operating revenues	$ 12,368	$ 11,789	$ 13,210
Operating costs and expenses:
Salaries and benefits	5,242	5,411	5,947
Supplies	2,042	1,963	2,151
Other operating expenses	2,958	2,957	3,303
Government and other legal settlements and related costs			93
Electronic health records incentive reimbursement			(1)
Pandemic relief funds	(148)	(601)
Depreciation and amortization	540	558	608
Impairment and (gain) loss on sale of businesses, net	24	48	138
Total operating costs and expenses	10,966	10,663	12,560
Income from operations	1,402	1,126	650
Interest expense, net	885	1,031	1,041
Gain (loss) on early extinguishment of debt	(79)	317	(54)
Equity in earnings of unconsolidated affiliates	(22)	(10)	(15)
Income (loss) before income taxes	499	422	(430)
Provision for (benefit from) income taxes	131	(185)	160
Net income (loss)	368	607	(590)
Less: Net income attributable to noncontrolling interests	138	96	85
Net income (loss) attributable to Community Health Systems, Inc. stockholders	230	511	(675)
Parent Company
Operating costs and expenses:
Equity in earnings of unconsolidated affiliates	(230)	(511)	675
Income (loss) before income taxes	230	511	(675)
Net income (loss)	230	511	(675)
Net income (loss) attributable to Community Health Systems, Inc. stockholders	$ 230	$ 511	$ (675)

Condensed Financial Informati_5

Condensed Financial Information of Parent - Condensed Statements of Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	$ 368	$ 607	$ (590)
Equity in other comprehensive (loss) income of affiliates, net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(1)	(3)
Net change in fair value of available-for-sale debt securities, net of tax	(5)	4	4
Amortization and recognition of unrecognized pension cost components, net of tax	3	(7)
Other comprehensive (loss) income	(2)	(4)	1
Comprehensive income (loss)	366	603	(589)
Less: Comprehensive income attributable to noncontrolling interests	138	96	85
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders	228	507	(674)
Parent Company
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	230	511	(675)
Equity in other comprehensive (loss) income of affiliates, net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(1)	(3)
Net change in fair value of available-for-sale debt securities, net of tax	(5)	4	4
Amortization and recognition of unrecognized pension cost components, net of tax	3	(7)
Other comprehensive (loss) income	(2)	(4)	1
Comprehensive income (loss)	228	507	(674)
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders	$ 228	$ 507	$ (674)

Condensed Financial Informati_6

Condensed Financial Information of Parent - Condensed Statement of Cash Flows (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net cash used in operating activities	$ (131)	$ 2,178	$ 385
Cash flows from investing activities:
Net cash provided by (used in) investing activities	(524)	177	(2)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements	(5)	(1)	(1)
Net cash provided by financing activities	(514)	(895)	(363)
Net change in cash and cash equivalents	(1,169)	1,460	20
Cash and cash equivalents at beginning of period	507	1,676	216	$ 196
Parent Company
Cash flows from operating activities:
Net cash used in operating activities	(11)	(12)	(4)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements	(5)	(1)	(1)
Changes in intercompany balances with affiliates, net	16	13	5
Net cash provided by financing activities	$ 11	$ 12	$ 4